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Chapter 1  
General introduction 
2 Chapter 1 
1.1 G-protein coupled receptors (GPCRs) 
1.1.1 GPCRs as drug target 
In the human genome, G-protein-coupled receptors (GPCRs) constitute the largest 
superfamily of membrane-bound receptors that transmit a wide variety of signals across the 
cell membrane. GPCRs respond to a broad range of extracellular messenger such as 
biogenic amines, purines, lipids, peptides and proteins, odorants, pheromones, tastants, ions 
and even photons (Jacoby et al., 2006). Approximately 800 genes encoding functional 
GPCRs have been identified in the human genome, and more than 50 % of these receptors 
are related to olfaction and taste (Gloriam et al., 2007). Roughly 130 of the remaining 
GPCRs that could present drug targets are so-called orphans, “proteins having similarity to 
receptors but whose endogenous ligands have not yet been conclusively identified” 
(Sharman et al., 2013). More than 50 GPCRs are targeted by approved drugs (Overington et 
al., 2006), which present 30 - 40 % of all marketed drugs (Stevens et al., 2013), emphasizing 
the current value for the treatment of human diseases and the prospects for the development 
of GPCR ligands as future drugs as well. 
1.1.2 Structure and classification 
The common architecture of a GPCR includes an extracellular N-terminus, seven α-helices 
spanning the plasma membrane and arranged in a counter-clockwise manner (TM1 – TM7), 
alternating intracellular (ICL1 –ICL3) and extracellular loops (ECL1 – ECL3) that interlink the 
seven transmembrane bundle and an intracellular C-terminus (see Figure 1.1). The 
transmembrane (TM) domains share the highest degree of sequence conservation, whereas 
the intracellular and extracellular domains display distinct variability in size and complexity. 
The extracellular and the transmembrane regions are involved in ligand binding, whereas the 
intracellular region is important for signal transduction. The classical way of signaling results 
from coupling to heterotrimeric G-proteins. However, G-protein coupling was not found for 
every GPCR and alternative signaling pathways involving interactions with various proteins 
have been described (Ritter and Hall, 2009). Therefore, the term “seven TM receptor” for this 
superfamily seems to be technically more correct, but the GPCR terminology is more 
common (Fredriksson et al., 2003). 
An important overview of the GPCR superfamily based on their ligands or sequence 
similarity gives the widely used A – F classification system (Kolakowski, 1994). The GPCRs 
are divided into six families, of which three families (families A, B, C) comprise the majority of 
known human receptors. This system is also used by the International Union of 
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Pharmacology, Committee on Receptor Nomenclature and Classification (NC-IUPHAR) 
(Foord et al., 2005). The complete sequencing of the human genome has enabled a detailed 
analysis of the GPCR phylogeny. Fredriksson and co-workers divided the human GPCRs 
into five families termed glutamate, rhodopsin, adhesion, frizzled/taste2 and secretin 
(shortened to the acronym GRAFS) (Fredriksson et al., 2003). The principle difference 
between the GRAFS system and the former classification system is the further division of 
family B into the secretin and adhesion family and the reclassification of the taste receptors 
into two subgroups, one within the glutamate group and one together with the frizzled/taste2 
group. 
 
Figure 1.1: Model of the active state of the human histamine H4R in complex with the endogenous
agonist histamine. The homology model is based on the recently published active state of the β2-
adrenergic receptor (AR) (Rasmussen et al., 2011a) (provided by (Wifling, 2012)). 
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The rhodopsin family (class A) contains about 670 full length human receptor proteins and is 
thus by far the largest family of GPCRs. Members of this family bind a wide variety of ligands 
such as peptides, small molecules like amines and purines or odorants in the case of 
olfactory receptors. Therefore, it is not surprising that this family represents the largest 
number of receptors that are targeted by clinically used drugs. Among the most widely 
prescribed classes of drugs are, for instance, “beta blockers” that antagonize the action of 
endogenous catecholamines on β-adrenergic receptors (β-ARs) and are used for the 
treatment of hypertension, coronary heart disease and cardiac arrhythmia. The rhodopsin 
family is characterized by several highly conserved structural motifs in the TM region such as 
the NSxxNPxxY in TM7 or the D(E)-R-Y(F) at the border between TM3 and IL2. The binding 
pocket for small molecule ligands is formed by the transmembrane spanning α-helices and 
therefore located within the seven TM bundle (Fredriksson et al., 2003; Jacoby et al., 2006). 
The secretin family (class B) is a small family with only 15 members that bind rather large 
peptide hormones such as secretin, calcitonin and parathyroid hormone. The name of this 
family originates from the first discovered receptor of this family, the secretin receptor from 
rat (Ishihara et al., 1991). Binding occurs at the proximal region and the juxtamembrane 
region of the N-terminus, the extracellular loops and the upper parts of the TM helices. Six 
conserved disulfide-bonded cysteine residues are found in a glycosylated extracellular 
amino-terminal tail in almost all receptors of the secretin receptor family (Jacoby et al., 2006; 
Lagerström and Schiöth, 2008). 
The adhesion family (class B) is the second largest receptor family in humans with 33 
members, of which the majority is orphan (Civelli et al., 2013). The family name is derived 
from the long and diverse N-terminus which contains motifs that are likely to participate in cell 
adhesion (Fredriksson et al., 2003). 
The glutamate receptor family (class C) comprises 22 receptor proteins including the 
metabotropic glutamate receptors, the γ-aminobutyric acid type B receptors, the calcium 
sensing receptor and the sweet/umami taste receptors. The ligand binding site is located in 
the N-terminal domain where two lobes of the region form a cavity in which glutamate binds, 
the so called “Venus fly trap” (Kunishima et al., 2000). In addition to drugs that bind to the 
glutamate binding domain, e.g. baclofen (McLean, 1993), there are also allosteric modulators 
that bind within the TM region such as cinacalcet (Iqbal et al., 2003). 
The frizzled/taste2 receptor family in humans consists of ten frizzled receptors and 25 
functional bitter taste receptors. The frizzled receptors are involved in cell development and 
proliferation. The name frizzled is related to the curled and twisted glycoprotein ligand (Wnt) 
of a receptor cloned from D. melanogaster (Fredriksson et al., 2003) (for reviews see Luttrell 
et al. (Luttrell, 2008) and Davies et al. (Davies et al., 2011)). 
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1.1.3 Advances in X-ray crystallography for GPCRs 
To better understand how GPCRs work at a molecular level, high resolution crystal structures 
are very helpful. So far, the structures of 18 different class A GPCRs have been published, 
alone 14 of them in the last three years (Venkatakrishnan et al., 2013). This required 
technical challenges to be overcome such as the production of large quantities (> 200 mg) of 
functional protein or the stabilization of the flexible ICL3 to increase the polar surface area 
potential for crystal contacts (Kobilka and Schertler, 2008). The latter has been resolved for 
the human (h) β2-AR structure by crystallizing the receptor in complex with an antibody 
fragment that bound to a structural epitope at the cytoplasmic base of TM5 and TM6 
(Rasmussen et al., 2007) and by insertion of the enzyme T4-lysozyme into ICL3 of the 
receptor (Cherezov et al., 2007). In another approach, first used for the structure 
determination of the turkey β1AR, the receptor was stabilized by a number of point mutations 
(Warne et al., 2008). 
The first three-dimensional structure of a GPCR was obtained from bovine rhodopsin 
containing the covalently bound inverse agonist 11-cis retinal (Palczewski et al., 2000). 
Interestingly, only bovine rhodopsin has successfully been crystallized from its native source, 
with intact sequence and without artificial stabilization. A comparison with non-rhodopsin 
structures revealed some structural differences. For instance, the ECL2 of rhodopsin forms a 
β-sheet lid that covers the bound 11cis-retinal and protects this from hydrolysis. In contrast, 
the ECL2 of the β1-AR and β2-AR forms a short helix that enables an open binding pocket 
(Kobilka and Schertler, 2008; Rosenbaum et al., 2009). A ionic interaction between R135 
(part of the highly conserved D(E)-R-Y(F) motif) of TM3 and E247 of TM6 in rhodopsin, the 
so called “ionic lock”, has been supposed to help hold the receptor in an inactive 
conformation (Hofmann et al., 2009). However, this ionic lock has not been observed in 
several other structures that bind antagonists. It is a matter of speculation that the ionic lock 
is lacking due to the presence of the antibody fragment or T4-lysozyme fusions that could 
have altered the receptor structure or due to the fact that the ligands are not in all cases full 
inverse agonists, since the ionic lock can only be observed in the full ground state 
conformation (Congreve et al., 2011) (for further recent reviews see Salon et al. (Salon et al., 
2011) and Hanson et al. (Hanson and Stevens, 2009). 
The first crystal structures of GPCRs represented inactive receptor conformations, since they 
were obtained in complex with antagonists or inverse agonists, respectively. To learn how 
binding of an agonist does activate a receptor, the crystal structure of an active receptor 
conformation was needed. This was first accomplished for opsin, the ligand-free form of 
rhodopsin (Park et al., 2008; Scheerer et al., 2008), but proved to be difficult for other 
GPCRs, since the interaction with a G-protein is essential to stabilize the active state of the 
receptor. Rasmussen and co-workers reached this milestone in GPCR research by 
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crystallization of the agonist-bound active-state β2-AR in complex with a nanobody as a 
replacement of the G-protein (Rasmussen et al., 2011a) and, more importantly, by the 
crystallization of the active state ternary complex consisting of the agonist-occupied 
monomeric β2-AR and the nucleotide-free Gs heterotrimer (Rasmussen et al., 2011b). Both 
structures consistently show that the largest difference between the inactive and active 
structures is a 11 - 14 Å outward movement of TM6. In complex with a G-protein, the active 
state of the β2-AR is stabilized by interactions of ICL2, TM5 and TM6 with the Ras-like 
GTPase domain of the Gαs subunit (GαsRas). Surprisingly, there is no interaction with the 
Gβγ subunit. Of particular interest is also a large movement of the α-helical domain of Gαs 
relative to GαsRas in the nucleotide-free β2-AR-Gs complex. The guanidine nucleotide 
binding pocket is formed by the interface of these two domains and stabilized by binding of 
guanosine triphosphate (GTP) or guanosine diphosphate (GDP) (see Figure 1.2). As the 
release of GDP is an essential step in the G-protein cycle (see section 1.1.4.1), it will be of 
particular interest to determine the functional significance of this large movement in future 
studies (Rasmussen et al., 2011b). 
 
Figure 1.2: Illustration of the agonist (A) bound, 
nucleotide-free β2-AR-Gs-protein complex. The Gαs 
subunit is formed by the Ras domain (αRas) and the α-
helical domain (αAH), which are both involved in 
nucleotide binding. In the nucleotide–free state, the αAH 
domain has a variable position relative the αRas domain 
(modified from (Rasmussen et al., 2011b)). 
 
Additional insights are expected from efforts to determine the structures of GPCRs in 
complex with other signaling proteins to characterize the role of protein dynamics in receptor 
function (Granier and Kobilka, 2012) (for a recent review see Venkatakrishnan et al. 
(Venkatakrishnan et al., 2013)). 
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1.1.4 Signal transduction 
1.1.4.1 G-protein mediated signal transduction 
The G-protein cycle is the “classical mode” of GPCR-mediated intracellular signaling. Agonist 
binding to extracellular or transmembrane domains of a GPCR promotes conformational 
changes that initiate coupling of intracellular receptor domains to heterotrimeric G-protein. 
This agonist-receptor-G-protein complex, termed as ternary complex, triggers a G-protein 
conformational change that catalyzes exchange of GTP for GDP on the Gα subunit. 
Subsequently, the activated heterotrimeric G-protein dissociates into Gα-GTP and Gβγ 
subunits, which then regulate the activity of intracellular effector proteins. The intrinsic 
GTPase activity of the GTP-bound Gα subunit terminates the signal by hydrolysis of GTP to 
GDP, i. e. the cycle is completed through the returning of the G-protein to the inactive 
heterotrimeric state (see Figure 1.3). 
 
 
The currently known 16 genes encoding for mammalian Gα subunits are divided into four 
subfamilies (Gαs, Gαi/o, Gαq11 and Gαq12/13) based on sequence homology (Cabrera-Vera et 
al., 2003). The best characterized G-protein-regulated enzyme is the adenylyl cyclase, which 
forms the second messenger cyclic-adenosine 3’,5’-monophosphate (cAMP) from adenosine 
triphosphate (ATP). cAMP is a ubiquitous second messenger in cells activating numerous 
cellular pathways such as the cAMP dependent protein kinase A (PKA). All of the nine 
Figure 1.3: Activation of a heterotrimeric G-protein by interaction with an agonist-occupied GPCR. The
activated receptor is represented by R*, whereas the inactive type is named R. The dissociated
subunits regulate their respective effector proteins such as the adenylyl cyclase (AC) and calcium
channels. Further details are described in the text (modified from (Rasmussen et al., 2011b)). 
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mammalian membrane bound ACs are stimulated by Gαs, whereas only some can be 
inhibited by activated Gαi/o (Hanoune and Defer, 2001; Pavan et al., 2009). Members of the 
Gαq11 family activate the phospholipases Cβ 1-3 (PLCβ), which catalyze the hydrolysis of 
phosphatidylinositol 4,5-bisphosphate (PIP2) to 1,2-diacylglycerol (DAG) and inositol-1,4,5-
trisphosphate (IP3). The latter second messenger controls calcium efflux from the 
endoplasmic reticulum. DAG and the released calcium control the activity of several protein 
kinase C (PKC) isoforms, which in turn activate a number of other proteins by 
phosphorylation. The main effector system activated by the Gα12/13 subfamily is the guanine 
nucleotide exchange factor RhoGEF, which triggers the GDP/GTP exchange on the small 
molecular weight G-protein Rho (Birnbaumer, 2007; Cabrera-Vera et al., 2003). 
In addition to the Gα subunits, five different Gβ subunits and 12 different Gγ subunits have 
been identified (Luttrell, 2008). The Gβγ heterodimer, originally thought to primarily facilitate 
signal termination and membrane attachment by binding to the Gα subunits, also activates 
several effector proteins such as the the PLCβ 2 and 3 (usually in combination with Gαi/o 
coupled GPCRs), GPCR kinases or potassium and calcium channels (Cabrera-Vera et al., 
2003). 
The complexity of G-protein signaling is demonstrated by the fact that GPCRs can couple to 
multiple G-proteins and activate multiple signaling pathways (Eason et al., 1992; Galandrin 
and Bouvier, 2006). Additionally, a fine tuning of the signaling through a complex of 
regulatory events occurs that has impact on the cellular responsiveness. Receptor-G-protein 
coupling is directly impaired by phosphorylation of specific residues within the intracellular 
domains of the receptor through second messenger dependent protein kinases like PKA and 
PKC (heterologous desensitization). Agonist-occupied GPCRs are phosphorylated by G-
protein-coupled receptor kinases (GRKs) resulting in β-arrestin binding and subsequent 
desensitization (homologous desensitization) and internalization into clathrin-coated pits (see 
section 1.1.4.2) (Luttrell and Gesty-Palmer, 2010). Gα subunit activity is modulated by direct 
binding of regulators of G-protein signaling proteins (RGS proteins), which accelerate the 
GTP hydrolysis of Gα-GTP and thus the termination of signaling (Hepler, 2003). Second 
messengers are enzymatically inactivated by cAMP phosohodiesterases (PDE), 
phosphatidylinositol phosphatases and diacylglycerol kinases (Luttrell, 2008). More 
regulatory mechanisms are summarized and reviewed by Luttrell et al. (Luttrell, 2008). 
1.1.4.2 β-Arrestin dependent signaling 
There are four known mammalian arrestins. Arrestin1 (rod arrestin) and -4 (cone arrestin) are 
expressed in the retina and exist primarily to regulate photoreceptor function. The two non-
visual arrestins, arrestin 2 and -3 (also referred to as β-arrestin 1 and -2) are found in most 
tissue types and were originally identified as mediators of GPCR desensitization (Luttrell and 
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Gesty-Palmer, 2010). All four arrestins bind directly to activated GRK-phosphorylated 
GPCRs and block the receptor-G-protein interaction. Next to desensitization, non-visual β-
arrestins have additional functions that are not shared with visual arrestins. Receptor-bound 
β-arrestin also serves as an adaptor linking the receptor to the clathrin-dependent 
endocytosis machinery. Once internalized the receptor can return back to the plasma 
membrane via recycling endosomes (resensitization) or be directed to lysosomes and 
degraded (down-regulation) (Gurevich and Gurevich, 2006). 
Within the past decade, it has been discovered that β-arrestins not only serve as adaptors in 
the context of GPCR desensitization and internalization, but also as multifunctional adaptor 
proteins that link GPCRs to several effector proteins such as mitogen-activated protein 
kinases (MAPKs), Src family kinases and nuclear factor-ΚB (Rajagopal et al., 2010). This led 
to a paradigm shift in GPCR signal transduction (DeWire et al., 2007; Miller and Lefkowitz, 
2001; Perry and Lefkowitz, 2002). As β-arrestin binding terminates G-protein signaling, both 
pathways should be temporally discrete. In fact, the well characterized extracellular signal-
regulated kinase (ERK) cascade showed that the beginning of β-arrestin ERK1/2 activation 
coincides with the decreasing of G-protein signaling and still persists when the receptor is 
internalized (see Figure 1.4) (Ahn et al., 2004; Luttrell and Gesty-Palmer, 2010). 
 
 
Figure 1.4: Comparison of the time course of G-protein- with β-arrestin mediated signaling. Unlike G-
protein signaling through second messenger, β-arrestin dependent signals originate within
stoichiometric complexes of receptors, β-arrestins, and effectors, often termed as signalosomes
(modified from (Luttrell and Gesty-Palmer, 2010). 
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1.1.4.3 Models of GPCR signaling, ligand classification and functional 
selectivity 
Early efforts to describe the functional effects of drugs on isolated tissues were based on the 
assumption that binding of a ligand to a receptor follows the law of mass action according to 
the Langmuir adsorption isotherm (Clark, 1937; Clark, 1933). This “classical model” of 
receptor function was successively modified due to constantly new experimental evidences 
in receptor pharmacology. For instance, Ariens introduced a proportionality factor termed 
intrinsic activity (also referred to as α) to the binding function in order to characterize the 
degree of receptor stimulation for different drugs (Ariens, 1954). α = 1 indicates agonists that 
induce the maximal response, α = 0.5 describes agonists that reach only half of the maximal 
response and an intrinsic activity of zero indicates no agonism. In the so called “two-state 
model”, which was originally formulated to describe ion channels (Del Castillo and Katz, 
1957), it is assumed that the receptor could persist in a inactive conformation (R) and change 
in complex with an agonist (L) into an active conformation (LR*) that triggers signaling (Leff, 
1995). The “two-state-model” was also helpful to explain experimental findings relating to 
constitutive activity in the late 1980s (Kenakin, 2009). High receptor density in genetically 
engineered cells uncovered the existence of a constitutively active receptor population 
(Costa and Herz, 1989). It was supposed that receptors could exist in a spontaneously active 
state (R*), just like ion channels can open without agonist binding (Kenakin, 2009). 
Observations of two affinity forms of the β-AR receptor (Lefkowitz et al., 1976; Maguire et al., 
1976) led to the assumption that the receptor interacts with other unknown membrane-bound 
proteins, which later turned out to be G-proteins, leading to the agonist promoted formation 
of a high-affinity ternary complex (LRT). This model is termed the “ternary complex model” 
(TCM) and was first described by DeLean and colleagues (see Figure 1.5 A) (De Lean et al., 
1980). Interestingly, although the existence of the heterotrimeric G-protein as a cellular 
signaling component was already known at that time (Rodbell et al., 1971; Ross and Gilman, 
1977), the link to the role as transducer protein (T) for receptor signaling was identified later 
(Gilman, 1987). 
The discovery of a constitutively active β2-AR mutant resulted in the modification of the TCM, 
which is called “extended ternary complex model” (ETCM) (Samama et al., 1993). According 
to this model, ligands are divided into five classes. The inactive receptors (Ri) can adopt 
either spontaneously or in complex with an agonist the active conformation (Ra or LRa), which 
then can induce signaling by forming a complex with the G-protein (RaT or LRaT) (see Figure 
1.5 B). Contrary, inverse agonists stabilize the inactive receptor state and prevent signaling. 
Partial agonists and partial inverse agonists also shift the equilibrium to the particular active 
or inactive conformation, but to a minor extent compared to full (inverse) agonists. Neutral 
antagonists do not prefer a receptor conformation and leave the basal activity unchanged. 
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From a thermodynamicalpoint of view, the ETCM is incomplete due to the missing interaction 
between the inactive receptor (ligand bound and unbound) and G-protein. The “cubic ternary 
complex model” accommodates this possibility and thus increases the number of states 
compared to the ETCM (Weiss et al., 1996) (see Figure 1.5 C). 
 
 
Figure 1.5: Models of GPCR signaling: Ternary complex model (A), extended ternary complex model
(B), cubic ternary complex model (C), multiple signaling-component model (D). Further details are
described in the text. Abbreviations are: L: ligand, R: receptor, T: transducer (e.g. G-protein or β-
arrestin), Ra: active receptor conformation, Ri: inactive receptor conformation (modified from
(Rajagopal et al., 2010). 
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Nowadays, it is assumed that GPCRs can adopt multiple conformations including more than 
one active state (Kenakin, 2007; Kobilka and Deupi, 2007). This assumption accounts for 
ligands that preferentially activate one possible downstream pathway over another (e.g. 
either G-protein or β-arrestin) in contrast to the endogenous ligand, which is considered to be 
neutral. These ligands are termed as biased agonists and would be expected to elicit a 
conformational change that can only stimulate G-protein signaling without β-arrestin 
recruitment, or vice versa. These type of effects has received various names, which include 
“stimulus trafficking”, “biased agonism”, “collateral efficacy” or generally accepted “functional 
selectivity (Kenakin, 2007). In fact, several biophysical studies on the β2-AR (Kahsai et al., 
2011; Swaminath et al., 2004) and on the α2-adrenergic receptor (Zurn et al., 2009) 
demonstrated that binding of functionally different ligands results in distinct conformations. 
Moreover, very recently for the β2-AR (Liu et al., 2012) and for the vasopressin type 2 
receptor (Rahmeh et al., 2012) it was shown that the functional β-arrestin outcome depends 
on movement of TM7 and helix 8, whereas conformational changes in TM6 are associated 
with G-protein activation (cf. section 1.1.3). Therefore, an additional state(s) for receptor 
activation is required (Ra1, Ra2,…) as well as additional ternary complexes which comprise 
also other transducers of signaling than G-proteins such as β-arrestin (T1, T2,…) (Figure 1.5 
D). Considering ligands that bind at allosteric sites and thereby affect receptor activity, further 
complexity is added to the “multi-state model” for receptor activation. The model includes the 
presence of biased ligands, which are useful as pharmacological tools to improve the 
understanding of protein dynamics in GPCR function and, most importantly, as more efficient 
and economical therapeutics that maximize beneficial effects and minimize side effects 
(Rajagopal et al., 2010). 
1.2 Histamine and the histamine receptor family 
1.2.1 The biogenic amine histamine 
About a hundred years ago, the discovery of histamine and the first description of its 
biological action were carried out by Sir Henry Dale owing to its ability to constrict the guinea 
pig ileum and its potent vasodepressor action (Dale and Laidlaw, 1910). Subsequently, 
additional histamine effects such as the induction of a shock-like syndrome, when injected 
into animal (Dale and Laidlaw, 1919), the stimulation of acid secretion from the stomach of 
dogs (Popielski, 1920) or the classic “triple response” to histamine consisting of a red spot 
(vasodilatation), a wheal (increased permeability) and flare (axon reflex) (Lewis and Grant, 
1924) were reported. Nowadays, histamine is considered to be a ubiquitous and 
multifunctional biogenic amine which is involved in various physiological and 
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pathophysiological situations. Histamine holds a key position in a number of brain functions 
including sleep-waking cycle, emotion or learning, it is involved in secretion of pituitary 
hormones, regulation of gastrointestinal and circulatory functions, inflammatory reactions and 
modulation of immune response (Dy and Schneider, 2004). 
Histamine is formed in the body from L-histidine by the action of the enzyme histidine 
decarboxylase (HDC). In the hematopoietic system, mast cells (Riley and West, 1952) and 
basophils (Falcone et al., 2006) store histamine in cytosolic granules, and can release the 
mediator in large amounts during degranulation in response to various immunological and 
non-immunological stimuli (Dy and Schneider, 2004). Histamine is also produced by 
enterochromaffin-like cells in the stomach (Prinz et al., 2003) and histaminergic neurons in 
the tuberomamillary nucleus (Haas et al., 2008). After liberation into the extracellular space, 
histamine is metabolized rapidly. The two main catabolic pathways are methylation by 
histamine N-methyltransferase (HNMT) to form Nτ-methylhistamine and deamination by the 
diamine oxidase (DAO) to form imidazole-4-acetaldehyd (Beaven, 1982). Both products are 
further metabolized by xanthin oxidase and DAO or ribosyltransferase as shown in Figure 
1.6.  
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Histamine can be protonated at the strongly basic amino group in the side chain (pKa2 = 9.4) 
and at the imidazole ring (pKa1 = 5.8) to form a dication. Under physiological conditions (pH 
7.4), however, the monocation predominates and is thus supposed to be the biologically 
active species. The monocation exists in an equilibrium mixture of two possible tautomeric 
forms, the Nπ-H tautomer and the Nτ-H tautomer. In aqueous solution, about 80 % of 
histamine monocation is in the Nτ-H form (Ganellin et al., 1973) (see Figure 1.7). 
  
Figure 1.6: Biosynthesis and metabolism of histamine. 
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1.2.2 Histamine receptors and their ligands 
Histamine exerts its biological effects via four receptor subtypes, namely the H1R, H2R, H3R 
and H4R, belonging all to class A (rhodopsin-like family) of GPCRs (Foord et al., 2005) (cf. 
section 1.1.2). The H3R and H4R displayed the highest overall sequence homology of about 
40 % (58 % in the TM regions) (Hough, 2001). The sequence similarity between the H1R and 
H2R is rather low (about 28 % identity) (De Backer et al., 1993). The comparison of the 
H1/2Rs with the H3/4Rs also yields a relatively low average sequence homology of about 20 % 
(Leurs et al., 2009; Lovenberg et al., 1999). 
1.2.2.1 The histamine H1 receptor 
The term H1R was introduced by Ash and Schild in the year 1966 after it was evident that two 
distinct receptors are involved in histamine response (Ash and Schild, 1966). Thus, the first 
antihistamines such as the adrenolytic benzodioxan, piperoxan (933F) (see Figure 1.8), 
which blocked the histamine effect in the guinea pig ileum (Ungar et al., 1937), are also 
referred to as H1R antagonists. The H1R was first cloned in 1993 and the corresponding 
receptor protein consists of 487 amino acids (De Backer et al., 1993). The H1R 
predominantly couples to Gαq/11 proteins upon agonist stimulation, leading to the release of 
calcium as described in section 1.1.4.1. Moreover, the activated H1R expressed in HEK293 
cells can increase the cAMP level as described recently (Esbenshade et al., 2003). The H1R 
is expressed in airway and vascular smooth muscle cells, neurons, endothelial and epithelial 
cells as well as hematopoietic cells (Dy and Schneider, 2004). H1Rs are involved in the 
pathophysiological process of allergy and inflammatory reactions. Histamine induces via the 
H1R, for instance, vasodilatation, bronchoconstriction, increased vascular permeability, pain 
and itching upon insect stings (Bongers et al., 2010). Accordingly, H1R antagonists have 
been successfully used for the treatment of allergic disorders such as hay fever, allergic 
rhinitis and urticaria (Parsons and Ganellin, 2006). Side effects, especially sedation, due to 
occupancy of H1R in the central nervous system (CNS) were characteristic of the first 
Figure 1.7: Tautomerism of histamine in the monocationic form. 
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generation of H1R antagonists such as mepyramine (Pyrilamine®) or diphenhydramine 
(Dolestan®) (see Figure 1.8). However, for instance, diphenhydramine 8-chlortheophyllinate 
(Dramamine®) is approved as antiemetic for the treatment of travel sickness. More polar 
compounds that penetrate poorly into the CNS, like cetirizine (Zyrtec®) or fexofenadine 
(Telfast®) (see Figure 1.8), have been developed to prevent CNS side effects. These 
compounds belong to the “non-sedating” second generation of H1R antagonist and are 
blockbuster drugs for the treatment of allergic disorders (Hill et al., 1997). 
 
H1R agonists do not have the same clinical prospects as H1R antagonist and are thus not 
readily available. The only clinically used H1R agonist is the centrally acting betahistine 
(Aequamen®) (see Figure 1.9), which can be orally administered for the treatment of 
Menière’s disease (Barak, 2008). Selective H1R agonists have been developed as well, and 
represent interesting pharmacological tools. Substitution in the 2-position of the imidazole 
ring of histamine presents a valuable method to obtain selective H1R agonists such as 2-(3-
bromophenyl)histamine and 2-[3-(trifluoromethyl)phenyl]histamine (Leschke et al., 1995) 
(see Figure 1.9). More recently, Schunack and colleagues developed a new class of highly 
potent and selective H1R agonists which are characterized by a 3,3-diphenylpropyl 
substituent and named histaprodifens (Elz et al., 2000a; Elz et al., 2000b). The dimerisation 
of histaprodifen with histamine resulted in the even more potent suprahistaprodifen (Menghin 
et al., 2003) (see Figure 1.9). 
Figure 1.8: Structures of selected H1R antagonists. 
 Histamine and the histamine receptor family 17 
 
1.2.2.2 The histamine H2 receptor 
The existence of a second histamine receptor subtype was confirmed by the discovery of the 
first selective H2R antagonist burimamide, which blocked the action of histamine on H2R 
containing tissues such as the histamine-induced gastric acid secretion and the chronotropic 
effect on the heart (Black et al., 1972). About 20 years after the first pharmacological 
characterization, the copy-DNA (cDNA) of the canine and subsequently of the human H2R 
were cloned by Gantz and coworkers (Gantz et al., 1991a; Gantz et al., 1991b). The H2R 
primarily couples to the Gαs family of G-proteins, leading to activation of AC (cf. section 
1.1.4.1) (Gantz et al., 1991a; Johnson et al., 1979; Klein and Levey, 1971). Depending on 
the used cell system, the H2R may additionally trigger calcium signaling by coupling to the 
Gαq/11 G-protein (cf. section 1.1.4.1) (Esbenshade et al., 2003; Mitsuhashi et al., 1989; Wang 
et al., 1996). H2Rs were found in numerous peripheral tissues and cells such as gastric 
parietal cells, heart, airways, uterus and vascular smooth muscle cells, hematopoietic cells 
(neutrophils, eosinophils, monocytes, dendritic cells, T and B lymphocytes) and in the brain 
(Baumer and Rossbach, 2010; Dove et al., 2004; Hill et al., 1997). The first marketed H2R 
antagonist cimetidine (Tagamet®) (see Figure 1.10) has revolutionized the treatment of 
peptic ulcer and gastro-oesophageal reflux disease (Parsons and Ganellin, 2006). Following 
the success of cimetidine, several other H2R antagonists were developed and launched onto 
the market like ranitidine (Zantac®) and famotidine (Pepdul®), which, unlike cimetidine, do 
not affect cytochrome P450 enzymes in the liver (Hill et al., 1997; Parsons and Ganellin, 
2006) (see Figure 1.10). In addition to the therapeutically used drugs, selective H2R 
antagonists with high affinity such as tiotidine (see Figure 1.10) and iodoaminopotentidine 
Figure 1.9: Structures of selected H1R agonists. 
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were successfully applied as pharmacological tools (Gajtkowski et al., 1983; Hirschfeld et al., 
1992). 
 
Dimaprit was one of the first available relatively selective H2R agonist (Durant et al., 1977) 
(see Figure 1.11). Highly potent and selective guanidine-type H2R agonists like impromidine 
(Durant et al., 1978; Durant et al., 1985) and arpromidine (Buschauer, 1989) (see Figure 
1.11) have been developed (Timmerman, 1992), which, however, showed poor oral 
bioavailability (Dove et al., 2004). In order to obtain agonists with an improved 
pharmacokinetic profile, the basicity was reduced by replacement of the guanidine group with 
an acylguanidine moiety, resulting in NG-acetylated imidazolylpropylguanidines such as UR-
AK24 (Ghorai et al., 2008) (see Figure 1.11). A further bioisosteric replacement of the 
imidazole ring with a 2-amino-4-methylthiazol-5-yl moiety led to agonists such as UR-PG278 
(see Figure 1.11) with substantially improved H2R selectivity compared to the other HxRs 
(Kraus et al., 2009). Recently, the application of the bivalent ligand approach to 
acylguanidines yielded UR-AK459 (see Figure 1.11), which is highly selective and 4000 
times more potent than histamine at the guinea pig right atrium (Birnkammer et al., 2012). 
Although Baumann and co-workers demonstrated in a clinical trial with impromidine about 30 
years ago that the combined vasodilator and inotropic action may be an effective treatment 
of severe catecholamine-insensitive congestive heart failure (Baumann et al., 1984), H2R 
agonists are still not used therapeutically. Nevertheless, they are important as 
pharmacological tools to study the (patho)physiological role of the H2R. 
Figure 1.10: Structures of selected H2R antagonists. 
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1.2.2.3 The histamine H3 receptor 
A third histamine receptor subtype was first described in a pharmacological approach by 
Arrang and colleagues in 1983, who found that histamine inhibits its own synthesis and 
release in rat cerebral cortical slices via presynaptic feedback mechanisms. Due to the fact 
that neither H1R nor H2R activity of histaminergic ligands correlated with these inhibitory 
effects, a novel subtype of histamine receptor was proposed (Arrang et al., 1983). The 
discovery of the agonist (R)-α-methylhistamine and the competitive antagonist thioperamide 
as selective pharmacological tools for the H3R confirmed its existence and enabled a detailed 
pharmacological characterization (Arrang et al., 1987). The molecular architecture of the H3R 
was unknown until Lovenberg and co-workers succeeded in the cloning of the receptor cDNA 
in 1999 by performing homology searches of expressed sequence tag database (Lovenberg 
et al., 1999). This confirmed that the H3R belongs, like the H1R and H2R, to the large super-
family of GPCRs. The elucidation of the genomic organization led also to the discovery of at 
least 20 hH3R isoforms of which, however, the full length 445 (aa) sequence  seems to 
encode the functionally dominant and abundantly expressed isoform (Berlin et al., 2011). The 
physiological significance of most of the other isoforms is unknown and needs to be further 
investigated. H3R signaling is mediated through Gαi/o proteins leading to inhibition of AC (cf. 
section 1.1.4.1) (Clark and Hill, 1996). Moreover, the H3R mediates the activation of 
Figure 1.11: Structure of selected H2R agonists. 
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phospholipase A2 (PLA2), MAPKs, phosphatidyl inositol-3 kinase, inhibition of the Na+/H+ 
exchanger and modulation of intracellular calcium (Bongers et al., 2007). The H3R is mainly 
expressed in the central nervous system where the highest densities of H3Rs were found in 
the basal ganglia, hippocampus and cortical areas (Martinez-Mir et al., 1990). In the 
peripheral nervous system, H3Rs are located, for instance, in the gastrointestinal tract, the 
airways and the cardiovascular system (Wijtmans et al., 2007). The H3R acts as presynaptic 
autoreceptor to regulate the release of histamine and as heteroreceptor on non-histaminergic 
neurons, regulating the release of several other important neurotransmitters such as 
acetylcholine, norepinephrine, dopamine and serotonin (Gemkow et al., 2009). The position 
at the crossroad of neurotransmission suggests a broad range of therapeutic indications 
including cognitive disorders, sleep disorders, pain and obesity. Consequently the H3R has 
become an attractive drug target for both academic research groups and pharmaceutical 
companies (Leurs et al., 2005). Antagonists for the H3R currently undergo clinical evaluation 
for the treatment of Alzheimer`s diseases, schizophrenia, attention deficit hyperactivity 
disorder, dementia, epilepsy, narcolepsy, obesity and neuropathic pain (Berlin et al., 2011; 
Gemkow et al., 2009; Leurs et al., 2011; Sander et al., 2008). Recently, pitolisant (formerly 
known as BF2.649) (see Figure 1.2) has been introduced as the first H3R inverse agonist/ 
antagonist in the clinics for the treatment of narcolepsy (Schwartz, 2011). The starting point 
for the design of the first potent H3R antagonists such as thioperamide (Arrang et al., 1987) 
and clobenpropit (van der Goot et al., 1992) was the structure of the endogenous ligand, 
histamine, so that these compounds have an imidazole ring in common (see Figure 1.12). 
As imidazole containing H3R antagonists exhibit insufficient drug-likeness due to the risk of 
CYP interactions, poor brain penetration and species-dependent differences (Sander et al., 
2008), several pharmaceutical companies developed non-imidazole H3R antagonists such as 
pitolisant and JNJ 5207852 (Barbier et al., 2004), containing other nitrogen heterocycles (see 
Figure 1.12). 
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Due to negative neurotransmitter modulation, beneficial effects of H3R agonists are expected 
at pathological conditions caused by elevated neurotransmitter levels. Thus, H3R agonists 
also have a variety of potential therapeutic application including inflammation, migraine, 
asthma, insomnia, pain, ulcer, hypertension, immunological regulation and ischemic 
arrhythmias (Berlin et al., 2011). Contrary to H3R antagonists, the imidazole moiety in H3R 
agonists seems to be essential to maintain agonistic activity (Leurs et al., 2005). Structures 
of H3R agonists closely resemble to histamine and contain only minor modifications in the 
imidazole side chain as, for example, in (R)-α-methylhistamine, Nα-methylhistamine, imetit 
and immepip (see Figure 1.13). Major drawbacks of these compounds are missing selectivity 
over the newly identified H4R and limited utilization in vivo due to low oral bioavailability and 
rapid metabolism. In the case of (R)-α-methylhistamine the latter problem was overcome by 
applying an azomethine prodrug concept to (R)-α-methylhistamine resulting in BP 2-94 
(Krause et al., 1995) (see Figure 1.13), which shows improved oral bioavailability and 
pharmacokinetic properties (Rouleau et al., 1997). To enhance selectivity over the H4R, new 
potent H3R agonists such as immethridine and methimmepip have been developed 
(Kitbunnadaj et al., 2004) (see Figure 1.13). 
Figure 1.12: Structures of selected H3R antagonists. 
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1.2.2.4 The histamine H4 receptor 
Early examples of H4 receptor signaling can be found in literature from the time in which the 
existence of the receptor was still unknown. In 1975 Clark and his co-workers observed 
histamine induced chemotaxis of human eosinophils that was not inhibited by H1 or H2 
receptor antagonists (Clark et al., 1975). Two decades later, Raible and his colleagues 
identified pertussis toxin-sensitive cytosolic calcium increase in eosinophils by histamine, 
which was blocked by H3R antagonists. Furthermore, known H3R agonists (R-α-
methylhistamine and Nα-methylhistamine) could trigger calcium increase, but the potencies 
were much lower than the potency of histamine. This led to the assumption that a fourth 
histamine receptor subtype is present on eosinophils (Raible et al., 1994). On the basis of 
high sequence homology with the H3R, several research groups independently identified the 
H4R sequence in the human genome at the beginning of the new century (Liu et al., 2001; 
Morse et al., 2001; Nakamura et al., 2000; Nguyen et al., 2001; Oda et al., 2000; Zhu et al., 
2001). The human H4R gene encodes for a 390 amino acid protein and contains, like the 
H3R, three exons and two introns. So far, only two non-signaling H4R isoforms have been 
identified, which are supposed to act as negative regulatory elements on full length receptor 
functionality (vanRijn et al., 2008). The H4R inhibits adenylyl cyclase via activation of Gαi/o 
proteins (cf. section 1.1.4.1) (Leurs et al., 2009). Additionally, stimulation of the H4R leads to 
pertussis-toxin sensitive activation of MAPK pathway (Morse et al., 2001) and calcium 
mobilization (Hofstra et al., 2003). Very recently, also hH4R mediated β-arrestin activation 
has been reported for several H4R ligands (Nijmeijer et al., 2012). The H4R is predominantly 
expressed in cells of hematopoietic origin including neutrophils, mast cells, eosinophils, 
basophils, dendritic cells, monocytes and T cells. Furthermore, the H4R has been identified 
on nerves from the nasal mucosa, in the enteric and, as with the other histamine receptors, 
Figure 1.13: Structure of selected H3R agonists. 
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in the central nervous system (Leurs et al., 2009). Concerns regarding the specificity of 
antibodies, which were used for the analysis of expression and localization of the H4R, have 
emerged recently and are currently under discussion (Beermann et al., 2012b; Gutzmer et 
al., 2012; Neumann et al., 2012; Seifert et al., 2013). Although the (patho)physiological role 
of the H4R is still not fully understood, the involvement in chemotaxis and cytokine release in 
cells of the immune system suggest that the H4R plays an important pro-inflammatory role in 
various diseases including allergic asthma, allergic rhinitis, pruritis and inflammatory pain 
(Leurs et al., 2011; Walter et al., 2011; Zampeli and Tiligada, 2009). Accordingly, H4R 
antagonists have the potential for the treatment of the aforementioned diseases. Due to 
overlapping function of the H4R in immunological responses with the H1R (cf. section 
1.2.2.1), dual H1R/H4R antagonists may offer additional benefit over monotherapy, 
particularly in the treatment of allergic reactions (Deml et al., 2009; Thurmond et al., 2008). 
Recent findings suggest that histamine is also an important modulator of biological 
processes such as cell proliferation, senescence and apoptosis via the H4R in malignant 
cells. Therefore, the H4R is considered as new drug target in the pharmacotherapy of cancer 
(Medina and Rivera, 2010). 
In the search for novel H4R antagonists or inverse agonists, the imidazole-containing H3R 
inverse agonist thioperamide has been identified as equipotent H4R inverse agonist and is 
until now a frequently used reference compound (Lim et al., 2005) (cf. Figure 1.12). 
However, the potential of H4R antagonists in the treatment of inflammatory diseases 
stimulated the search for selective H4R ligands. A high-throughput screening campaign 
resulted in the early identification of the indole carboxamide JNJ 7777120 (see Figure 1.14) 
as selective H4R antagonist (Jablonowski et al., 2003). JNJ 7777120 is reported as 
equipotent at the human, mouse and rat H4R (Thurmond et al., 2004), and served as 
standard antagonist for the investigation of the biological function of the H4R in animal 
models (Beermann et al., 2012a; Cowden et al., 2010; Deml et al., 2009; Dunford et al., 
2006; Morgan et al., 2007; Rossbach et al., 2009a; Rossbach et al., 2009b; Zampeli et al., 
2009). However, in vivo results of JNJ 7777120 must be interpreted with caution in view of 
partial agonistic activity at mouse and rat H4Rs, which have only low constitutive activity, in a 
GTPase assay (Schnell et al., 2011) and agonist-like beta-arrestin recruitment to the hH4R 
(Nijmeijer et al., 2012; Rosethorne and Charlton, 2011; Seifert et al., 2011). Meanwhile, other 
highly selective and potent H4R antagonists such as quinazolines (Smits et al., 2008) and 2-
aminopyrimidines (Cowart et al., 2008; Mowbray et al., 2011) have been developed (see 
Figure 1.14). 
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To further investigate the pathophysiological role of the H4R, selective agonists are of 
particular interest as pharmacological tools. Considering the high degree of sequence 
homology with the H3R, it is not surprising that the H4R is activated by numerous compounds 
which were originally designed as H3R agonists, and, consequently, contain an imidazole 
ring, for instance (R)-α-methylhistamine, Nα-methylhistamine and imetit (cf. Figure 1.13). The 
first ligand with improved selective H4R activation is OUP-16, a chiral tetrahydrofuran analog 
which was derived from imifuramine (Hashimoto et al., 2003). Thereafter, various compounds 
originally developed as H2R agonist, for example (4)5-methylhistamine (Lim et al., 2005) and 
the dimaprit analog VUF 8430 (Lim et al., 2006), turned out to be H4R agonists with about 
100- and 30-fold selectivity over the other HxR subtypes, respectively. Similarly, NG-
acetylated imidazolylpropylguanidine-type H2R agonists such as UR-AK24 (cf. Figure 1.11) 
were found to be more potent at the hH3R and hH4R. Modification of the NG-acyl groups in 
UR-AK24 resulted in potent nearly full H4R agonists such as UR-PI294, which possess 
improved selectivity over the hH1R and hH2R, but show residual activity at the hH3R (Igel et 
al., 2009b). Tritium labeling of the NG-propionyl group in UR-PI294 yielded a novel high 
affinity radioligand for the H3R and H4R (c.f. chapter 3 and 5) (Igel et al., 2009c). Aiming at 
improved selectivity for the H4R, the acylguanidine moiety was replaced by a non-basic 
cyanoguanidine group. Further structural optimization provided highly potent and selective 
cyanoguanidine-type H4R agonists such as UR-PI376 and trans-(+)-(1S,3S)-UR-RG98 
(Geyer, 2011; Igel et al., 2009a) (see Figure 1.15). Other recently reported structural classes 
comprising selective H4R agonists are oxime analogs of JNJ 7777120 (Yu et al., 2010) and 
2-arylbenzimidazoles (Lee-Dutra et al., 2006). Of importance are the oxime-type compounds, 
especially owing to their applicability as pharmacological tools for investigating the H4R in 
rodent animal models. Other H4R agonists (and antagonists) are often unsuitable due to 
species-dependent discrepancies, including potencies, receptor selectivities and even 
opposite qualities of action (Esbenshade et al., 2003; Igel et al., 2010; Strasser et al., 2013). 
Figure 1.14: Structures of selected H4R antagonists. 
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Figure 1.15: Structure of selected H4R agonists. 
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The discovery of histamine H3 and H4 receptors has stimulated the evaluation of these 
GPCRs as potential drug targets for the treatment of a variety of diseases. This includes the 
identification and characterization of new compounds in terms of affinity, potency, quality of 
action (agonism or antagonism) and receptor subtype selectivity, preferably by simple, fast 
and robust binding and functional assays. Since translational animal models are 
indispensable for the investigations on the (patho)physiological role of the respective 
receptor of interest and for preclinical studies of potential clinical candidates, additionally, 
there is a great need for in vitro models to identify pharmacological differences between H3 
and H4 receptor species orthologs at an early stage of drug discovery and development. 
This thesis aims at the development of binding and functional assays for the hH4R, mH4R, 
rH4R, hH3R and rH3R. It is planned to establish radioligand binding assays using whole 
HEK293T cells for the determination of ligand affinities. Therefore, HEK293T cells are to be 
genetically engineered by the respective receptor cDNA to achieve stable expression of the 
receptor proteins. 
For the development of functional assays, the receptor expressing cells will be stably co-
transfected with a luciferase reporter gene, the transcription of which is under control of a 
cAMP responsive element (CRE). This ought to enable the quantification of the inhibitory 
effect on forskolin-stimulated adenylyl cyclase in response to H3R and H4R activation, since 
both receptors are coupling to Gαi/o proteins. The resulting luminescence signal should be 
detected by a luminescence plate reader, making the assay amenable to the 96-well format. 
Furthermore, HEK293T cells which only express the CRE-directed luciferase reporter gene 
will be established. These engineered cells will enable the identification of ligand-induced off-
target effects in control experiments and the use as “cellular building blocks” for the co-
transfection with further H3R and H4R species orthologs. 
For validation of the assays, a large panel of known H3R and H4R ligands including agonists, 
inverse agonists and antagonist will be investigated at optimized assay conditions and 
compared with data reported in literature. 
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3.1 Radioligand binding assay for the human histamine 
H4 receptor 
3.1.1 Introduction 
Since the cloning of the fourth histamine receptor (H4R) one decade ago by several research 
groups (Liu et al., 2001a; Morse et al., 2001; Nguyen et al., 2001; Oda et al., 2000; Zhu et 
al., 2001), various binding assays were established using [3H]histamine and disrupted 
cellular preparations such as cell membranes or homogenates of hH4R expressing SK-NMC 
cells (Kitbunnadaj et al., 2004; Lim et al., 2005; Liu et al., 2001a), HEK293 cells (Morse et al., 
2001; Nguyen et al., 2001) or Sf9 insect cells (Schneider and Seifert, 2009; Schnell et al., 
2011). 
The present work focused on radioligand binding assays using whole HEK293T cells, which 
were stably transfected with the hH4R (HEK293-SF-hH4R-His6). By performing receptor 
binding assays with intact cells, the receptor can be examined in a native environment, which 
is the most obvious advantage. So, for example, the gradients of pH or other ions that 
normally exist across the membrane remain intact as well as receptor associated 
components such as G-proteins, nucleotides and other modulators persist in their natural 
cytosolic environment (Bylund and Toews, 1993). Additionally, a whole cell binding assay 
allows a more direct comparison of binding properties with functional cell-based data (Bylund 
and Toews, 1993). What may be detrimental in the use of whole cells is the difficulty to 
control the assay conditions on the cytosolic side. The influence of the pH value, ion or 
especially GTP concentrations on the binding property cannot be investigated (Bylund and 
Toews, 1993). The HEK293T cell line is a widely used expression system for recombinant 
proteins. Furthermore, HEK293T cells are particular suitable for the expression of histamine 
receptors due to the lack of endogenous histamine receptor proteins (Mosandl, 2009). 
As radioactive tracer, the recently described high affinity histamine H3 and H4 receptor 
radioligand [3H]UR-PI294 (Igel et al., 2009c) was selected. Compared to the standard H4R 
radioligand [3H]histamine, [3H]UR-PI294 exhibits a high specific activity (78.5 Ci/mmol), which 
is required for an adequate signal, in particular, when the receptor density is low. However, it 
must be considered that the binding of [3H]UR-PI294, which acts, like [3H]histamine, as an 
agonist at the hH4R, could be influenced by G-protein coupling (Kenakin, 2009; Lazareno, 
2001), preference of only a portion of the receptor population (the high affinity state for 
GPCRs) (Bylund and Toews, 1993) or internalization. 
In conventional radiochemical assays, separation of bound from free radioligand is required. 
Standard procedures for this purpose in the case of whole cells are filtration and, less 
commonly, centrifugation. Compared to centrifugation, the filtration method, which was used 
 Introduction 43 
in this study, is of advantage due to faster and more efficient separation und thus lower 
nonspecific binding. However, the filtration is not suitable for low-affinity, rapidly dissociating 
radioligands with a dissociation constant (KD-value) > 10-8 M (Lazareno, 2001), since in the 
required washing step specifically bound radioligand could be flushed away. 
For the purpose of validation, a set of imidazoles and non-imidazoles, comprising agonists, 
inverse agonists and antagonists, was investigated in competition binding assays using 
HEK293-SF-hH4R-His6 cells. The tested substances included several compounds which 
were originally designed as H3R ligands and identified as H4R ligands after the discovery of 
the fourth histamine receptor. Affinity to both receptor subtypes is not surprising due to the 
high sequence homology of the H4R with the H3R (cf. section 1.2.2). 
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3.1.2 Materials and Methods 
3.1.2.1 Cell culture 
HEK293T cells (DSMZ, Braunschweig, Germany) were cultured in Dulbecco’s Modified 
Eagle Medium (DMEM) (Sigma, Munich, Germany) containing L-glutamine, 4500 mg/L 
glucose, 3.7 g/L NaHCO3 (Merck, Darmstadt, Germany), 110 mg/L sodium pyruvate (Serva, 
Heidelberg, Germany) and 10 % fetal calf serum (FCS) (Biochrom, Berlin, Germany). The 
HEK293T cells, stably expressing the FLAG epitope (F)- hexahistidine (His6)-tagged human 
H4 receptor (HEK293-SF-hH4R-His6; S stands for the cleavable signal peptide from influenza 
hemagglutinin), were kindly provided by Dr. David Schnell (Department of Pharmacology and 
Toxicology, University of Regensburg, Germany) and cultured in the above-mentioned 
medium with the addition of 600 µg/mL Geneticin (G418) (Biochrom). Cells were maintained 
at 37 °C and 5 % CO2 in water saturated atmosphere in 75-cm2 culture flasks (Sarstedt, 
Nümbrecht, Germany) and diluted twice a week 1:10 with fresh medium after 0.05 % trypsin / 
0.02 % EDTA treatment. The tenfold concentrate of trypsin / EDTA (PAA, Pasching, Austria) 
was diluted with phosphate buffered saline (PBS) (KCL 2.7 mM; KH2PO4 1.5 mM; NaCL 137 
mM; Na2HPO4 5.6 mM; NaH2PO4 1.1 mM in Millipore water, pH 7.4; all chemicals were from 
Merck, Darmstadt, Germany) and sterile filtered before use. 
3.1.2.2 Chemosensitivity assay 
In order to determine the sensitivity of HEK293T cells to G418, a chemosensitivity assay was 
performed as described previously (Bernhardt et al., 1992). Cells were seeded into flat-
bottomed 96-well plates (Greiner, Frickenhausen, Germany) at a density of 10 – 15 cells per 
microscope-field (320-fold magnification). After 48 h of incubation the medium was replaced 
by fresh medium containing various concentrations of G418. Wells without G418 served as 
control. At various time points the growth was stopped by fixation with glutardialdehyde 
(Merck). Subsequently, the cells were covered with PBS and the plates were stored at 4 °C. 
After simultaneous staining of the plates with an aqueous 0.02 % crystal violet solution 
(Serva), the excess of dye was removed by rinsing the plates three times with water. The 
amount of cell-bound crystal violet was determined by the addition of 70 % ethanol to the 
dried plates, followed by shaking for 2 -3 h and measurement of the absorbance at 580 nm 
using a GENios ProTM microplate reader (Tecan, Salzburg, Austria). 
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The effect of G418 on HEK293T cells were expressed as corrected T/C values according to 
்
஼ ܿ݋ݎݎሺ%ሻ ൌ
்ି஼బ
஼ି஼బ · 100  (equation 1), 
where T is the mean absorbance of the treated cells, C the mean absorbance of the controls 
and C0 the mean absorbance at the time when G418 was added (t = 0). 
If the absorbance of treated cells was less than the absorbance at t = 0 (cytocidal drug 
effect), the extend of killed cells was calculated as 
ܿݕݐ݋݈ܿ݅݀ܽ ݂݂݁݁ܿݐ ሺ%ሻ ൌ ்ି஼బ஼బ · 100  (equation 2). 
3.1.2.3 H4 receptor ligands 
For the validation of the binding assay, a set of imidazole-containing and non-imidazole 
reference ligands were used. Histamine (HA) (1) was purchased from Alfa Aesar (Karlsruhe, 
Germany). (R)-α-Methylhistamine (RAMH) (2), (S)-α-methylhistamine (SAMH) (3), Nα-methyl-
histamine (NAMH) (4), 5(4)-methylhistamine (5(4)MH) (5), immepip (IMMEP) (6), VUF 5681 
(7), immethridine (IMMET) (8), imetit (IME) (9), clobenpropit (CLOB) (10), iodophenpropit 
(IODO) (11), proxyfan (PRO) (13), ciproxifan (CIP) (14), clozapine (CLOZ) (18) and 
conessine (CON) (22) were from Tocris Bioscience (Ellisville, USA). Thioperamide (THIO) 
(12), UR-PI294 (15), UR-PI376 (16), trans-(+)-(1S,3S)-UR-RG98 (17), JNJ 7777120 (19), 
VUF 8430 (20) and JNJ 5207852 (21) were synthesized in our laboratory. Chemical 
structures of ligands are depicted in Figure 3.1. Except for 16, 17 and 18 all stock solutions 
(10 mM) were prepared in Millipore water. Stock solution of 18 was made in 20 mM HCl. 
Stock solutions of 17 and 18 were prepared in 50 % DMSO. The dilution series of the water 
dissolved ligands and 18 were prepared in Millipore water. The dilution series of 16 and 17 
were made in 10 % DMSO. 
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3.1.2.4 Whole cell radioligand binding assay 
With some modifications, the radioligand binding assay was performed as described 
previously (Mosandl, 2009). HEK293-SF-hH4R-His6 cells were seeded into 175-cm2 culture 
flasks until they reached 80 – 100 % confluency. After trypsinization, the cells were detached 
with Leibovitz’s L-15 medium without phenol red (Invitrogen, Karlsruhe, Germany) including 1 
% FCS and centrifuged for 10 min at 300 g. The supernatant was discarded and the cells 
were re-suspended in the aforementioned medium. After counting the cells in a 
hemocytometer, the cell density was adjusted to 2-3·106 cells/mL. 
As radioactive tracer [3H]UR-PI294 was used, which was synthesized in our laboratory (see 
Figure 3.2) (Igel et al., 2009c). For saturation binding experiments 160 µL of the 
aforementioned cell suspension was added into each cavity of a flat-bottomed 96-well plate 
(Greiner). To the wells, which were intended for the determination of specific binding, 20 µL 
of Millipore water were added, whereas 20 µL of an aqueous solution containing 100 µM of 
thioperamide (12) was added to the wells for the determination of non-specific binding. 
Samples were completed by addition of 20 µL of the respective [3H]UR-PI294 solution. All 
Figure 3.1: Structures of the examined ligands.  
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added solutions were tenfold concentrated compared to the final concentration. Samples 
were incubated under light protection and slight shaking for 90 min prior to harvesting. Cell-
bound radioactivity was separated from free radioactivity by filtration through a GF/C 
(Skatron Instruments, Sterling, USA) glass fiber filter pretreated with 0.3 % (v/v) 
polyethyleneimine (Sigma) solution and washed once with PBS (4 °C) using a Combi Cell 
Harvester 11025 (Skatron). Filter discs (with adhering cells) were punched out and 
transferred into 6 mL mini-vials (Sarstedt). Every vial was filled with 3 mL Rotiszint® eco plus 
(Carl Roth, Karlsruhe, Germany), shaken and incubated overnight. On the next day, 
radioactivity was determined by liquid scintillation counting using a LS 6500 Liquid 
Scintillation Counter (Beckman Coulter, Krefeld, Germany). Dpm (decays per minute) values 
of total and non-specific binding were processed with GraphPad Prism® 5.04 (GraphPad 
Software, San Diego (CA), USA). Specific binding was calculated by subtraction of non-
specific binding from the respective values for total binding. Values for total, non-specific and 
specific binding were plotted against the concentration of [3H]UR-PI294 and analyzed by 
nonlinear regression (GraphPad Prism®). The KD value (molar concentration of a radioligand 
required to occupy 50 % of the receptor population) of [3H]UR-PI294 is presented as the 
mean value ± SEM (standard error of the mean) of three independent experiments performed 
in triplicate. 
 
 
 
For competition binding assays, either 20 µL of a tenfold concentrated feed solution of the 
ligand of interest or 20 µL of the solvent (total binding) and 20 µL of a 50 nM [3H]UR-PI294 
solution were added to 160 µL of cell suspension. The following procedure was identical to 
that of the saturation binding experiments. Dpm values were converted to percentage values 
at which the total binding was set at 100 % and non-specific binding at 0 %. The percentage 
values were analyzed by nonlinear regression and best fitted to sigmoidal curve (GraphPad 
Prism®). 
IC50 values (molar concentration required to inhibit the radioligand binding by half) were 
converted to Ki values according to the Cheng-Prusoff equation 
  
 Figure 3.2: Structure of the radioligand [3H]UR-PI294. 
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ܭ௜ ൌ ூ஼ఱబ·௄ವሺ௄ವାሾ௅ሿሻ  (equation 3), 
where [L] represents the concentration of [3H]UR-PI294 used in the competition binding 
assay (Cheng and Prusoff, 1973). Ligand binding affinity is presented as mean pKi (negative 
decadic logarithm of the Ki value) value ± SEM from at least three independent experiments 
performed in duplicate. 
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3.1.3 Results and discussion 
3.1.3.1 Effect of Geneticin (G418) on HEK293T cells 
HEK293T cells have been extensively used as an expression tool for various recombinant 
proteins such as GPCRs. In literature the concentration of the antibiotic G418 used for the 
selection of transfected HEK293 cells range from 200 µg/mL (Lamb et al., 2001) to 1000 
µg/mL (Shyu et al., 1999). To ensure that the concentration of G418 is sufficient for selection, 
the sensitivity of HEK293T wild type cells was determined in a crystal violet chemosensitivity 
assay (see Figure 3.3). G418 exhibited a cytotoxic effect, i.e. the cells recovered after a first 
initial damage, at the two lowest concentrations 50 µg/mL and 100 µg/mL. The effect at 
concentrations between 300 µg/mL and 1000 µg/mL was cytocidal and almost identical. The 
cells died after an incubation period of three days at these concentrations. Therefore, a 
concentration of 600 µg/mL was chosen to maintain the selection pressure during the 
cultivation of transfected HEK293T cells. 
 
 
 
 
 
 
 
 
 
3.1.3.2 Saturation binding assay 
The radioligand [3H]UR-PI294 bound specifically and in a saturable manner to HEK293-SF-
hH4R-His6 cells. The non-specific binding, determined in the presence of thioperamide (12) 
(10 µM), was low (see Figure 3.4 A). The determined KD value of 7.5 ± 1.8 nM was in good 
agreement with data obtained in binding experiments using a membrane preparation of Sf9 
insect cells expressing the hH4R (Igel et al., 2009c). The corresponding Scatchard plot 
Figure 3.3: Effect of G418 on proliferating HEK293T cells. Crystal violet assay (mean values ± SD 
(n=16)). 
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analysis of the specific binding isotherm showed a linear correlation within the investigated 
concentration range indicating that the radioligand binds to a single binding site (see Figure 
3.4 B). 
  
 
3.1.3.3 Competition binding assay 
In competition binding experiments a set of imidazole containing and non-imidazole H4R 
ligands were investigated for their ability to inhibit specific binding of 5 nM [3H]UR-PI294 in 
HEK293-SF-hH4R-His6 cells. The obtained pKi values were compared with affinities reported 
from competition binding experiment using [3H]histamine or [3H]UR-PI294 and either 
membrane preparations or cell homogenates of hH4R expressing cells. The results are 
summarized in Table 3.1 and compared with data from literature. 
Histamine (1) and its methylated analogs (R)-α-methylhistamine (2), (S)-α-methylhistamine 
(3), Nα-methylhistamine (4) and 5(4)-methylhistamine (5) displaced [3H]UR-PI294 on 
HEK293-SF-hH4R-His6 cells in a concentration-dependent manner (see Figure 3.5). The 
introduction of a methyl group led to a decreased affinity at the hH4R, since histamine (1) (pKi 
value 7.22 ± 0.04) achieved a higher affinity than its analogs. Although the pKi values of 1-5 
were lower than described in literature, the rank order was identical to the reported order (1 > 
5 > 4 > 2 > 3) (see Figure 3.8), and the recently reported stereoselectivity of the hH4R for 
(R)-α-methylhistamine (2) (pKi = 5.75 ± 0.07) over (S)-α-methylhistamine (3) (pKi = 4.92 ± 
0.15) could be confirmed (Lim et al., 2005). 
Figure 3.4: Representative [3H]UR-PI294 saturation binding experiment, performed in triplicate, using
HEK293-SF-hH4R-His6 cells. Non-specific binding was determined in the presence of 10 µM of
thioperamide. Saturation binding curve, best fitted by nonlinear regression to a one-site model (A).
Corresponding Scatchard plot of saturation binding data, best fitted by linear regression (B). 
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Figure 3.5: Displacement of [3H]UR-PI294 by 
HA (1), RAMH (2), SAMH (3), NAMH (4) and 
5(4)MH (5) on HEK293-SF-hH4R-His6 cells. 
Reaction mixtures contained 5 nM [3H]UR-
PI294 and ligand concentrations indicated on 
the abscissa. Data were analyzed by nonlinear 
regression and best fittet to one-site 
(monophasic) competition curves. Data points 
are the mean of at least four independent 
experiments performed in duplicate. 
Immepip (6) and its pyridine analog immethridine (8) inhibited specific binding of [3H]UR-
PI294 with acceptable pKi values of 7.32 ± 0.11 and 6.90 ± 0.07, respectively (see Figure 
3.6). Interestingly, the extension of the spacer length by two carbon atoms between the 
imidazole and the piperidine ring in immepip (6), led to a significantly reduced affinity at the 
hH4R as shown by VUF 5681 (7) (see Figure 3.6). Lower affinity of VUF 5681 (7) compared 
to immepip (6) was determined at the hH3R as recently reported (Kitbunnadaj et al., 2005). 
While the affinity of immepip (6) was marginally lower than reported, the affinities of its 
analogs VUF 5681 (7) and immethridine (8) were in good correlation with reported data. 
 
Figure 3.6: Inhibition of [3H]UR-PI294 binding 
by IMMEP (6), VUF 5681 (7) and IMMET (8) 
on HEK293-SF-hH4R-His6 cells. Reaction 
mixtures contained 5 nM [3H]UR-PI294 and 
ligand concentrations indicated on the 
abscissa. Data were analyzed by nonlinear 
regression and best fittet to one-site 
(monophasic) competition curves. Data points 
are the mean of at least three independent 
experiments performed in duplicate. 
Imetit (9), the isothiourea analog of histamine (1), displayed a pKi value of 7.57 ± 0.12 at the 
hH4R. Clobenpropit (10) and iodophenpropit (11), which have an increased spacer length 
and a large lipophilic moiety in the side chain compared to imetit (9), exhibited considerable, 
but slightly lower affinities than imetit (9) at the hH4R. Although the pKi values were lower 
than described in literature, again, the rank order was in agreement with the reported order 
(9 > 10 > 11) (see Figure 3.8). The pKi value of the H3/4R inverse agonist thioperamide (12) 
(pKi = 6.68 ± 0.13) was in accordance to binding data described in literature. Further 
investigated ligands were proxyfan (13) and ciproxifan (14). The affinity of proxyfan (13) was 
only moderate and clearly lower than determined in competition binding assays using 
[3H]histamine on SK-N-MC/hH4R cell homogenates (see Table 3.1 and (Lim et al., 2005)). In 
-10 -9 -8 -7 -6 -5 -4
0
20
40
60
80
100
120
Log C (ligand, M)
[3
H
]U
R
-P
I2
94
 [%
]
HA (1)
RAMH (2)
SAMH (3)
NAMH (4)
5(4)MH (5)
-10 -9 -8 -7 -6 -5 -4
0
20
40
60
80
100
120
Log C (ligand, M)
[3
H
]U
R
-P
I2
94
 [%
]
IMMEP (6)
VUF 5681 (7)
IMMET (8)
52 Chapter 3 
-10 -9 -8 -7 -6 -5 -4
0
20
40
60
80
100
120
Log C (ligand, M)
[3
H
]U
R
-P
I2
94
 [%
] UR-PI294 (15)
UR-PI376 (16)
trans-(+)-(1S,3S)-UR-RG98 (17)
CLOZ (18)
JNJ 7777120 (19)
VUF8430 (20)
contrast, the affinity of ciproxifan (14) was low, but in good agreement with binding data 
determined in the aforementioned assay system (see Table 3.1 and (Zhao et al., 2008)). The 
recently described NG-acylated imidazolylpropylguanidine UR-PI294 (15 (Igel et al., 2009b), 
the cyanoguanidines UR-PI376 (16) and trans-(+)-(1S,3S)-UR-RG98 (17) (Geyer, 2011; Igel 
et al., 2009a) as well as the non-imidazoles clozapine (18), JNJ 7777120 (19) and VUF 8430 
(20) inhibited specific binding of [3H]UR-PI294 on HEK293-SF-hH4R-His6 cells (see Figure 
3.7). The pKi of UR-PI294 (15) (8.28 ± 0.07) was in good agreement with the pKD value of its 
tritiated analog (cf. section 3.1.3.2). The cyanoguanidine UR-PI376 (16) and its cyclopentyl 
analog trans-(+)-(1S,3S)-UR-RG98 (17) exhibited comparable affinity at the hH4R in 
competition binding assays (pKi = 7.10 ± 0.04 and pKi = 7.29 ± 0.05, respectively). Whereas 
the affinity of UR-PI376 (16) corresponded well to data determined in competition binding 
experiments using [3H]histamine on Sf9 insect cell membranes expressing the hH4R, the pKi 
value of trans-(+)-(1S,3S)-UR-RG98 (17) was slightly lower (see Table 3.1). 
 
 
 
 
 
 
The antipsychotic drug clozapine (18) revealed only low affinity at the hH4R, whereas the 
selective H4R antagonist JNJ 7777120 (19) bound with high affinity (pKi = 7.80 ± 0.16). With 
a pKi value of 6.78 ± 0.04, the dimaprit analog VUF8430 (20) reached moderate affinity at the 
hH4R. Whereas the affinity of JNJ 7777120 (19) was in good agreement with the reported 
data, the pKi-values of clozapine (18) and VUF8430 (20) were lower than described in 
literature (see Table 3.1). JNJ 5207852 (21) and the alkaloid conessine (22) were not able to 
inhibit specific binding of [3H]UR-PI294 to the hH4R. Both compounds, 21 and 22, were 
described as selective H3R ligands (see Table 3.1). 
Figure 3.7: Inhibition of [3H]UR-PI294 binding by UR-PI294 (15), UR-PI376 (16), trans-(+)-(1S,3S)-
UR-RG98 (17), CLOZ (18), JNJ 7777120 (19) and VUF 8430 (20) on HEK293-SF-hH4R-His6 cells.
Reaction mixtures contained 5 nM [3H]UR-PI294 and ligand concentrations indicated on the abscissa.
Data were analyzed by nonlinear regression and best fitted to one-site (monophasic) competition
curves. Data points are the mean of at least three independent experiments performed in duplicate. 
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Table 3.1: pKi values of reference H4R ligands determined in competitive binding experiments, using 
[3H]UR-PI294 and HEK293-SF-hH4R-His6 cells, in comparison to pKi values reported in literature.  
Ligand 
hH4R 
pKi N  pKi 
HEK293-SF-hH4R-His6   Reported 
Histamine (1) 7.22 ± 0.04 10  7.6-8.1e, j, l, m, p, r 
(R)-α-Methylhistamine (2) 5.75 ± 0.07 6  6.5-6.8f, j, l, m, r 
(S)-α-Methylhistamine (3) 4.92 ± 0.15 4  5.4-5.5j, m 
Nα-Methylhistamine (4) 5.94 ± 0.09 6  6.5-7.6j, m, r 
5(4)-Methylhistamine (5) 6.56 ± 0.14 4  7.3-7.7j, o 
Immepip (6) 7.32 ± 0.11 5  7.7-8.2i, j, l, r 
VUF 5681 (7) 6.20 ± 0.03 3  6.2g 
Immethridine (8) 6.90 ± 0.07 3  6.6h, j 
Imetit (9) 7.57 ± 0.12 3  7.8-8.6j, l, m, r 
Clobenpropit (10) 7.28 ± 0.13 3  7.7-8.1e, j, l, m 
Iodophenpropit (11) 7.11 ± 0.05 3  7.7-7.9j, r 
Thioperamide (12) 6.68 ± 0.13 4  6.3-7.6e, f, j, l, m, p, r 
Proxyfan (13) 6.58 ± 0.15 3  7.3j 
Ciproxifan (14) 5.60 ± 0.04 3  5.7q 
UR-PI294 (15) 8.28 ± 0.07 3  7.8o 
UR-PI376 (16) 7.10 ± 0.04 3  7.1-7.2d, o 
trans(+)UR-RG98 (17) 7.29 ± 0.05 3  7.7c 
Clozapine (18) 5.50 ± 0.04 3  5.9-6.7a, j, l, r 
JNJ 7777120 (19) 7.80 ± 0.16 5  7.5-8.4c, d, h, l 
VUF 8430 (20) 6.78 ± 0.04 3  7.5k 
JNJ 5207852 (21) < 4 1  < 5b 
Conessine (22) < 4 1  < 5q 
Mean values ± SEM. N: number of independent experiments performed in duplicate. Reference data 
taken from: [3H]histamine binding on Sf9 cell membranes a (Appl et al., 2011), d (Igel et al., 2009a), o 
(Schnell et al., 2011);  b (Barbier et al., 2004); [3H]UR-PI294 binding on Sf9 cell membranes c (Geyer, 
2011), e (Igel et al., 2009c); [3H]histamine binding on SK-N-MC cell membranes f (Jablonowski et al., 
2003), l (Liu et al., 2001a); [3H]histamine binding on SK-N-MC cell homogenates g (Kitbunnadaj et al., 
2003), h (Kitbunnadaj et al., 2004), I (Kitbunnadaj et al., 2005), j (Lim et al., 2005), k (Lim et al., 2006); 
[3H]histamine binding on HEK293 cell membranes m (Morse et al., 2001), p (van Rijn et al., 2006); q 
(Zhao et al., 2008); [3H]histamine binding on Cos-1 cell membranes r (Zhu et al., 2001). 
In summary, using whole HEK293-SF-hH4R-His6 cells and [3H]UR-PI294 as radioligand, 
binding data of H4R ligands could be determined in a highly reproducible manner. However, 
two tendencies were noticeable. Firstly, most pKi values of H4R agonists (1–6, 9-11, 13, 17, 
18, 20) were slightly to considerably lower, whereas all pKi values of antagonists (7, 12, 14, 
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19) were in agreement with or in the same range as those described in literature as shown in 
Figure 3.8 (see section 4.1.3.8 and (Lim et al., 2005) for the classification, whether a ligand 
is an agonist or antagonist at the hH4R). Only the H4R partial agonists immethridine (8), UR-
PI294 (15) and UR-PI376 (16) (intrinsic activities 0.5, 0.93 and 0.93) (Igel et al., 2009a; Igel 
et al., 2009b; Lim et al., 2005) showed equal or higher affinities in the whole cell radioligand 
binding assay. Secondly, the rank order of agonist affinity was in accordance with the 
reported affinities (see Figure 3.8) and the order of potency (cf. section 4.1.3.8); this is 
essential with respect to the pharmacological characterization of H4R agonists. 
 
A possible explanation for these tendencies could be the so called GTP-shift (Kenakin, 2009; 
Lazareno, 2001). In brief, the binding of an agonist to a GPCR is described by a two stage 
binding reaction, represented as 
ሾܣሿ ൅ ሾܴሿ
݇ଵ֎
݇ିଵ
ሾܣܴሿ ൅ ሾܩሿ
݇ଶ֎
݇ିଶ
ሾܣܴܩሿ  (equation 4). 
The agonist [A] binds to the receptor [R] with k1. The agonist-receptor complex [AR] binds 
subsequently due to the activation of the receptor to the G-protein [G] with the constant k2 
and forms the ternary complex [ARG], consisting of agonist, receptor and G-protein (cf. 
section 1.1.4.3). The formation of the ternary complex will drive the equilibrium to the right, 
i.e., the concentration of [AR] complex will be shifted in favor of [ARG]. Hence, all in all more 
agonist binds to the receptor and the observed affinity will be higher than in the absence of 
G-protein. Especially in assay systems allowing for accumulation of the ternary complex, high 
affinity binding can be observed. One crucial factor is the concentration of GTP (or GTPγS). 
Figure 3.8: Affinities of the examined H4R ligands 1-7, 9-14, 17-20 in whole cells (dark gray bars) and
reported data from broken cell preparations (light gray bars). Data are the mean values according to
table 3.1. Additionally, the span coverd by reported pKi values is given (“error bars”). Black arrows
indicate H4R antagonists for which the affinity was comparable to reported data. 
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In the presence of a high GTP concentration, as in whole cells, the formation of the ternary 
complex is followed promptly by the hydrolysis of GTP and the dissociation of the 
heterotrimeric G-protein into α- and βγ subunits (i.e. the ternary complex cannot accumulate). 
Since in broken-cell preparations, such as membranes or cell homogenates, the GTP 
concentration is low, the ternary complex can accumulate and two stage binding is observed. 
Due to the fact that in the referenced literature invariably broken-cell preparations were used 
to study H4R ligands, the GTP shift could be the reason for lower agonist affinities in whole 
cell radioligand binding assays. 
In contrast, for binding studies using membranes of Sf9 insect cells, co-expressing the hH4R 
+ Gαi2 +Gβ1γ2, a GTPγS resistant high affinity agonist binding hH4R state was assumed, 
since the presence of 10 µM GTPγS did not alter the KD value of [3H]histamine (Schneider et 
al., 2009). However, on the one hand, the KD value of [3H]histamine was not determined in 
this study, and, on the other hand, the influence of GTPγS on the affinity of agonists in 
competition binding experiments was not investigated with Sf9 cell membranes (Schneider et 
al., 2009). Therefore, comparison of the results with data from the literature, obtained under 
different conditions, is impossible.  
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3.2 Radioligand binding assay for the mouse histamine 
H4 receptor 
3.2.1 Introduction 
After cloning of the mouse (m) H4R, it became clear that the human and mouse H4R only 
share 68 % the amino acid sequence (Liu et al., 2001b), which causes substantial 
differences with respect to affinities (Lim et al., 2010; Liu et al., 2001b; Neumann et al., 2010; 
Schnell et al., 2011), potencies and efficacies of the pharmacological tools (Liu et al., 2001b; 
Schnell et al., 2011). Affinities were determined in binding assays using [3H]histamine on 
membrane preparations of HEK293T (Lim et al., 2010) or SK-NM-C cells (Liu et al., 2001b) 
expressing the mH4R. By contrast, no specific-binding of [3H]histamine was found on Sf9 cell 
membranes expressing the mH4R (Schnell et al., 2011). 
To evaluate species-dependent discrepancies regarding affinities of the pharmacological 
tools in a whole-cell radioligand binding assay, HEK293T cells were stably transfected with 
the mH4R. For this purpose the FLAG epitope (F)- and hexahistidine (His6)-tagged mH4R 
cDNA was subcloned into a mammalian expression vector, pcDNA3.1(+). The commercially 
available pcDNA3.1(+) vector (Invitrogen, Karlsruhe, Germany) contains an ampicillin 
resistance for the propagation of DNA in bacteria and a resistance gene against G418 for the 
selection of the transfected cells. Furthermore, the SV40 origin in the pcDNA3.1(+) vector 
together with the SV40 Large T-antigen in HEK293T cells allows episomal replication of the 
plasmid, which in turn leads to a amplification of the plasmid and extended temporal 
expression of the mH4R (DuBridge et al., 1987; Mahon, 2011; Pear et al., 1993). Stable 
transfection is preferred compared to transient transfection. Once a stable cell line is 
generated, ideally, a defined, constant quantity of the recombinant protein is expressed over 
a long period of time, affording reproducible results. 
The affinity of the standard mH4R radioligand [3H]histamine as well as of the putative mH4R 
ligand [3H]UR-PI294 were determined in saturation binding assay using HEK293-SF-mH4R-
His6 cells. Thereupon, the most suitable radioligand was chosen to evaluate the feasibility of 
performing competition binding experiments on the mH4R. 
For validation of the competition binding assay, a selection of standard H4R ligands was 
investigated for the ability to inhibit specific binding of the radioligand. Due to the need for 
ligands as pharmacological tools for the mH4R, the enantiomers of the 
imidazolylcyclopentylmethylcyanoguanidines UR-RG94 and UR-RG98 were additionally 
investigated in competition binding experiments. 
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3.2.2 Materials and methods 
3.2.2.1 Subcloning of the pcDNA3.1(+)SF-mH4R-His6 vector 
The FLAG epitope (F)- and hexahistidine (His6)-tagged mH4R cDNA cloned in pGEM-3Z 
(Schnell et al., 2011) was subcloned into a mammalian expression vector, pcDNA3.1(+) 
(including the tagged hH3R, was kindly provided by Dr. Schnell, University of Regensburg, 
Germany) , at HindIII and XbaI restriction sites. 
  
 
3.2.2.1.1 Restriction enzyme digestion 
The double digestion with HindIII (Fermentas GmbH, St. Leon-Rot, Germany) and XbaI 
(Fermentas) for a preparative agarose gel electrophoresis was performed in the reaction 
buffer TangoTM (Fermentas) with 2-fold excess of HindIII at 37 °C (recommendations of the 
manufacturer) for 3 h. The final volume of the enzyme restrictions digestion was 50 µL of 
Millipore water containing 5 µL of the 10x reaction buffer, 4 µL of the HindIII stock solution 
(10 U/µL), 2 µL of the XbaI (10 U/µL) stock solution and 3500 – 7000 ng of DNA. For the 
agarose gel electrophoresis 10 µL of the 6x gel loading buffer (Peqlab, Erlangen, Germany) 
were added to each sample to yield a final volume of 60 µL. 
Figure 3.9: Vector maps of pGEM-3Z and pcDNA3.1 (+/-) vectors (adopted from manuals provided by
Promega (Mannheim, Germany) and Invitrogen, respectively). 
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The restriction analysis at the HindIII and XbaI restrictions sites was performed with the 
enzymes HindIII-HFTM (New England Biolabs, Ipswich Massachusetts, USA) and XbaI (New 
England Biolabs) in the reaction buffer NEBuffer 4 with BSA (New England Biolabs) at 37 °C 
for 90 min. The final volume was 15 µL of Millipore water containing 1.5 µL of the 10x 
reaction buffer, 1 µL of HindIII-HFTM stock solution (20 U/µL), 1 µL of the XbaI stock solution 
(20 U/µL) (only for the double digestion) and 600 – 800 ng of DNA. For agarose gel 
electrophoresis 10 µL of the digestion, 3 µL of the 6x gel loading dye (New England Biolabs) 
and 5 µL of Millipore water were mixed to a final volume of 18 µL. 
3.2.2.1.2 Agarose gel electrophoresis, gel extraction and determination of DNA 
concentration 
For the preparation of the agarose gels 0.5 g of agarose (pegGOLD Universal-Agarose, 
Peqlab) were dissolved in 50 mL TAE buffer containing 40 mM tris-acetate (tris was from 
Pro-Lab, Hamburg, Germany; conc. acetic acid was from Merck) and 1 mM EDTA (Titriplex 
III; Merck) under heating and continuous stirring. 2 µL of an aqueous ethidium bromide 
solution (10 mg/mL; Janssen Chimica, Beerse, Belgium) were added and the warm agarose 
solution was poured into the gel chamber of the perfectBlueTM Mini S gel system (Peqlab). A 
comb served as placeholder for the wells. Prior to electrophoresis, the gel was covered with 
TAE buffer and the comb was carefully removed. The above mentioned digestion samples 
(see section 3.2.2.1.1) as well as 15 µL of the MassRulerTM DNA ladder mix (Fermentas), 
ready to use or 6 µL of 1kb DNA Ladder (New England Biolabs) were added into the wells of 
the gel.  
The preparative gel electrophoresis (150 V) was stopped after a period of 45 min and the 
analytical gel electrophoresis (90 V) after 75 min. The gels were analyzed by 
transillumination at 254 nm (Gel Doc 2000; Bio-Rad Laboratories, Munich) using the Quantity 
one software (Bio-Rad Laboratories).  
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The DNA bands of the SF-mH4R-His6 (1336 bp) (see Figure 3.10, lane A (very weak)) insert 
consisting of the cleavable signal peptide from influenza hemagglutinin (S), the FLAG 
epitope (F)- and hexahistidine (His6)-tagged mH4R as well as the empty and linearized 
pcDNA3.1(+) vector (5352 bp) (see Figure 3.10, lane B) were extracted from the agarose gel 
using the QIAquick Gel Extraction Kit (QIAGEN, Hilden, Germany) according to the 
manufactures protocol. The DNA was finally eluted with 50 µL of the buffer provided. 
The DNA concentration of a 1:20 dilution was determined with the BioPhotometer plus 
(Eppendorf, Hamburg, Germany) and the samples were stored at -20 °C until the ligation. 
3.2.2.1.3 Ligation of DNA fragments 
50 ng of the digested pcDNA3.1(+) vector, 62.4 ng of the digested SF-mH4R-His6 insert (5-
fold excess over the vector with regard to molar amounts) from section 3.2.2.1.2 and 2µL of a 
10x T4-DNA- ligase buffer stock solution (New England Biolabs) were filled up with Millipore 
water to 19.5 µL. After heating for 5 min at 45 °C, 1 µL of T4-DNA-Ligase (6 Weiss U/µL) 
(New England Biolabs) was added, and the completed sample was incubated at 15 °C 
overnight. On the next day, the ligase was inactivated by heating the sample for 10 min at 65 
°C. The sample was stored at -20 °C until transformation of competent bacteria. 
3.2.2.1.4 Preparation of media and agar plates 
For the preparation of LB medium, 10 g of bacto tryptone (Difco, Detroit, USA), 5 g of yeast 
extract (Roth) and 10 g of NaCl (Merck) were added to 800 mL of Millipore water. After 
Figure 3.10: Restriction analysis at HindIII and XbaI restriction sites. Digestion of pGEM-3Z-SF-
mH4R-His6 (A). Digestion of pcDNA3.1(+)-SF-hH3R-His6 (B). 1 kb DNA Ladder (New England Biolabs)
(M). 
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dissolving of the ingredients, the pH value was adjusted to 7.5 with NaOH solution (1 M) 
(Merck). The solution was filled up to 1000 mL with Millipore water and sterilized by 
autoclaving for 20 min at 121 °C. Selective LB medium was made by adding a sterile 
thousand-fold concentrated ampicillin (Sigma) solution (100 mg/mL). 
For the preparation of selective agar plates, 15 g of agar (Roth) were dissolved in 1 L LB 
medium under constant heating and stirring. After autoclaving, the solution was allowed to 
cool down to approx. 60 °C, before ampicillin was added, and plates were casted (approx. 20 
mL per plate). After cooling, selective plates were stored at 4 °C for 3 to 4 weeks. 
SOC medium was prepared by addition of 20 g bacto tryptone, 5 g of yeast extract, 0.5 g of 
NaCl, 2.5 mL of KCl (Merck) (1M), 10 mL MgCl2 (Merck) (1M) to 900 mL of Millipore water. 
After adjustment of the pH value to 7.0 with NaOH (1 M), the solution was filled up to 1000 
mL with Millipore water and autoclaved. Finally, 20 mL of glucose (Merck) (1 M) were added 
under sterile conditions.  
3.2.2.1.5 Transformation of competent E. coli 
Competent E. coli (TOP10 strain) cells were prepared according to a recently described 
method and stored at -80 °C (Mosandl, 2009). An aliquot of competent bacteria was carefully 
thawed and kept on ice for 10 min. For chemical transformation, 1 µL of the ligation reaction 
mixture (corresponds to approx. 2 ng of plasmid vector which was applied for ligation, see 
section 3.2.2.1.3) was added to 100 µL of the competent bacterial suspension prior to the 
incubation on ice for 30 min. Then, the suspension was heat-shocked at 42 °C for 90 s and 
cooled on ice for another 3 min. 900 µL of pre-warmed SOC medium were added, and the 
bacteria were incubated at 37 °C for 1 h under slight shaking (150 rpm). 
To ensure a sufficient quantity of colonies on the selective agar plates, the bacterial 
suspension was plated in two densities. For a low density, 100 µL of the suspension were 
streaked onto a pre-warmed selective agar plate. For a high bacterial density the residual 
800 µl were centrifuged for 5 min at 3000 rpm. Thereafter, 800 µL of the supernatant were 
discarded, and the bacterial pellet was re-suspended in the residual volume of 100 µL. The 
concentrated suspension was streaked on a pre-warmed selective agar plate. The plates 
were incubated overnight at 37 °C and stored at 4 °C up to 4 weeks. 
3.2.2.1.6 Preparation of glycerol cultures and plasmid DNA (Maxi-Prep) 
Some colonies were picked, and 5 mL of the selective LB medium containing ampicillin (100 
µg/mL) were inoculated with the bacteria in each case. The bacteria were incubated at 37 °C 
overnight under slight shaking (150 rpm). On the next day, 700 µL of the overnight cultures 
were transferred into a 1.5 mL reaction vessel (Eppendorf) containing 300 µL of a 50 % (v/v) 
glycerol solution. After a brief mixing, the glycerol culture was stored at -80 ° C. 
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One overnight culture was chosen in order to prepare the start culture for large scale 
preparation of plasmid DNA (Maxi-Prep). 200 µL of the overnight culture were added to 100 
mL of selective LB medium, and the bacteria were allowed to grow overnight at 37 °C and 
150 rpm. The following steps were performed using the Qiagen Plasmid Purification kit 
(Qiagen) according to the manufacturer’s instructions. The determination of DNA 
concentration was performed as described in section 3.2.2.1.2. 
3.2.2.1.7 Restriction analysis and sequencing of pcDNA3.1(+)SF-mH4R-His6 
The linearization of pcDNA3.1(+)SF-mH4R-His6 with the restriction enzyme HindIII resulted in 
the expected band with a length of 6688 bp (see Figure 3.11, lane A). The double digestion 
at HindIII and XbaI restriction sites gave two fragments with a length of 5352 and 1336 bp, 
respectively (see Figure 3.11, lane B), which corresponds to the pcDNA3.1(+) vector (5352 
bp), lacking an insert (cf. Figure 3.10, lane B) and the SF-mH4R-His6 insert (1336 bp, very 
weak) (cf. Figure 3.10, lane A). 
 
The sequencing of the pcDNA3.1(+)SF-mH4R-His6 vector (performed by Entelechon, Bad 
Abbach, Germany) confirmed correctness of the mammalian shuttle vector. 
Figure 3.11: Restriction analysis of pcDNA3.1(+)SF-mH4R-His6. Linearized vector at HindIII restriction
site (A). Double digestion with HindIII and XbaI (B). 1kb DNA Ladder (New England Biolabs) (M). 
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3.2.2.2 Stable transfection of HEK293T cells with the pcDNA3.1(+)SF-
mH4R-His6 vector 
HEK293T cells were cultured as described in section 3.1.2.1. One day before transfection, 
cells were detached with 5 mL of DMEM +10 % FCS from a densely grown 75-cm2 culture 
flask. The cell suspension was seeded dropwise at different densities into the cavities of a 
24-well-plate (Becton Dickinson, Heidelberg, Germany), so that 8 (2 vertical rows) wells 
contained the same number of cells. Approx. 500 µL DEMEM + 10 % FCS was added, and 
the cells were evenly distributed in the wells by gentle shaking. The next day, two rows with a 
confluency of 60 – 70 % were selected for transfection. The medium was carefully removed 
by suction and replaced by 475 µL of fresh DEMEM +10 % FCS. A few hours later, 100 µL of 
the transfection complex containing 2 µg of DNA and either 4 µL (ratio: 4:2) or 6 µL (ratio: 
6:2) of FuGene®HD (Roche Diagnostics GmbH, Mannheim, Germany) transfection reagent 
were prepared according to the manufactures protocol. 25 µL of the transfection complexes 
were each added to the wells, and the cells were incubated for 48 h. After short 
trypsinization, 4 wells (of ratio 4:2 and 6:2, respectively) were pooled in a 25-cm2 culture flask 
(Sarstedt) with DMEM + 10 % FCS. For selection, the medium was replaced after 24 h by 
DMEM + 10 % FCS containing 800 µg/mL G418. After another 72 h, the medium was again 
replaced by DMEM + 10 % FCS containing 600 µg/mL G418. At that time, the stable 
transfectants (HEK293-SF-mH4R-His6, 4:2 and 6:2 batches) had formed colonies in the 
selective medium, the extent of receptor expression was determined in a radioligand binding 
assay. 
3.2.2.3 Whole cell radioligand binding assay 
The preparation of the HEK293-SF-mH4R-His6 cells, the separation of bound from free 
radioligand and the data processing were performed as described in section 3.1.2.4. For 
selection of the transfectant with the higher expression level, specific binding of 50 nM 
[3H]UR-PI294 and 100 nM [3H]histamine (specific activity of 14.2 Ci/mmol; Perkin Elmer, 
Rodgau, Germany)  was determined. For the determination of non-specific binding 
thioperamide (12) (100 µM) was used. 
In saturation binding assays with [3H]UR-PI294 and [3H]histamine, non-specific binding was 
determined in the presence of JNJ 7777120 (19) at a final concentration of 10 µM. The KD 
value of [3H]UR-PI294 was calculated as means of two independent experiments performed 
in triplicate. In competition binding assays 50 nM [3H]UR-PI294 were used. The determined 
Ki values are given in Table 3.3 and Table 3.4. To save radioligand in saturation and 
competition binding experiments with [3H]UR-PI294, 50 % and 75 %, respectively, were 
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replaced by the unlabeled form, UR-PI294 (15). The dilution was feasible due to a high 
specific activity of [3H]UR-PI294 (78.5 Ci/mmol) (synthesized in our laboratory). 
3.2.2.4 Imidazolylcyclopentylmethylcyanoguanidines UR-RG94 and UR-
RG98 
The three stereoisomers of the (S,S)-configured phenylthioethyl-substituted cyanoguanidine 
UR-RG98 (cf. Figure 3.1, compound no. 17) and the stereoisomers of the methyl-substituted 
cyanoguanidine UR-RG94 were investigated for the ability to inhibit specific binding of 
[3H]UR-PI294 at the mH4R. Trans-(-)-(1R,3R)-UR-RG98 (23), cis-(-)-(1S,3R)-UR-RG98 (24), 
cis-(+)-(1R,3S)-UR-RG98 (25), trans-(-)-(1R,3R)-UR-RG94 (26), trans-(+)-(1S,3S)-UR-RG94 
(27), cis-(-)-(1S,3R)-UR-RG94 (28) and cis-(+)-(1R,3S)-UR-RG94 (29) were synthesized in 
our laboratory as described recently (Geyer, 2011). Chemical structures of the stereoisomers 
23-29 are depicted in Figure 3.12. All stock solutions (10 mM) were made in 50 % DMSO. 
The dilution series were prepared in 10 % DMSO. 
 
Figure 3.12: Structures of the stereoisomers of UR-RG98 (23-25, (S,S)-configured stereoisomer 17: 
cf. Figure 3.1) and UR-RG94 (26-29). The designation includes the relative and absolute configuration, 
the sign of optical rotation and the lab code according to Geyer (Geyer, 2011). 
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3.2.3 Results and discussion 
3.2.3.1 Selection of the transfected cells 
HEK293T cells were stably transfected with the pcDNA3.1(+)-SF-mH4R-His6 vector with two 
different ratios of transfection reagent volumes (µL) to DNA amount (µg), namely 4:2 and 6:2. 
For selection, the total-, non-specific- and the resulting specific binding of 50 nM [3H]UR-
PI294 and 100 nM [3H]histamine were determined (see Figure 3.13). Although the total 
binding of 50 nM [3H]UR-PI294 was nearly identical in the two transfection batches, the 6:2 
cells revealed a distinctly higher specific binding compared to the 4:2 cells (78 % vs. 43 %, 
relating to the total binding) as shown in Figure 3.13 A, B. Similarly, the specific binding of 
100 nM [3H]histamine was clearly higher in the 6:2 than in the 4:2 batch (see Figure 3.13 C, 
D). Moreover, the extent of specific binding (72 %) was in good agreement with the specific 
binding determined with [3H]UR-PI294 (Figure 3.13 B, D). In conclusion, the HEK293-SF-
mH4R-His6 6:2 cells were used for further radioligand binding studies. 
 
 
 
 
 
 
 
 
 
 
Figure 3.13: Selection of the HEK293-SF-mH4R-His6 transfection batches pertaining to specific
binding of radioligands. Total-, non-specific-, and specific binding of 50 nM [3H]UR-PI294 referring to
the 4:2 batch (A) and the 6:2 batch (B). Total-, non-specific-, and specific binding of 100 nM
[3H]histamine referring to the 4:2 batch (C) (the specific binding was negative, therefore it was
assumed to be zero) and the 6:2 batch (D). Non-specific binding was obtained in the presence of 100
µM of thioperamide (12). Shown are the mean values ± SEM. Each experiment was performed in
triplicate. 
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3.2.3.2 Saturation binding assays 
The binding of [3H]UR-PI294 was specific and saturable up to a concentration of 125 nM as 
shown for two independent saturation binding experiments in Figure 3.14. Since in initial 
saturation binding experiments the values for the non-specific binding strongly fluctuated 
using thioperamide (12) (data not shown), non specific binding was determined in the 
presence of JNJ 7777120 (19) (10 µM). The non-imidazole 19, which exhibited high affinity at 
the mH4R (Lim et al., 2010), was capable to keep non-specific binding sufficiently low (see 
Figure 3.14 ). [3H]UR-PI294 bound to the mH4R with a ten-fold lower affinity (KD = 75 ± 9 nM) 
than to the hH4R (see Table 3.2). This result was not unexpected, as previous studies 
revealed also a decrease in affinity for H4R ligands at the mH4R compared to the hH4R (Lim 
et al., 2010; Lim et al., 2008; Liu et al., 2001b; Schnell et al., 2011).  
  
 
Contrary to Sf9 insect cell membranes expressing the mH4R (Schnell et al., 2011), specific 
binding of [3H]histamine was detected on HEK293-SF-mH4R-His6 cells (see Figure 3.15). 
However, although the non-specific binding in the presence of JNJ 7777120 (19) (10 µM) 
seemed to be sufficiently low, the binding of [3H]histamine was apparently not saturable up to 
a concentration of 125 nM (see Figure 3.15). 
  
Figure 3.14: Representative [3H]UR-PI294 saturation binding experiments using HEK293-SF-mH4R-
His6 cells, each  performed in triplicate (A and B). Non-specific binding was determined in the
presence of 10 µM of JNJ 7777120 (19). Saturation binding curves, best fitted by non-linear
regression to a one-site model. 
0 25 50 75 100 125
0
500
1000
1500
2000
2500
3000
3500
4000
4500
non-specific binding
specific binding
total binding
[3H]UR-PI294 [nM]
dp
m
A
0 25 50 75 100 125
0
500
1000
1500
2000
2500
3000
3500
4000
4500
[3H]UR-PI294 [nM]
dp
m
B
66 Chapter 3 
 
 
 
 
 
 
Table 3.2: Results from saturation binding experiments with [3H]UR-PI294 at the mH4R and hH4R, 
using HEK293-SF-m/hH4R-His6 cells, in comparison with data reported in literature.  
Mean values ± SEM. N: number of independent experiments performed in duplicate; n.d.: not 
determinable. Reference data taken from: [3H]UR-PI294 binding on Sf9 cell membranes expressing 
the hH4R-RGS19 fusion protein a (Igel et al., 2009c); [3H]histamine binding on HEK293T cell 
membranes expressing the human and mouse H4R, respectively  b (Lim et al., 2010); [3H]histamine 
binding on SK-N-MC cell membranes stably expressing the human and mouse H4R, respectively c (Liu 
et al., 2001b); [3H]histamine binding on HEK293 cell membranes expressing the hH4R d (Morse et al., 
2001); [3H]histamine binding on Sf9 cell membranes expressing the hH4R-RGS19 fusion protein e 
(Schnell et al., 2011); [3H]histamine binding on Cos-1 cell membranes transiently expressing the hH4R 
f (Zhu et al., 2001). 
In summary, [3H]UR-PI294 revealed considerably lower affinity to the mH4R compared to the 
hH4R (see Table 3.2), limiting the explanatory power of binding studies. Since the specific 
binding of [3H]histamine to HEK293-SF-mH4R-His6 cells was not saturable, [3H]UR-PI294 
was chosen to perform competition binding studies at the mH4R. 
3.2.3.3 Competition binding assay 
The mH4R affinities of selected standard H4R ligands (1, 5, 10, 12, 18–20; cf. Figure 3.1) 
were determined in competition binding experiments. For this purpose, HEK293-SFmH4R-
His6 cells were co-incubated with 50 nM of [3H]UR-PI294 and increasing ligand 
concentrations. For comparison, the determined pKi values and reported data from 
Radioligand 
mH4R hH4R 
KD [nM]  KD [nM] KD [nM]  KD [nM] 
HEK293-SF-mH4R-
His6 N reported 
HEK293-SF-hH4R-
His6 N reported 
[3H]UR-PI294 75 ± 9 2 - 7.5 ± 1.8 3 5.1
a 
[3H]Histamine n.d. 2 42-75b,c - - 9-18
b –f 
Figure 3.15: Representative non-saturable binding of [3H]histamine to HEK293-SF-mH4R-His6 cells.
Non-specific binding was determined in the presence of 10 µM of JNJ 7777120 (19). 
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competition binding experiments using [3H]histamine and homogenates of mH4R expressing 
SK-N-MC cells (Lim et al., 2010; Liu et al., 2001b) are summarized in Table 3.3. 
All tested H4R standard ligands were able to inhibit specific binding of [3H]UR-PI294 on 
HEK293-SF-mH4R-His6 cells in a concentration dependent manner (Figure 3.16, competition 
curves of compound 5-(4)-methylhistamine (5) and clozapine (18) are not shown). The pKi 
value of histamine (1) was in good accordance with the reported binding data. Interestingly, 
histamine (1) showed only a slight decrease in affinity at the mH4R compared to the hH4R (cf. 
Table 3.1). The determined affinity of 5-(4)-methylhistamine (5) was considerably lower than 
reported (see Table 3.3) and by one order of magnitude lower compared to the Ki value at 
the hH4R (cf. Table 3.1). Clobenpropit (10) displayed good affinity at the mH4R (pKi = 7.10 ± 
0.06), which was comparable with reported data. Furthermore, clobenpropit (10) bound with 
nearly the same affinity to both the mH4R and the hH4R (hH4R: pKi = 7.28 ± 0.13). 
Thioperamide (12) showed only moderate binding at the mH4R (pKi = 5.84 ± 0.32), whereas 
the reported affinity was about two orders of magnitude higher. The obvious low affinity of 
thioperamide (12) at the mH4R could be the reason why the use of 12 for the non-specific 
binding in section 3.2.3.2 failed. Clozapine (18) showed, as at the hH4R, also only moderate 
affinity at the mH4R (pKi = 5.18 ± 0.14), which was consistent with the reported affinity (see 
Table 3.3). JNJ 7777120 (19) displayed the highest affinity of all investigated ligands (pKi = 
7.40 ± 0.14) at the mH4R, and the decrease in affinity compared to the hH4R was very low 
(cf. Table 3.1). The pKi value at the mH4R reported by Lim et al. is even by one order of 
magnitude higher (Lim et al., 2010). VUF 8430 (20) bound only with a moderate affinity to the 
mH4R (pKi = 5.89 ± 0.14) and, similar to JNJ 7777120 (19), the affinity described in literature 
was significantly higher (see Table 3.3). 
 
Figure 3.16: Inhibition of [3H]UR-PI294 
binding by HA (1), CLOB (10), THIO (12), JNJ 
7777120 (19) and VUF 8430 (20) on HEK293-
SF-mH4R-His6 cells. Reaction mixtures 
contained 50 nM [3H]UR-PI294 and ligand 
concentrations indicated on the abscissa. Data 
were analyzed by nonlinear regression and 
best fitted to one-site (monophasic) 
competition curves. Data points are the mean 
of at least two independent experiments 
performed in duplicate. 
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Table 3.3: pKi values of reference H4R ligands determined in competitive binding experiments, using 
HEK293-SF-mH4R-His6 cells and [3H]UR-PI294, in comparison to pKi values reported in literature.  
Ligand 
mH4R 
pKi   pKi 
HEK293-SFmH4R-His6 N  Reported 
Histamine (1) 6.89 ± 0.14 2  7.1-7.4a, b 
5(4)-Methylhistamine (5) 5.49 ± 0.46 2  6.8a 
Clobenpropit (10) 7.10 ± 0.06 2  7.3-7.8a, b 
Thioperamide (12) 5.84 ± 0.32 3  7.6a, b 
Clozapine (18) 5.18 ± 0.14 2  5.5a, b 
JNJ 7777120 (19) 7.40 ± 0.14 3  8.4a 
VUF 8430 (20) 5.89 ± 0.14 2  6.7a 
Mean values ± SEM. N: number of independent experiments performed in duplicate. Data taken from: 
[3H]histamine binding on HEK293T cell membranes  a (Lim et al., 2010); [3H]histamine binding on SK-
N-MC cell membranes b (Liu et al., 2001b). 
Additionally, UR-PI294 (15), UR-PI376 (16) and the stereoisomers of UR-RG98 (17, 23 -25) 
as well as of UR-RG94 (26-29) (cf. Figure 3.1 and Figure 3.12) were investigated in 
displacement studies using [3H]UR-PI294 and HEK293-SF-hH4R-His6 cells. The results are 
summarized in Table 3.4. 
UR-PI294 (15), UR-PI376 (16) and trans-(+)-(1S,3S)-UR-RG98) (17) displaced [3H]UR-PI294 
from the mH4R, however, with lower pKi values in comparison to the hH4R (see Figure 3.17, 
cf. Table 3.1). UR-PI294 (15) revealed a ten-fold lower affinity at the mH4R (pKi = 7.23 ± 
0.08), which was consistent with the KD value of [3H]UR-PI294 at the mH4R (cf. Table 3.2). 
UR-PI376 (16) showed a decreased affinity at the mH4R (pKi = 6.54 ± 0.13) compared to the 
hH4R (pKi = 7.10 ± 0.04); this was expected due to the results from steady state [33P]GTPase 
assay using Sf9 insect cell membranes either expressing the hH4R or the mH4R (Schnell et 
al., 2011). A marked difference between the human and mouse H4R orthologs was observed 
for trans-(+)-(1S,3S)-UR-RG98) (17), which bound to the mH4R with a ten-fold lower affinity 
(cf. Table 3.1). Interestingly, the pKi value (5.94 ± 0.35) of trans-(-)-(1R,3R)-UR-RG98 (23) at 
the mH4R was the same as that reported for the hH4R (Geyer, 2011). cis-(-)-(1S,3R)-UR-
RG98 (24) and cis-(+)-(1R,3S)-UR-RG98 (25) (see Figure 3.17) displayed the same affinity 
at the mH4R, whereas the hH4R was found to prefer 25 as recently reported (Geyer, 2011). 
Among the methyl-substituted cyanoguandines 26-29, cis-(+)-(1R,3S)-UR-RG94 (29) had the 
highest affinity (pKi = 6.43 ± 0.02), whereas cis-(-)-(1S,3R)-UR-RG94 (28) showed no 
noteworthy binding at the mH4R (see Table 3.4). The mH4R affinities of trans-(-)-(1R,3R)-UR-
RG94 (26) as well as of trans-(+)-(1S,3S)-UR-RG94 (27) were very low (pKi = 5.15 ± 0.00 
and pKi = 4.57 ± 0.53, respectively). The affinity of 27 at the mH4R was about two orders of 
magnitude lower compared to the hH4R (Geyer, 2011). 
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Table 3.4: pKi values of guanidine-type H4R ligands determined in competitive binding experiments 
using HEK293-SF-mH4R-His6 cells and [3H]UR-PI294 as radioligand.  
Ligand 
mH4R 
pKi N 
HEK293-SF-mH4R-His6 
UR-PI294 (15) 7.23 ± 0.08 2 
UR-PI376 (16) 6.54 ± 0.13 2 
trans-(+)-(1S,3S)-UR-RG98 (17) 6.27 ± 0.05 2 
trans-(-)-(1R,3R)- UR-RG98 (23) 5.94 ± 0.35 2 
cis-(-)-(1S,3R)-UR-RG98 (24) 6.07 ± 0.08 2 
cis-(+)-(1R,3S)-UR-RG98 (25) 6.02 ± 0.27 2 
trans-(-)-(1R,3R)-UR-RG94 (26) 5.15 ± 0.00 1 
trans-(+)-(1S,3S)-UR-RG94 (27) 4.57 ± 0.53 3 
cis-(-)-(1S,3R)-UR-RG94 (28) < 4 3 
cis-(+)-(1R,3S)-UR-RG94 (29) 6.43 ± 0.02 2 
Mean values ± SEM. N: number of independent experiments performed in duplicate. 
 
 
Figure 3.17: Inhibition of [3H]UR-PI294 binding by UR-PI294 (15), UR-PI376 (16), trans-(+)-(1S,3S)-
UR-RG98 (17) and cis-(+)-(1R,3S)-UR-RG98 (25) in HEK293-SF-mH4R-His6 cells. Reaction mixtures
contained 50 nM [3H]UR-PI294 and ligand concentrations indicated on the abscissa. Data were
analyzed by nonlinear regression and best fitted to one-site (monophasic) competition curves. Data
points are the mean of at least two independent experiments, each performed in duplicate. 
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3.3 Summary and Conclusion 
Stably transfected HEK293T cells are appropriate as expression tool for the human and 
mouse H4 receptor. By the treatment with 600 µg/mL of G418, HEK293-SF-h/mH4R-His6 cells 
expressed a defined and constant quantity of the recombinant protein for a long period of 
time. 
[3H]UR-PI294 bound with high affinity to the HEK293-SF-hH4R-his6 cells. In competition 
binding assays the affinity of standard H4R ligands was determined in a highly reproducible 
manner. However, not least by the investigation of a high number of diverse ligands, it was 
shown that the pKi values of almost every agonist at the hH4R was lower than reported in 
broken cell test systems, whereas the pKi values of every antagonist was either identical or in 
the same range as the reported data. The discrepancies between agonistic binding data may 
be caused by the so called GTP-shift, which can arise in intact cells due to high GTP 
concentration, contrary to broken cell preparations. 
After stable transfection of HEK293T cells with the tagged mH4R, specific binding of 
[3H]histamine as well as of [3H]UR-PI294 was detected in saturation binding experiments. 
However, binding of [3H]histamine appeared to be not saturable and [3H]UR-PI294 revealed 
a substantial decrease in affinity compared to the hH4R. Affinities of H4R ligands at the mH4R 
were determined by competition binding studies using whole HEK293-SF-mH4R-His6 cells 
and [3H]UR-PI294. However, although [3H]UR-PI294 exhibited high specific activity, the 
determination and interpretation of binding data proved to be difficult due to the relatively 
high KD value of 75 nM. This became obvious from comparison with the very reliable data 
from competition binding assays at the hH4R, which bind [3H]UR-PI294 with 10-fold higher 
affinity. A possible explanation could be a removal of specifically bound radioligand during 
the washing step, which can occur with low affine radioligands in the used filtration method 
(Lazareno, 2001). Furthermore, the need to apply 10-fold more radioligand in competition 
binding assays at the mH4R compared to the hH4R increases costs and the amount of 
radioactive waste. Nevertheless, the established binding assay at the mH4R with [3H]UR-
PI294 will be useful in the search for new pharmacological tools with higher affinity for the 
mH4R. 
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4.1 Development of a reporter gene assay for the human 
histamine H4 receptor 
4.1.1 Introduction 
A reporter gene assay provides a highly sensitive, reliable and convenient method for the 
measurement of functional response to Gαs, Gαi/o and Gαq coupled GPCRs (Tang et al., 
2004). Reporter gene assays are based on the modulation of transcriptions factors by 
GPCR-signaling. The binding of these factors to regulatory elements in the promoter region 
of a target gene causes an enhanced or repressed transcription rate of the gene. In the 
genetically engineered cells, used for a reporter gene assay, the transcription of the reporter 
gene is under control of a promoter capable of binding a specified transcription factor. The 
choice of the promoter is determined by the GPCR signaling pathway of interest (for detailed 
information on promoters and their suitability for the different signaling pathways see (Hill et 
al., 2001). For instance, the reporter gene encoding for luciferase is very often used, as the 
enzymatic activity of the gene product can be conveniently assayed in the cell lysate.  
The H4R is coupling to Gαi/o G-proteins which mediate inhibition of the adenylyl cyclase (AC), 
resulting in a decrease in cAMP formation. Therefore, in case of the H4R, the cAMP 
response element (CRE) has been used as the preferred promoter, for instance, to control β-
galactosidase gene transcription in SK-NM-C cells expressing the H4R (Lim et al., 2005; Liu 
et al., 2001a; Liu et al., 2001b). In order to detect a negative regulation of the AC, the 
reporter gene assay must be performed in the presence of the diterpene forskolin (see 
Figure 4.1), a direct stimulator of the AC (Seamon et al., 1981), to raise the cAMP level. 
A scheme showing the H4R signaling pathway monitored by a CRE-linked reporter gene is 
given in Figure 4.2 A. Agonist activation of the H4R decreases forskolin stimulated luciferase 
activity, reflecting the inhibitory quality of the Gαi/o protein. Inverse agonists shift the 
constitutively active receptors to an inactive conformation, which results in a lowering of the 
(constitutive) inhibition of the AC and, subsequently, in an increased forskolin stimulated 
luciferase activity. Since antagonists do not change the receptor state, the luciferase activity 
remains at the level of forskolin stimulation (see Figure 4.2 B). 
 
Figure 4.1: Chemical structure of the diterpene forskolin. O
O
OH
O
OH
H
OH
O
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Furthermore, two luciferase reporter gene assays in HEK293 cells were described, where the 
luciferase is under the control of a multiple response element (MRE)/ CRE (Zhu et al., 2001) 
or of a serum response element (SRE) (Jiang et al., 2008; Yu et al., 2010). In case of the 
latter, the H4R was co-expresssed along with the chimeric Gα-protein qi5-HA in order to 
redirect the H4R signaling to the Gαq-mediated mitogen-activated protein (MAP) kinase 
pathway, which in turn can activate the SRE. Additionally, the co-expression with the 
chimeric Gα-protein qi5-HA re-directed the H4R to an intracellular calcium response, which 
can be measured using the fluorimetric imaging plate reader (FLIPRTM) (Liu et al., 2001b; 
Morse et al., 2001; Strakhova et al., 2009; Zhu et al., 2001). More proximal functional assays 
for the H4R are the steady-state [33P]GTPase activity (Igel et al., 2009b; Schneider and 
Seifert, 2009) and the [35S]GTPγS assay binding assay (Geyer and Buschauer, 2011; Morse 
et al., 2001; Sander et al., 2009) on membrane preparations of Sf9 insect cells co-expressing 
the H4R  with the G-protein Gαi2 and Gβ1γ2 subunits. Furthermore, functional assays including 
chemotaxis and changes of cellular calcium levels in human eosinophils, endogenously 
expressing the hH4R, were described (Buckland et al., 2003; Ling et al., 2004; O'Reilly et al., 
2002; Reher et al., 2012). However, these assays are hampered by poor availability and an 
elaborate preparation of the human eosinophils (Reher et al., 2012). Another study used 
mouse mast cells, endogenously expressing the H4R, for the detection of H4R mediated 
chemotaxis and calcium mobilization (Hofstra et al., 2003). 
Figure 4.2: Schematic illustration of a CRE-controlled reporter gene assay. The adenylyl cyclase (AC)
is directly stimulated by forskolin to allow for the quantification of Gαi/o-mediated response. The AC
produces cAMP, which activates protein kinase A (PKA). The catalytic subunit of PKA gets into the
nucleus and phosphorylates a CRE binding protein (CREB), enabling this protein to bind to CRE in the
promoter of the reporter gene and to induce transcription (A). Activation of the Gi/o coupled H4R by
agonists results in inhibition of the AC and thus in a decreased transcription, whereas increased
transcription refers to inverse agonism. Forskolin-induced luciferase activity in cells in the absence of
H4R ligands serves as control (B).  
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The aim of this work was to develop a CRE-directed luciferase reporter gene assay in 
HEK293T cells, stably expressing the hH4R. As a distal readout, reporter gene assays are 
characterized by signal amplification between ligand binding and transcription. This may lead 
to increased agonist efficacy (George et al., 1997). Therefore, the reporter gene assay was 
validated by evaluating a set of H4R ligands (cf. section 3.1.2.3). The determined potencies 
and efficacies were, if possible, compared with results from a CRE-driven β-galactosidase 
reporter gene assay in SK-N-MC/hH4R cells (Lim et al., 2005) and with results from the 
(more proximal) functional assays on Sf9 cell membranes (Schnell et al., 2011; Wifling, 
2012). For the determination of possible non-H4R mediated ligand effects, HEK293T reporter 
gene cells were established, which stably express the CRE-directed luciferase reporter gene, 
but are devoid of the recombinant GPCR. This enables control experiments which may be 
necessary to exclude interferences with the signaling cascade caused by factors other than 
the GPCR of interest. For example, explicit evidence for an endogenous β2-adrenergic 
receptor in HEK293T cells, which was additionally active in a MRE (multiple response 
element)/CRE-directed luciferase reporter gene assay, was reported recently (Fitzgerald et 
al., 1999; Zhu et al., 2001). Furthermore, the engineered cells can be used as “building 
blocks”, since they are suitable for the transfection with every Gαi coupled GPCR of interest. 
This can lead to a tremendous saving of time in the development of the reporter gene assay 
as well as to improved comparability of functional data. Moreover, binding and reporter gene 
assays can be performed on the same cellular system. 
The concentration of forskolin used for pre-stimulation depends on the cell type (Williams, 
2004) and should correspond to the EC50 value of forskolin in the assay system (Rodrigues 
and McLoughlin, 2009). Therefore, the potency of forskolin was determined to optimize 
assay sensitivity. Furthermore, the use of the phosphodiesterase (PDE) inhibitor 3-isobutyl-1-
methylxanthine (IBMX) for stabilizing the cAMP level was evaluated. Due to the protracted 
gene transcription, incubation periods of at least 4 - 6 h are required (Hill et al., 2001). 
However, this raises the risk of agonist mediated receptor desensitization, which can lead to 
a decrease in agonist potencies (Hill et al., 2001): Therefore, the time course of the 
luciferase reporter gene transcription was determined to find the minimum incubation period 
required for appropriate signal strength. The luciferase enzyme from the American firefly 
Photinus pyralis catalyzes in a multistep reaction the formation of oxyluciferin from the 
natural substrate D-Luciferin, accompanied by emission of yellow/green light (560 nm) (see 
Figure 4.3). After injection of the substrate light is emitted, the intensity of which decreases 
during several seconds and reaches a plateau. The luciferase reaction is highly efficient, 
achieving high quantum yields for bioluminescence and a high signal-to-noise ratio, since 
cells or cell lysates normally do not emit interfering light (Bronstein et al., 1994; Shinde et al., 
2006). 
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Figure 4.3: Conversion of D-luciferin by firefly luciferase to oxyluciferin (according to (Shinde et al., 
2006)). 
In order to increase the throughput, the reporter gene assay was adapted to the 96-well 
format. Furthermore, all used buffers and solutions were self-made to keep the costs down.
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4.1.2 Materials and Methods 
4.1.2.1 Chemosensitivity assay 
To determine the sensitivity of HEK293-SF-hH4R-His6 cells to hygromycin B (A.G. Scientific, 
San Diego, USA) in the presence of 600 µg/mL of G418, a chemosensitivity assay was 
performed as described in section 3.1.2.2.  
4.1.2.2 Preparation of the pGL4.29[luc2P/CRE/Hygro] vector (Maxi-Prep) 
and sequencing 
The pGL4.29[luc2P/CRE/Hygro] vector (see Figure 4.4) was purchased from Promega, 
Mannheim, Germany. The preparation of media and agar plates was performed as described 
in section 3.2.2.1.4. The transformation of competent E. coli was carried out according to 
section 3.2.2.1.5. For glycerol culture and large scale preparation of plasmid DNA (Maxi-
Prep) cf. section 3.2.2.1.6. The determination of DNA concentration was performed as 
described in section 3.2.2.1.2. The sequencing (performed by Entelechon) of the DNA 
obtained from large scale preparation confirmed the identity of pGL4.29[luc2P/CRE/Hygro]. 
4.1.2.3 Stable transfection of HEK293-SF-hH4R-His6 cells with the 
pGL4.29[luc2P/CRE/Hygro] vector 
HEK293-SF-hH4R-His6 cells were cultured as described in section 3.1.2.1. The transfection 
was performed according to section 3.2.2.2. For an initial selection of the 4:2 and 6:2 
transfection mixture, the medium was replaced by DMEM containing 10 % FCS, 600 µg/mL 
 
Figure 4.4: Map of pGL4.29[luc2P/CRE/Hygro] 
vector (adopted from the manual provided by 
Promega). The luc2P gene, which encodes the 
luciferase, is under control of CRE. The 
hygromycin resistance (Hyg) enables the stable 
expression in mammalian cells, whereas 
ampicillin resistance (Amp) enables selection of 
transformed competent bacteria. 
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of G418 and 100 µg/mL of hygromycin B. After 72 h, the HEK293-SF-hH4R-His6-CRE-Luc 
cells were passaged and then maintained in DMEM containing 10 % FCS, 600 µg/mL of 
G418 and 200 µg/mL of hygromycin B. 
4.1.2.4 Stable transfection of HEK293T cells with the vector 
pGL4.29[luc2P/CRE/Hygro] 
Culture of HEK293T cells cf. section 3.1.2.1. The transfection was performed as described in 
section 3.2.2.2 with the exception that the ratios of transfection reagent (µL) to DNA amount 
(µg) were 6:2 and 8:2. The transfectants were selected and maintained in DMEM containing 
10 % FCS, 600 µg/mL of G418 and 200 µg/mL of hygromycin B. 
4.1.2.5 Luciferase reporter gene assay in the 24-well format 
The reporter gene assay was performed with some modifications as described recently 
(Mosandl, 2009). Approx. 0.5 – 1.0 · 105 HEK293-SF-hH4R-His6-CRE-Luc cells were seeded 
per cavity of a 24-well plate in DMEM supplemented with 10 % FCS and selection antibiotics 
(600 µg/mL of G418 and 200 µg/mL of hygromycin B). The cells were grown to 100 % 
confluency within 4 - 5 days at 5 % CO2 and 37 °C in a water saturated atmosphere. In order 
to start the assay, the medium was carefully removed by suction and replaced by 495 µL of 
fresh medium (same composition as described above) including histaminergic ligands. To 
determine the response to forskolin, medium without histaminergic ligands, containing 5 µL 
of a hundred-fold concentrated forskolin (Sigma) solution, prepared in 50 % (v/v) DMSO, was 
added for pre-stimulation of the AC. Forskolin-free wells served for the determination of the 
basal luciferase expression. After 5 h of incubation under the above mentioned culture 
conditions, the medium was removed again, and the cells were washed once with 500 µL of 
PBS. 100 µL of lysis buffer (Biotium, Hayward, USA) were added to each well, and the cells 
were lysed for 30 min under constant shaking (150 rpm). For the preparation of 
luminescence measurements, 20 µL of the lysate were transferred into luminometer tubes, 
and the luminometer Lumat LB 9501(Berthold Technologies, Bad Wildbad, Germany) was 
primed with a D-luciferin potassium salt (Synchem, Felsberg, Germany) solution (0.2 mg/mL) 
in luciferase assay buffer (Biotium). Light emission was induced by successive injection of 
100 µL of the D-luciferin solution into each luminometer tubes. The luminescence signal was 
measured for 10 s and expressed as relative light units [RLU]. For analysis, the basal RLUs 
were subtracted from each value and finally normalized to total protein content, which was 
quantified by Bradford’s protein assay. For this purpose 5 µL of the lysate were diluted with 
95 µL of Millipore water directly in a cuvette. The sample was finalized by adding 1 mL of the 
1:5 diluted Protein Assay Dye reagent Concentrate (Bio-Rad Laboratories) into the cuvette. 
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After mixing and incubating for 10 min, absorbance at 595 nm was determined by VIS 
spectroscopy. The protein amounts were calculated by means of a linear calibration curve 
determined with HSA (Behringwerke, Marburg, Germany). Finally, the data were analyzed by 
nonlinear regression and best fitted to sigmoidal concentration response curve. Each 
experiment was performed in triplicate. 
4.1.2.6 Luciferase reporter gene assay in the 96-well format 
4.1.2.6.1 Preparation of stock solutions, dilution series and buffers 
Forskolin stock solution was prepared in 100 % DMSO. All forskolin dilutions were freshly 
made in DMEM supplemented with 10 % FCS and either 1 % DMSO or 10 % DMSO. Dilution 
series of compounds 1–15 and 18–20 were prepared in DMEM supplemented with 10 % 
FCS, whereas dilution series of 16, 17 and 23–29 contained additionally 10 % DMSO. 
The lysis buffer was prepared as recently described (Memminger, 2009) and stored at 4 °C 
(see Table 4.1). The luciferase assay buffer was made as shown in Table 4.2 and stored at 
4 °C (Ma et al., 1998). Tricine (N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine), EGTA 
(ethyleneglycoltetraacetic acid), Gly-Gly (Glycyl-glycine), ATP (adenosin 5’-triphosphate 
disodium salt) and DTT (dithiotreitol) were from Sigma. Glycerol 87 %, MgSO4 · 7H2O and 
KH2PO4 were from Merck. TritonTM X-100 was from Serva. All stock solutions for the buffers 
were prepared in Millipore water, except for the D-Luciferin stock solution, which was made 
in 25 mM tricine (pH7.8) and 10 mM DTT. 
Table 4.1: Composition and preparation of the lysis buffer. 
Ingredient Stock concentration Stock solution Final concentration
Tricine 250 mM (pH 7.8)b 10 mL 25 mM 
Glycerol 87 % (v/v)a 11.15 mL 10 % (v/v) 
EGTA 0.1 M (pH 7.8)b 2 mL 2 mM 
TritonTM X-100 100 %a 1 mL 1 % (v/v) 
MgSO4 · 7H2O 0.5 Mb 1 mL 5 mM 
H2O  to final 100 mL  
 
Added directly before use to give a volume of 10 mL: 
DTT 1 Mc 10 µL 1 mM 
Storage temperature: a RT; b 4 - 8 °C; c -20 °C. 
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Table 4.2: Composition and preparation of the luciferase assay buffer. 
Ingredient Stock concentration Stock solution Final concentration 
Gly-Gly 1 Ma 12.5 mL 25 mM 
MgSO4 · 7H2O 1 Ma 7.5 mL 15 mM 
KH2PO4 1 M (pH 7.8)a 7.5 mL 15 mM 
EGTA 0.1 M (pH7.8)a 20 mL 4 mM 
H2O  to final 500 mL  
    
Added directly before use to 10 mL: 
ATP 100 mMb 200 µL 2 mM 
DTT 1 Mb 20 µL 2 mM 
D-Luciferin 10 mg/mL1, c  200 µL 0.2 mg/mL 
1 Stock solution was prepared in 25 mM of tricine (pH7.8) and 10 mM of DTT. 
Storage temperature: a 4 – 8 °C; b -20 °C; c -80 °C. 
4.1.2.6.2 Preparation of the cells 
A suspension of reporter gene cells (HEK293-SF-hH4R-His6-CRE-Luc or HEK293-CRE-Luc) 
in DEMEM + 10 % FCS (devoid of selection antibiotics) with a density of approx. 1.2 · 106 
cells/mL was prepared in a crystallization dish. In order to keep a homogenous distribution of 
the cells, the cell suspension was continuously stirred. 160 µL or 180 µL of the suspension 
were seeded per well on a flat-bottomed 96-well plate (Greiner). The cells were allowed to 
adhere during the following 17 h at 37 °C, 5 % CO2 and water saturated atmosphere.  
4.1.2.6.3 Determination of hH4R ligand activity 
20 µL of a H4R ligand solution and 20 µL of a forskolin solution (4 µM, 1 % DMSO) were 
successively added to 160 µL of cell culture medium per well (c.f. section 4.1.2.6.2) to a final 
volume of 200 µL. For assays performed in the agonist mode, only forskolin was added, 
whereas in the antagonist mode the forskolin solution was supplemented with 1 µM of 
histamine (1). All added solutions were diluted 1:10 within the assay. The cells were 
incubated for 5 h at 37 °C, 5 % CO2 and water saturated atmosphere. After measuring of the 
luminescence values (cf. section 4.1.2.6.7), the basal luciferase activity was subtracted from 
each value by Microsoft ® Office Excel 2007 before the data were transferred to GraphPad 
Prism® 5.04. EC50 values (molar concentration of agonist causing 50 % of the maximal 
response) and IC50 values (molar concentration required to reduce the agonist response by 
half) were analyzed by nonlinear regression and best fitted to sigmoidal concentration-
response curves in GraphPad Prism® 5.04. IC50 values were converted to KB values 
(dissociation constant of the antagonist-receptor complex) using the Cheng-Prussoff 
equation (Cheng and Prusoff, 1973) (see equation 3 in section 3.1.2.4). The intrinsic activity 
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of ligands was referred to the maximal response to histamine (1), defined as α = 1 (full 
agonist). Agonist potencies were represented as pEC50 values (negative decadic logarithm of 
the EC50 value) and antagonist affinities were given as pKB values (negative decadic 
logarithm of the KB value). Measured RLUs were converted to percental values referred to 
the span between the maximum effect induced by forskolin and the residual luciferase 
activity in the presence of histamine at the highest tested concentration. All presented data 
are mean values ± SEM of N independent experiments performed in triplicate. 
4.1.2.6.4 Determination of non-H4R-mediated ligand effects 
The procedure was the same as described in section 4.1.2.6.3, but “reporter gene cells” 
devoid of H4R, i. e. HEK293-CRE-Luc cells, were used. All RLUs were referred to the 
luciferase activity at 1 µM forskolin, which was used for pre-stimulation and set at 100 %. If 
non-H4R mediated effects were detected, the corresponding ligand concentrations were 
excluded from EC50 calculations. 
4.1.2.6.5 Determination of the optimal forskolin concentration 
20 µL of a tenfold concentrated forskolin solution (containing 10 % DMSO) were added to 
180 µL of cell culture medium per well (c.f. section 4.1.2.6.2). The cells were incubated for 5 
h at 37 °C and 5 % CO2 in a water saturated atmosphere. Forskolin was investigated at 
concentrations up to 10 µM to determine the EC50 value. For measurement of luminescence 
cf. 4.1.2.6.7, for data processing and EC50 calculation cf. section 4.1.2.6.3. On a percental 
scale, basal luciferase expression was defined as 0 % and the maximum forskolin effect at 
10 µM as 100 %. EC50 values are mean values of N independent experiments performed in 
triplicate. 
4.1.2.6.6 Monitoring the time course of luciferase expression 
20 µL of a forskolin solution (100 µM, 1% DMSO) were added to 180 µL of cell culture 
medium per well (c.f. section 4.1.2.6.2). The luciferase expression was stopped and 
luminescence was measured (cf. 4.1.2.6.7) after 0.0, 0.5, 1.0, 2.0, 3.0, 5.0, 8.0 and 24 h. The 
basal luciferase activity was subtracted from each signal, and the obtained values were 
plotted against the time. 
4.1.2.6.7 Measurement of luminescence with a microplate reader 
After incubation, the medium was discarded, the cells were washed once with 100 µL of PBS 
and lysed in 40 µL of lysis buffer under shaking (180 rpm) for 45 – 60 min. For luminescence 
measurement, 20 µL of each lysate was transferred into a white flat-bottomed 96-well plate 
(Greiner) and the GENios ProTM microplate reader (Tecan, Salzburg, Austria) was primed 
with the luciferase assay buffer. Light emission was induced by the injection of 80 µL of the 
luciferase assay buffer into each well. RLUs were measured for 10 s. 
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4.1.2.7 Aminopyrimidines 
ST-1006 (30) and ST-10012 (31) were kindly provided by Prof. Dr. Holger Stark (Institute of 
Pharmacy and Medicinal Chemistry, Johann Wolfgang Goethe University, Frankfurt am Main, 
Germany). Functional activities of the aminopyrimidines were investigated in the luciferase 
reporter gene assay. The stock solutions (10 mM) were made in 50 % DMSO. The solution 
series were prepared in DMEM supplemented with 10 % FCS and 10 % DMSO. 
 
 
 
 Figure 4.5: Chemical structures of ST-1006 and ST-1012. 
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4.1.3 Results and discussion 
4.1.3.1 Effect of hygromycin B on HEK293-SF-hH4R-His6 cells 
The pGL4.29[luc2P/CRE/Hygro] vector contains a resistance gene for hygromycin to allow 
for the selection of the transfected HEK293-SF-hH4R-His6 cells. In literature, the 
concentration of hygromycin B used for selection ranges from 100 µg/mL (Werthmann et al., 
2012) to 500 µg/mL (Eishingdrelo et al., 2011). In order to find the sufficient concentration of 
hygromycin B, a chemosensitivity assay was performed with HEK293-SF-hH4R-His6 cells. In 
addition to different concentrations of hygromycin B, the cells (including control) were 
permanently exposed to 600 µg/mL of G418 (see Figure 4.6). At 10 µg/mL of hygromycin B 
the cells recovered completely after initial impairement (cytotoxic effect). A concentration of 
50 µg/mL was also insufficient for selection, since the cells started to grow again after five 
days. However, the cells were fatally damaged at concentrations of 100 µg/mL to 400 µg/mL 
of hygromycin B after two days of incubation (cytocidal effect). Since the cytocidal effect at 
200 µg/mL and 400 µg/mL was almost equal and clearly higher than at 100 µg/mL, a 
concentration of 200 µg/mL of hygromycin B was chosen for the selection of the transfected 
HEK293-SF-hH4R-His6 cells. 
 
 
 
 
 
 
 
 
  
Figure 4.6: Cytotoxic effect of hygromycin B on proliferating HEK293-SF-hH4R-His6 cells in the
presence of 600 µg/mL of G418. Crystal violet assay (mean values ± SD (n = 16)). 
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4.1.3.2 Testing and selection of the HEK293-SF-hH4R-His6-CRE-Luc cells 
After transfection of the HEK293-SF-hH4R-His6 cells with pGL4.29[luc2P/CRE/Hygro], the 
transfectants (4:2 and 6:2 transfection batches) were evaluated regarding luciferase 
expression upon forskolin stimulation. As shown in Figure 4.7, forskolin activated AC and 
thus luciferase expression in HEK293-SF-hH4R-His6-CRE-Luc cells in a concentration 
dependent manner, i.e. the gene expression was under the control of the CRE. A difference 
between the two transfection batches was already observed at this time, since the maximum 
expression at 10 µM of forskolin at a DNA to fugene ratio of 6:2 was about five times higher 
than for the 4:2 batch. 
  
 
The next step was to test, if the activated AC was influenced by the Gαi/o coupled hH4R. For 
this purpose the cells were co-incubated with 100 nM of forskolin and either 100 µM of the 
endogenous full agonist histamine (1) or 100 µM of the inverse agonist thioperamide (12). 
Both transfection batches resulted in cellular systems enabling the detection of distinct hH4R 
mediated effects (see Figure 4.8). In the presence of histamine (1), the forskolin-induced 
stimulation of the AC was counteracted by hH4R-mediated Gαi/o activation and, thus, the 
transcription of the reporter gene was almost completely inhibited. By contrast, thioperamide 
(12) reduced the portion of constitutively active hH4Rs, resulting an additional stimulation of 
the AC and in an increased reporter gene expression. The pronounced forskolin effect in the 
6:2 cells became obvious again. In the present experiment the normalized 6:2 RLU values 
were about ten times higher compared to the 4:2 approach. Therefore, the 6:2 cells were 
preferred to perform the reporter gene assay with the hH4R. 
Figure 4.7: Stimulation of the luciferase expression by forskolin activated adenylyl cyclase in HEK293-
SF-hH4R-His6-CRE-Luc cells performed in 24-well format. 4:2 transfection batch (A). 6:2 transfection
batch (B). 
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4.1.3.3 Adaptation of the luciferase reporter gene assay to the 96-well 
format 
To keep the costs of the luciferase reporter gene assay down, all buffers and solution were 
home-made as described in section 4.1.2.6.1. The use of TritonTM X100 in the lysis buffer 
offered the advantage that the detergent increased the intensity and duration of the firefly 
luciferase-catalyzed reaction above the critical micelle concentration. The micelles are 
thought to sequester or separate the oxyluciferin product (cf. Figure 4.3), which otherwise 
inhibits the luciferase activity (Kricka and De Luca, 1982; Williams et al., 1989). 
In order to increase the throughput, the luciferase reporter gene assay was adapted to the 
96-well format. Firstly, to avoid a complete replacement of the medium at the beginning of 
the reporter gene assay (cf. section 4.1.2.5), the volume of the cell suspension was reduced 
to 160 µL and 180 µL. By addition of 20 µL of a tenfold feed solution (of forskolin and H4R 
ligands) each sample was finally filled up to 200 µL and the feed solution was diluted 1:10 
within the assay. Secondly, the need for normalization based on the protein content was 
evaluated. Usually, the protein determination according to Bradford was performed in single 
cuvettes, which promised no high throughput. Additionally, there was a serious interference 
of the detergent TritonTM X-100 in the lysis buffer with Bradford’s protein assay in the 
microplate format (data not shown). Potencies and intrinsic activities of histamine (1) and 
thioperamide (12) were determined with and without normalization to the total protein content 
of HEK293-hH4R-His6-CRE-Luc cells (see Figure 4.9). The cells were seeded two days prior 
the assay in a 96-well plate. The comparison of the normalized with the non-normalized 
pEC50 and α values showed no significant differences. The curves presenting the data as 
percental values were almost completely superimposable (see Figure 4.9). Therefore, the 
normalization of the luminescence values was omitted in subsequent reporter gene assays. 
However, in order to prevent noteworthy differences in cell number, the incubation of the 
Figure 4.8: Gαi/o-mediated hH4R response in the 4:2 transfection batch (A) and 6:2 transfection batch
(B). Effects of the agonist histamine (HA, 1) and the inverse agonist thioperamide (THIO, 12) upon
pre-stimulation by 100 nM of forskolin in HEK293-SF-hH4R-His6-CRE-Luc cells. 
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cells in the 96-well plate before the assay was shortened to 17 h. In the remaining incubation 
time the cells adhere to surface and do not markedly proliferate. 
 
 
Ligand 
hH4R 
With normalization 
 
Without 
normalization 
pEC50 α pEC50 α 
HA (1) 8.55 ± 0.40 1.00  8.45 ± 0.32 1.00 
THIO 
(12) 6.69 ± 0.27 -0.87  6.76 ± 0.21 -0.89 
 
The volume of the lysis buffer per well was reduced from 100 µL to 40 µL as well as the 
injection volume of the luciferase assay buffer from 100 µL to 80 µL, which contributes to the 
lower cell number. By analogy with the measurements unsing a luminometer, the RLUs were 
measured for 10 s with the microplate reader. 
4.1.3.4 Optimization of the period of incubation 
In literature, the incubation period for luciferase reporter gene assays ranges from 4 h (Kemp 
et al., 1999) to 8 h (Li et al., 2007). For optimization, the time course of the luciferase 
expression in HEK293-SF-hH4R-His6-CRE-Luc cells was investigated. Luciferase gene 
transcription was stimulated with 10 µM of forskolin, and the cells were lysed after various 
incubation periods as shown in Figure 4.10. After a latency period of 0.5 h, expression 
steeply increased until 5 h. The maximum was reached after a period of 8 h and sustained 
for a period of 24 h. Therefore, an incubation period of 5 h appeared to be sufficient, 
particularly as 88 % of the maximum expression was reached. Furthermore, longer 
incubation periods carry the risk of receptor desensitization by agonists. 
Figure 4.9: Representative reporter gene assay using a 96-well plate with histamine (HA, 1) and
thioperamide (THIO, 12) in HEK293-SF-hH4R-His6-CRE-Luc cells. The cells were seeded two days
prior to the assay. The luciferase expression was pre-stimulated with 500 nM of forskolin, and the
incubation time was 5 h. The response to forskolin was defined as 100 %. The luminescence values
were normalized according to section 4.1.2.5 or not before they were analyzed by nonlinear
regression and best fitted to sigmoidal concentration-response curves. The pEC50 values are the
means ± SEM of two independet experiments performed in triplicate.
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Figure 4.10: Representative time course of 
luciferase expression in HEK293-hH4R-His6-
CRE-Luc cells after the stimulation with 10 
µM of forskolin. Luciferase activity was 
determined after the indicated incubation 
periods (mean values ± SEM; n = 9). 
4.1.3.5 Optimization of pre-stimulation with forskolin 
In literature, the concentration of forskolin used in reporter gene assays for Gαi/o coupled 
GPCRs ranges from 500 nM (Kemp et al., 1999) to 10 µM (Liu et al., 2001a). To optimize 
assay performance, the pEC50 value of forskolin in the cAMP reporter gene assay system 
was determined (Rodrigues and McLoughlin, 2009). Furthermore, the use of the universal 
PDE inhibitor IBMX was evaluated. 
HEK293-SF-hH4R-His6-CRE-Luc cells were incubated with increasing forskolin 
concentrations (see Figure 4.11 A). Forskolin stimulated luciferase expression in a 
concentration dependent manner up to a concentration of 10 µM. High forskolin 
concentrations caused a decrease in luciferase expression as already described for several 
cell types expressing the luciferase gene reporter (George et al., 1997; Kemp et al., 2002; 
Stroop et al., 1995). To exclude the possibility that the effect arose from limited solubility of 
forskolin, the dilutions were freshly prepared for every assay. Furthermore, the wells were 
monitored in terms of the presence of forskolin precipitates during the assay by a light 
microscope. The cell viability was not apparently affected by forskolin, since the cell layer 
remained intact during the washing step. Therefore, intracellular mechanisms, like, for 
example, an alteration of the PDE activity may have caused the downturn. However, the 
decline of the concentration response curve was not prevented by co-incubation with 50 µM 
of the PDE inhibitor IBMX (see Figure 4.11 B). The curve was shifted to the left, so that the 
maximum was already reached at 3.2 µM, and the downturn started at 10 µM of forskolin. 
Further investigations by Kemp et al. showed that the activitation of the induceable cAMP 
early repressor (ICER) was responsible for the negative regulation of luciferase gene 
expression in CHO cells (Kemp et al., 2002), suggesting that also the activation of 
endogenous ICER’s provoked the downregulation in the present reporter gene assay in 
HEK293T cells. 
  
0 2 4 6 8 10 12
0
5.0106
1.0107
1.5107
2.0107
2.5107
22 24
Time [min]
Lu
ci
fe
ra
se
 a
ct
iv
ity
 [R
LU
]
 Results and discussion 91 
  
 
As the concentration-response curve shows an optimum, only the ascending part of the 
curve was considered up to a forskolin concentration of 10 µM (see Figure 4.12). The 
determined EC50 value of forskolin was 395 ± 44 nM with a Hill slope of 1.09 ± 0.15. 
Therefore, a concentration of 400 nM of forskolin was used for pre-stimulating the HEK293-
SF-hH4R-His6-CRE-Luc cells. 
In cAMP assays, the inhibition of the PDE with 50 µM of IBMX was necessary to stabilize the 
cAMP level (Geßele, 1998). In the presence of IBMX (50 µM) the concentration-response 
curve of forskolin on HEK293-SF-hH4R-His6-CRE-Luc-cells was shifted to the left, resulting in 
an EC50 value of 141 ± 21 nM (N = 3) with a Hill slope of 1.06 ± 0.20 (see Figure 4.12). 
Additionally, IBMX increased the receptor-independent luciferase activity by about a factor of 
four (data not shown). 
 
 
Forskolin Forskolin + 50 µM IBMX 
EC50 [nM] N EC50 [nM] N 
395 ± 44 6 141 ± 21 3 
 
Figure 4.12: Concentration response curves of forskolin on HEK293-SF-hH4R-His6-CRE-Luc cells.
Cells were incubated with the indicated concentrations of forskolin alone or in the presence of 50 µM
of IBMX. Data were analyzed by nonlinear regression and best fitted to sigmoidal concentration-
response curves. Data points shown are the mean ± SEM of N independent experiments performed in
triplicate. 
Figure 4.11: Forskolin-stimulated luciferase expression in HEK293-SF-hH4R-His6-CRE-Luc cells.
Representative “bell-shaped” concentration response curve (A). Representative concentration-
response curve in the presence of the PDE inhibitor IBMX, i.e.  forskolin solutions were supplemented
with 500 µM of IBMX (containing 15 % DMSO) (B). Data points are the mean values ± SEM of one
representative experiment performed in triplicate.
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In order to investigate the influence of IBMX on the concentration response curve of H4R 
ligands, a reporter gene assay was performed with the full hH4R agonist histamine (1) and 
the hH4R inverse agonist thioperamide (12). HEK293-SF-hH4R-His6-CRE-Luc cells were pre-
stimulated with 500 nM of forskolin in the absence and presence of 50 µM of IBMX (see 
Figure 4.13). The absolute effects of histamine (1) and thioperamide (12) and thus the 
signal-to-noise ratio were clearly reduced in the presence of IBMX. Furthermore, the α value 
of the inverse agonist thioperamide (12), referred to the maximal response of 1, decreased 
from -0.89 to -0.54. In the presence of IBMX, the potency of histamine (1) was clearly 
reduced, whereas the potency of thioperamide (12) was slightly increased. However, it 
should be noted that the standard error of the mean (SEM) for the pEC50 of thioperamide (12) 
value was very high, probably due to the low signal-to-noise ratio. Hence, IBMX was omitted 
from all subsequent experiments. However, if the use of a PDE inhibitor is indicated, the 
changed potency of forskolin must be considered in the respective assay system. In the case 
of the used HEK293-SF-hH4R-His6-CRE-Luc cells, the forskolin concentration could be 
reduced to 140 nM (cf. Figure 4.12). 
 
 
Ligand 
hH4R 
500 nM forskolin 
 
500 nM forskolin 
+ 50 µM IBMX 
pEC50 α pEC50 α 
HA (1) 8.45 ± 0.32 1.00  7.68 ± 0.13 1.00 
THIO 
(12) 6.76 ± 0.21 -0.89  7.03 ± 0.82 -0.54 
 
To account for positive α values in case of agonism and negative α values in case of inverse 
agonism, the signs of relative changes in luciferase activity were inverted. A illustraion is 
given in Figure 4.14. 
  
Figure 4.13: Reporter gene assay with histamine (HA, 1) and thioperamide (THIO, 12) in HEK293-SF-
hH4R-His6-CRE-Luc cells. Reaction mixtures contained ligands at the concentrations indicated on the
abscissa to achieve saturated concentration response curves. The cells were pre-stimulated with 500
nM of forskolin alone or in the presence of 50 µM of IBMX. The effect of forskolin or of forskolin plus
IBMX was defined as 100 % luciferase activity. Data were analyzed by nonlinear regression and best
fitted to sigmoidal concentration-response curves. Data points and pEC50 values are the mean ± SEM
of two independent experiments performed in triplicate. 
Log C (ligand, M)
%
 F
or
sk
ol
in
 s
tim
ul
at
ed
lu
ci
fe
ra
se
 a
ct
iv
ity
0
50
100
150
200
250
-9 -8 -7 -6 -5 -4
HA (1)
HA (1) (50 µM IBMX)
THIO (12)
THIO (12) (50 µM IBMX)
co
nt
ro
l
 Results and discussion 93 
Log C (ligand, M)
R
el
at
iv
e 
ch
an
ge
 in
lu
ci
fe
ra
se
 a
ct
iv
ity
-1.0
-0.5
0.0
0.5
1.0
-9 -8 -7 -6 -5 -4
full agonist
antagonist
"full" inverse agonist
co
nt
ro
l
forskolin (400 nM)
 
 
 
 
 
 
 
To conclude, the luciferase gene expression was stimulated by forskolin in a highly sensitive 
manner (cf. Figure 4.11 and Figure 4.12). As the concentration-response curve shows an 
optimum, only the ascending part of the curve was considered up to a forskolin concentration 
of 10 µM for the determination of the EC50 value. The decrease in luciferase expression at 
higher concentrations of forskolin may be interpreted a hint to endogenous cAMP dependent 
ICER activity in HEK293T cells. Pre-stimulation with 400 nM of forskolin turned out to be 
suitable to perform the reporter gene assay with HEK293-SF-hH4R-His6-CRE-Luc cells (cf. 
Figure 4.12). The use of the PDE inhibitor IBMX in combination with 500 nM of forskolin led 
to alteration in potencies, efficacies and the signal-to-noise ratio in the luciferase reorter gene 
assay with histamine (1) and thioperamide (12). Therefore, IBMX was omitted in subsequent 
experiments. 
4.1.3.6 Selection of the HEK293-CRE-Luc cells 
HEK293T cells were stably transfected with pGL4.29[luc2P/CRE/Hygro] using two different 
ratios of transfection reagent volume (µL) to DNA amount (µg), namely 6:2 and 8:2. For 
selection of the HEK293-CRE-Luc transfection batches, luciferase expression was induced 
by 10 µM of forskolin as shown in Figure 4.15 A. The maximum luciferase activity was 
satisfactory at both transfection batches. Nevertheless, the 6:2 cells were chosen for further 
investigations due to a slightly higher maximum. The concentration response curve of 
forskolin, which was constructed according to section 4.1.2.6.5, offered an EC50 value of 3.75 
± 0.96 µM with a Hill slope of 1.33 ± 0.17 in the HEK293-CRE-Luc 6:2 cells (see Figure 4.15 
B). Thus, the potency of forskolin was ten times lower in comparison to the HEK293-SF-
hH4R-His6-CRE-Luc cells, indicating a lower expression level of the CRE-controlled 
Figure 4.14: Illustration of agonistic and inverse agonistic effects in the cAMP reporter gene assay at
the H4R. As the luminescens signal is an inverse readout, maximum change of 1 indicates full
agonism, -1 is defined as “full” inverse agonism, whereas 0 indicates the luminescens signal detected
after direct stimulation of adenylyl cyclase by 400 nM forskolin in the absence of H4R ligands (control).
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luciferase in HEK293-CRE-Luc cells. However, 1 µM of forskolin turned out to be sufficient 
for the pre-stimulation in HEK293-CRE-Luc cells. 
  
 
According to section 4.1.2.6.6, the HEK293-CRE-Luc (6:2) cells were incubated with 10 µM 
of forskolin for the indicated period of time in order to investigate the time course of luciferase 
expression (see Figure 4.16). The time course was almost identical to that shown in Figure 
4.10 (section 4.1.3.4). After 5 h, 94 % of maximum luciferase expression was detected, 
whereas after 24 h of incubation luciferase activity was only approx. one third of the maximal 
value measured at 8 h. 
Figure 4.16: Time course of the luciferase 
expression in HEK293-CRE-Luc cells after 
stimulation with 10 µM of forskolin. The 
luciferase activity was determined after the 
indicated incubation periods (mean values ± 
SEM; n = 9). 
4.1.3.7 Off-target effects 
In control experiments, HEK293-CRE-Luc cells devoid of H4R expression were pre-
stimulated with 1 µM forskolin and co-incubated with selected compounds (see Figure 4.17). 
Changes in CRE-controlled luciferase activity result from off-target effects, presumably, 
Figure 4.15: Stimulation of the luciferase expression by forskolin in HEK293-CRE-Luc cells.
Stimulation of the cells from the 6:2 and 8:2 transfection batches by 10 µM of forskolin (mean values ±
SEM; n = 3) (A). Concentration response curve of forskolin in the 6:2 cells. Data were analyzed by
nonlinear regression and best fitted to sigmoidal concentration-response curves. Data points shown
are the mean ± SEM of six independent experiments performed in triplicate (B). 
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owing to their binding to (unknown) endogenously expressed GPCRs in HEK293T cells 
(Atwood et al., 2011). Therefore, these unintended activities were considered in the following 
reporter gene assays to avoid misinterpretation of biological responses at concentrations ≥10 
µM. 
 
 
 
 
 
 
 
 
4.1.3.8 Functional activities of histamine H4 receptor ligands at the 
human histamine H4R 
Binding studies were performed with HEK293T cells stably expressing the hH4R and [3H]UR-
PI294 as radioligand (cf. section 3.1.3.3). Additionally, the co-expression of a CRE-controlled 
luciferase reporter gene enabled the functional analysis of H4R ligands in HEK293-SF-hH4R-
His6-CRE-Luc cells. The endogenous H4R ligand histamine (1) inhibited forskolin (400 nM) 
stimulated luciferase gene transcription in the optimized reporter gene assay to an extent of 
79.6 ± 8.6 % (N = 6), promising a sufficient signal-to-noise ratio. Thioperamide (12), 
described as inverse agonist at the hH4R (Lim et al., 2005; Liu et al., 2001a; Morse et al., 
2001; Schnell et al., 2011), increased the forskolin-stimulated CRE activity by 17.0 ± 3.7 % 
(N = 6), indicating only moderate constitutive activity of the hH4R in HEK293-SF-hH4R-His6-
CRE-Luc cells. For the purpose of validation, a set of imidazole and non-imidazole ligands 
including agonists, inverse agonists and antagonists (cf. section 3.1.2.3, section 3.2.2.4, 
section 4.1.2.7), were investigated for their ability to change forskolin (400 nM) stimulated 
luciferase activity in HEK293-SF-hH4R-His6-CRE-Luc cells. The determined pEC50 values or 
pKB values were compared, as far as possible, with ligand activities from a CRE-driven β-
Figure 4.17: Off-target effects of selected ligands in a CRE-controlled luciferase reporter gene assay
in HEK293T cells. The effect of (1 µM) forskolin was defined as 100 % luciferase activity. Data are
means ± SEM of one representative experiment performed in triplicate. 
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galactosidase reporter gene assay in SK-N-MC-/hH4R cells (Kitbunnadaj et al., 2003; Lim et 
al., 2005) and with results from functional studies using more proximal readouts in G-protein 
mediated signal transduction, namely the functional [35S]GTPγS binding assay (Geyer, 2011; 
Sander et al., 2009; Wifling, 2012) and the steady-state [33P]GTPase activity assay (Sander 
et al., 2009; Schnell et al., 2011), which were both performed on a membrane preparation of 
Sf9 cells expressing the hH4R. The obtained results as well as the reported data are 
summarized in Table 4.3. 
Histamine (1) and its methylated analogs (R)-α-methylhistamine (2), (S)-α-methylhistamine 
(3), Nα-methylhistamine (4) and 5(4)-methylhistamine (5) inhibited forskolin stimulated 
luciferase activity in a concentration dependent manner in HEK293-SF-hH4R-His6-CRE-Luc 
cells and acted, with the exception of (S)-α-methylhistamine (3), as full agonists (see Figure 
4.18). 
 
 
 
 
 
 
 
Except for the potency of Nα-methylhistamine (4), which was higher than reported, both 
potencies and efficacies of 1–3 and 5 were in good agreement with reported data from a β-
galactosidase reporter gene assay using SK-N-MC/hH4R cells. Furthermore, the pEC50 value 
of histamine (1) was consistent with results from [33P]GTPase and [35S]GTPγS binding 
assays. Although, the pEC50 values were higher compared to the pKi values (cf. section 
3.1.3.3), the rank order of potencies and affinities (1 > 5 > 4 > 2 > 3) was identical, indicating 
a good correlation of binding and functional data in the hH4R expressing HEK293T cells. 
Contrary to the [35S]GTPγS binding assay, in which immepip (6) behaves as strong partial 
agonist (α = 0.81), 6 was able to fully activate the hH4R in the luciferase reporter gene assay 
Figure 4.18: Change in forskolin (400 nM) stimulated luciferase activity by HA (1), RAMH (2), SAMH
(3), NAMH (4) and 5(4)MH (5) in HEK293-SF-hH4R-His6-CRE-Luc cells. Maximum change of 1 is
defined as full agonism, whereas 0 indicates the luminescence signal detected after direct stimulation
of adenylyl cyclase by forskolin in the absence of H4R ligands (control). Data were analyzed by
nonlinear regression and best fitted to sigmoidal concentration-response curves. Data points shown
are mean values ± SEM of at least three independent experiments performed in triplicate. 
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(see Figure 4.19). Nevertheless, the pEC50 value of 7.64 ± 0.12 was in good agreement with 
reported data. Interestingly, VUF 5681 (7), having an extended spacer length compared to 
immepip (6), displayed no functional activity at the hH4R, which was consistent with 
functional data from literature (see Figure 4.19). In the antagonist mode, VUF 5681 (7) 
antagonized the histamine induced decrease in luciferase activity, resulting in a pKB value of 
6.16 ± 0.20, which was in accordance to its binding affinity (cf. section 3.1.3.3). Immethridine 
(8), the pyridine analog of immepip (6), acted only as partial agonist at the hH4R, which was 
in agreement with results from a β-galactosidase reporter gene assay (see Figure 4.19). 
 Figure 4.19: Potencies and efficacies of 
IMMEP (6), VUF 5681 (7) and IMMET (8) at 
the hH4R. Maximum change of 1 is defined as 
full agonism, whereas 0 indicates the 
luminescence signal detected after direct 
stimulation of adenylyl cyclase by 400 nM 
forskolin in the absence of H4R ligands 
(control). Data were analyzed by nonlinear 
regression and best fitted to sigmoidal 
concentration-response curves. Data points 
shown are mean values ± SEM of at least 
three independent experiments performed in 
triplicate. 
Since pronounced non-H4R mediated effects became obvious at 100 µM of clobenpropit (10), 
iodophenpropit (11) and thioperamide (12) in forskolin-stimulated HEK293-CRE-Luc cells, 
the respective RLU values were excluded from the EC50 calculations (see Figure 4.17 and 
Figure 4.20 B). 
Imetit (9), the isothiourea analog of histamine (1), was a potent and almost full agonist, which 
was consistent with recently reported results (see Figure 4.20 A). Clobenpropit (10) and 
iodophenpropit (11) are structurally related and can be considered as analogs of imetit (9) 
with an increased distance between the basic moieties and a large lipophilic group in the side 
chain. Interestingly, the intrinsic activity of both isothiourea-type compounds was clearly 
higher than described in literature. Clobenpropit (10) exerted almost full instead of partial 
agonistic activity (α = 0.45) in the [35S]GTPγS binding assay as reported. Most strikingly, 
iodophenpropit (11), described as antagonist (Lim et al., 2005), displayed strong partial 
agonistic activity with a pEC50 value of 7.30 ± 0.14 and an α value of 0.73 ± 0.02 (see Figure 
4.20 A). However, partial agonistic activity was also determined at 10 µM of iodophenpropit 
(11) in a Ca2+ mobilization assay in HEK293 cells, co-transfected with the hH4R and the 
chimeric G-protein Gqi5, which directed the H4R signaling to the Gq pathway (Zhu et al., 
2001). Thioperamide (12) revealed inverse agonist activity at the hH4R, and the pEC50 value 
was in accordance to other functional assays (see Figure 4.20 A). However, the constitutive 
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activity of thioperamide (12) was rather low compared to functional assays on Sf9 cell 
membranes. Moreover, the extent of detectable constitutive activity varied seriously between 
the different assay systems. The α values of thioperamide (12), which refer to the intrinsic 
activity of histamine (1) (α = 1), were -1.39, -0.95, -0.52 and -0.32 in the [35S]GTPγS binding 
assay, the steady state [33P]GTPase assay, the β-galactosidase reporter gene assay (the α 
value consists of the data for the inhibitory effect of histamine (1) (58 %) and the stimulatory 
effect of thioperamide (12) (130 %), c.f. (Lim et al., 2005)) and the present luciferase reporter 
gene assay, respectively. However, it should be noted that the extent of constitutive activity 
for thioperamide (12) was distinctly higher in initial reporter gene assays compared to later 
experiments performed after cryo conservation of the HEK293-SF-hH4R-His6-CRE-Luc cells 
in liquid nitrogen (cf. Figure 4.9 and Figure 4.13). 
  
 
In accordance with results from a β-galactosidase reporter gene assay in SK-NM-C/hH4R 
cells, proxyfan (13) showed partial agonistic activity at the hH4R with a pEC50 value of 6.93 ± 
0.06 (see Figure 4.21 A). Whereas H4R-independent (“off-target”) effects of proxyfan (13) 
were negligible at concentrations >10 µM, the structural analog ciproxifan (14) induced a 
strong increase (by up to 250 %) in luciferase activity at concentrations from 1 to 100 µM in 
HEK293-CRE-Luc cells devoid of H4R expression (see Figure 4.17 and Figure 4.21 B). This 
seriously hampered the pharmacological characterization of ciproxifan (14) in the luciferase 
reporter gene assay (see Figure 4.21). The stimulation of the luciferase activity possibly 
Figure 4.20: CRE-mediated response of IME (9), CLOB (10), IODO (11) and THIO (12). Potencies
and intrinsic activies at the hH4R in the luciferase reporter gene assay using HEK293-SF-hH4R-His6-
CRE-Luc cells. Maximum change of 1 indicates full agonism, -1 is defined as “full” inverse agonism,
whereas 0 indicates the luminescence signal detected after direct stimulation of adenylyl cyclase by
400 nM forskolin in the absence of H4R ligands (control). Data were analyzed by nonlinear regression
and best fitted to sigmoidal concentration-response curves. Data points shown are mean values ±
SEM of at least three independent experiments performed in triplicate (A). Non-specific effects in the
luciferase reporter gene assay using HEK293-CRE-Luc cells. Data are presented as percental change
in forskolin (1 µM) stimulated luciferase activity (100 %). Data shown are from one representative
experiment performed in triplicate (B). 
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resulted from interactions of ciproxifan (14) with endogenously expressed GPCRs in 
HEK293T cells. For example, a moderate affinity of ciproxifan (14) at the human α2a and α2c 
adrenergic receptors was recently demonstrated (Esbenshade et al., 2003b).  
  
 
The acylguanidine UR-PI294 (15) as well as the cyanoguanidines UR-PI376 (16), trans-(+)-
(1S,3S)-UR-RG98 (17), trans-(-)-(1R,3R)-UR-RG98 (23) and trans-(+)-(1S,3S)-UR-RG94 
(27) changed forskolin induced luciferase gene transcription in HEK293-SF-hH4R-His6-CRE-
Luc cells (see Figure 4.22). In agreement with data from the [33P]GTPase and the 
[35S]GTPγS binding assay, UR-PI294 (15) and UR-PI376 (16) proved to be full agonists, 
equipotent with histamine (1) (16) and approximately 10 times more potent (15) than the 
reference substance. Interestingly, trans-(+)-(1S,3S)-UR-RG98 (17) and trans-(+)-(1S,3S)-
UR-RG94 (27) were described as strong partial agonists with α values of 0.71 – 0.75 in the 
[35S]GTPγS binding assay, whereas both fully activated the hH4R in the luciferase reporter 
gene assay with pEC50 values of 7.65 ± 0.04 and 7.18 ± 0.04, respectively. The increase in 
intrinsic activity as an agonist became even more obvious in case of trans-(-)-(1R,3R)-UR-
RG98 (23), which was a weak neutral antagonist in the [35S]GTPγS binding assay and a 
moderately potent partial agonistic in the reporter gene assay with a pEC50 value of 6.26 ± 
0.11. Nevertheless, the recently described high agonistic potency of the eutomer trans-(+)-
(1S,3S)-UR-RG98 (17) and the stereodiscrimination between trans-(+)-(1S,3S)-UR-RG98 
Figure 4.21: Relative change of the CRE-activity by PRO (13) and CIP (14). Concentration response
curves in the luciferase reporter gene assay using HEK293-hH4R-His6-CRE-Luc cells. Maximum
change of 1 indicates full agonism, -1 is defined as “full” inverse agonism, whereas 0 indicates the
luminescence signal detected after direct stimulation of adenylyl cyclase by 400 nM forskolin in the
absence of H4R ligands (control). Data were analyzed by nonlinear regression and best fitted to
sigmoidal concentration-response curves. Data points shown are the mean values ± SEM of at least
three independent experiments performed in triplicate (A). Non-specific effects in the luciferase
reporter gene assay using HEK293-CRE-Luc cells. Data are represented as percentage change in
forskolin (1 µM) stimulated luciferase activity (100 %). Data shown are from one representative
experiment performed in triplicate (B). 
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(17) and trans-(-)-(1R,3R)-UR-RG98 (23) (Geyer, 2011) by the receptor was confirmed in the 
luciferase reporter gene assay. 
 
 
 
 
 
 
 
 
Besides the widely used non-imidazole H4R ligands clozapine (18), JNJ 7777120 (19) and 
VUF 8430 (20), two recently described aminopyrimidines, ST1006 (30) and ST1012 (31) 
(Sander et al., 2009), were investigated in the reporter gene assay as shown in Figure 4.23 
A. With a pEC50 value of 6.56 ± 0.09, clozapine (18) exhibited only moderate potency at the 
hH4R, which was in agreement with reported data. However, there are distinct discrepancies 
regarding the intrinsic activity of clozapine (18) in the different assay systems. While 
clozapine (18) acted as partial agonist in the systems using a proximal readout in G-protein 
signaling, the [33P]GTPase and the [35S]GTPγS binding assays, the hH4R was fully activated 
in the β-galactosidase reporter gene assay in SK-NM-C/hH4R cells. In the luciferase reporter 
gene assay, the maximal agonistic response of clozapine (18) surpassed that of histamine 
(1) by 40 %. Investigations with respect to non-H4R mediated effects revealed only a slight 
increase in CRE-activity at 100 µM (see Figure 4.17 and Figure 4.23 B), suggesting that the 
(super) agonistic effect of clozapine (18) was mediated by the hH4R. However, due to the 
pleiotropic character of clozapine, effects mediated by targets other than the H4R must be 
taken into account. The indole derivative JNJ 7777120 (19) has become the standard 
antagonist in laboratories working in the H4R field. In line with the reported data, JNJ 
7777120 (19) antagonized the histamine (1) response in HEK293-SF-hH4R-His6-CRE-Luc 
cells with a pKB value of 7.81 ± 0.19, which was in accordance with the binding data of 19 (cf. 
section 3.1.3.3). By analogy with ciproxifan, but much less pronounced, JNJ 7777120 (19) 
Figure 4.22: Potencies and efficacies of UR-PI294 (15), UR-PI376 (16), trans-(+)-(1S,3S)-UR-RG98
(17), trans-(-)-(1R,3R)-UR-RG98 (23) and trans-(+)-(1S,3S)-UR-RG94 (27) in HEK293-hH4R-His6-
CRE-Luc cells. Maximum change of 1 is defined as full agonism, whereas 0 indicates the
luminescence signal detected after direct stimulation of adenylyl cyclase by 400 nM forskolin in the
absence of H4R ligands (control). Data were analyzed by nonlinear regression and best fitted to
sigmoidal concentration-response curves. Data points shown are the mean values ± SEM of at least
four independent experiments performed in triplicate. 
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produced receptor-independent increases in luciferase activity at concentrations ≥10 µM in 
control experiments using cells devoid of H4R expression (see Figure 4.17 and Figure 4.23 
B). The corresponding values were therefore omitted in the construction of concentration-
response curves of JNJ 7777120 (19), when studied in the antagonist mode. In the 
[33P]GTPase and the [35S]GTPγS binding assay, JNJ 7777120 (19) showed partial inverse 
agonistic activity. In agreement with reported data, VUF 8430 (20) acted as full agonist at the 
hH4R with a pEC50 value of 7.04 ± 0.10. Contrary to [33P]GTPase and the [35S]GTPγS 
assays, surprisingly, ST 1006 (30) was an almost full agonist in the luciferase reporter gene 
assay with a slightly lower pEC50 value of 8.05 ± 0.05. The potency and intrinsic activity of ST 
1012 (31) were consistent with reported data.  
  
 
In summary, agonistic, inverse agonistic and and antagonistic activies at the hH4R were 
determined on genetically engineered HEK293 cells (HEK293-SF-hH4R-His6-CRE-Luc cells) 
co-expressing the hH4R and a CRE controlled luciferase reporter gene. The agonistic and 
inverse agonistic potencies of the examined H4R ligands were consistent with data from a β-
galactosidase reporter gene assay in SK-NM-C/hH4R cells as well as with data from 
[33P]GTPase and the [35S]GTPγS binding assays on hH4R expressing Sf9 cell membranes. 
Furthermore, the pKB values of neutral H4R antagonist versus histamine (1) in the reporter 
gene assay were in good agreement with antagonist affinities from competition binding 
assays (cf.section 3.1.3.3). However, differences in ligand efficacies became obvious 
Figure 4.23: CRE-mediated response of CLOZ (18), JNJ 7777120 (19), VUF 8430 (20), ST-1006 (30)
and ST-1012 (31). Potencies and intrinsic activies at the hH4R in the luciferase reporter gene assay
using HEK293-SF-hH4RHis6-CRE-Luc cells. Maximum change of 1 indicates full agonism, -1 is
defined as “full” inverse agonism, whereas 0 indicates the luminescence signal detected after direct
stimulation of adenylyl cyclase by 400 nM forskolin in the absence of H4R ligands (control). Data were
analyzed by nonlinear regression and best fitted to sigmoidal concentration-response curves. Data
points shown are the mean values ± SEM of at least three independent experiments performed in
triplicate (A). Non-specific effects in the luciferase reporter gene assay using HEK293-CRE-Luc cells.
Data are represented as percental change in forskolin (1 µM) stimulated luciferase activity (100 %).
Data shown are from one representative experiment performed in triplicate (B). 
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comparing assays based on proximal and distal readouts. Presumably, due to signal 
amplification in the second messenger cascade downstream from G-protein activation, 
several partial agonists turned out to be full agonists in the reporter gene assay. Most 
strikingly, iodophenpropit (11) and trans-(-)-(1R,3R)-UR-RG98 (23), which were previously 
described as neutral hH4R antagonist, acted as partial agonists in the luciferase reporter 
gene assay in HEK293-SF-hH4R-His6-CRE-Luc cells.  
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4.2 Development of a reporter gene assay for the mouse 
and rat histamine H4R 
4.2.1 Introduction 
The H4R is preferably expressed on cells of hematopoietic origin, such as eosinophils and 
mast cells, and thus supposed to be involved in inflammatory diseases like allergic asthma 
and pruritis (de Esch et al., 2005; Leurs et al., 2009; Leurs et al., 2011; Thurmond et al., 
2008; Zhang et al., 2007). To investigate the (patho)physiological role of the H4R, several 
studies used translational animal models like murine models for allergic asthma and allergic 
contact dermatitis (Beermann et al., 2012; Deml et al., 2009; Dunford et al., 2006; Morgan et 
al., 2007; Rossbach et al., 2009) or rat models such as carrageenan induced acute 
inflammation and conjunctivitis (Coruzzi et al., 2007; Zampeli et al., 2009). Although most of 
the studies confirmed the pro-inflammatory role of the H4R by blocking H4R-mediated 
response with the standard H4R antagonist JNJ 7777120, which is reported as equipotent at 
the human, mouse and rat H4R (Thurmond et al., 2004), there were also controversial 
reports: The administration of the selective H4R agonist 5(4)-methylhistamine was beneficial 
in a murine asthma model (Morgan et al., 2007), and JNJ 777120 increased the ocular 
histamine concentration in a rat conjunctivitis model (Zampeli et al., 2009) (for a recent 
review cf. Neumann et al. (Neumann et al., 2010)). Furthermore, in various in vitro assay 
systems, the recombinantly expressed mouse and rat H4R revealed substantial species-
dependent differences compared to the human receptor concerning affinity, potency and 
quality of action of pharmacological tools, compromising the predictive value with respect to 
translational animal models (Esbenshade et al., 2003a; Lim et al., 2010; Liu et al., 2001b; 
Schnell et al., 2011). For example, in comparison to the human H4R, the NG-acetylated 
imidazolylpropylguanidine UR-PI294 (Igel et al., 2009b) and the cyanoguanidine UR-PI376 
(Igel et al., 2009a) displayed considerably lower potencies and efficacies (UR-PI376) in the 
[33P]GTPase and [35S]GTPγS binding assays on membrane preparations of Sf9 insect cells 
expressing the mouse or the rat H4R (Schnell et al., 2011; Wifling, 2012). Most strikingly, JNJ 
7777120 exhibited stimulatory effects at the mouse and the rat H4R in functional assays on 
Sf9 cell membranes (Schnell et al., 2011). Moreover, the use of JNJ 7777120 as standard 
antagonist in animal models was questioned due to stimulation of G-protein independent β-
arrestin recruitment (Rosethorne and Charlton, 2011). Biased signaling of the hH4R has also 
been shown for other H4R ligands (Nijmeijer et al., 2012). 
The aforementioned controversial findings underline the necessity to evaluate 
pharmacological tools at the H4R species orthologs of interest using different assay systems. 
For this purpose, a CRE-controlled luciferase reporter gene assay in HEK293T cells, stably 
106 Chapter 4 
expressing the mouse or the rat H4R, was established. For validation, potencies and 
efficacies of a set of imidazole and non-imidazole H4R ligands, including agonists, inverse 
agonists and antagonists, were determined and, if possible, compared to results from the 
(more proximal) functional assays on Sf9 cell membranes. In order to find new 
pharmacological tools for the mouse and rat histamine H4R, the purified stereoisomers of the 
cyanoguanidines UR-RG98 and UR-RG94 (cf. section 3.1.2.3 and section 3.2.2.4) as well as 
two selected aminopyrimidines ST-1006 and ST-1012 (cf. section 4.1.2.7) were investigated 
in the cAMP sensitive reporter gene assay. 
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4.2.2 Material and Methods 
4.2.2.1 Stable transfection of HEK293-SF-mH4R-His6 cells with 
pGL4.29[luc2P/CRE/Hygro] 
HEK293-SF-mH4R-His6 cells were cultured according to section 3.1.2.1 and section 3.2.2.2. 
The transfection was performed according to section 3.2.2.2 with the exception that the ratios 
of transfection reagent (µL) to DNA amount (µg) were 6:2 and 8:2. The transfection batches 
were initially selected as well as maintained with DMEM containing 10 % FCS, 600 µg/mL of 
G418 and 200 µg/mL of hygromycin B.  
4.2.2.2 Preparation of the pcDNA3.1(+)-SF-rH4R-His6 vector and 
sequencing 
The pcDNA3.1(+)-SF-rH4R-His6 vector was kindly provided by Prof. Dr. Seifert (Institute of 
Pharmacology, Medical School of Hannover, Hannover, Germany). The preparation of media 
and agar plates were performed as described in section 3.2.2.1.4. The transformation of 
competent E. coli was conducted according to section 3.2.2.1.5. The subsequent glycerol 
culture and the large scale preparation of plasmid DNA (Maxi-Prep) was performed as 
described in section 3.2.2.1.6. The DNA concentration was determined according to section 
3.2.2.1.2. The sequencing (performed by Entelechon) of the large scale preparation product 
confirmed the right identity and composition of the SF-rH4R-His6 insert in pcDNA3.1(+). 
4.2.2.3 Stable transfection of HEK293-CRE-Luc cells with the 
pcDNA3.1(+)-SF-rH4R-His6 vector 
HEK293-CRE-Luc cells were cultured as described in section 3.1.2.1 and section 4.1.2.4. 
The transfection was performed according to section 3.2.2.2 with the exception that the ratios 
of transfection reagent (µL) to DNA amount (µg) were 6:2 and 8:2. The transfectants were 
initially selected with DMEM containing 10 % FCS, 800 µg/mL of G418 and 200 µg/mL of 
hygromycin. Subsequently, the HEK293-CRE-Luc-SF-rH4R-His6 cells were maintained in 
DMEM containing 10 % FCS, 600 µg/mL of G418 and 200 µg/mL of Hygromycin B. 
4.2.2.4 Luciferase reporter gene assay 
For the implementation see section 4.1.2.6. The KB values of neutral antagonists / inverse 
agonists were determined in the antagonist mode at the mH4R and rH4R versus histamine 
(150 and 1000 nM, respectively) as the agonist. 
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4.2.3 Results and discussion 
4.2.3.1 Selection of the HEK293-SF-mH4R-His6-CRE-Luc transfectants 
In order to investigate H4R ligand activity at the mH4R in the luciferase reporter gene assay, 
the HEK293-SF-mH4R-His6 cells were stably transfected with the pGL4.29[luc2P/CRE/Hygro] 
vector at two different ratios of transfection reagent (µL) to DNA amount (µg), namely 6:2 and 
8:2. For comparison of the two transfection batches, the effect of histamine (1) (100 µM) and 
thioperamide (12) (100 µM) on forskolin (1µM) stimulated luciferase activity was determined 
(see Figure 4.24). In the 6:2 and the 8:2 cells the luciferase gene transcription was clearly 
induced by forskolin, indicating a successful transfection with the CRE controlled luciferase 
gene. Furthermore, histamine (1) gave an appropriate response by the activation of the Gαi/o-
coupled mH4R. Thioperamide (12) acted as inverse agonist at the hH4R (cf. 4.1.3.8) and 
increased the forskolin stimulated luciferase activity in the 8:2 transfectants by 24 %. 
However, off-target effects of thioperamide (12) at 100 µM on HEK293-CRE-Luc cells must 
be taken into account (cf. section 4.1.3.7 and 4.1.3.8). Although both transfection baches 
gave appropriate cellular systems for performing a luciferase reporter gene assay, the 8:2 
cells were chosen for further assays due to the pronounced effect of histamine (1) (see 
Figure 4.24). 
  
 
Forskolin concentration dependently increased the luciferase activity in HEK293-SF-mH4R-
His6-CRE-Luc (6:2). An EC50 value of 1.14 ± 0.10 µM with a Hill slope of 1.43 ± 0.16 was 
determined (see Figure 4.25). Therefore, pre-stimulation with 1 µM of forskolin was 
considered appropriate. 
Figure 4.24: Testing of Gαi/o-mediated mH4R response. The effect of 100 µM of the agonist HA (1)
and the inverse agonist THIO (12) upon pre-stimulation by 1 µM of forskolin in HEK293-SF-mH4R-
His6-CRE-Luc cells. 6:2 transfection (A). 8:2 transfection batch (B). 
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Determination of the time course of luciferase expression in HEK293-SF-mH4R-His6-CRE-
Luc cells (6:2) (data are not shown) revealed no significant differences compared to that 
depicted in Figure 4.16. 
4.2.3.2 Selection of the HEK293-CRE-Luc-SF-rH4R-His6 cells 
For the extension of the luciferase reporter gene assay to the rH4R, HEK293-CRE-Luc cells 
(cf. section 4.1.3.6) were stably transfected with the pcDNA3.1(+)-SF-rH4R-His6 vector. The 
inhibition of the forskolin (1 µM) stimulated luciferase activity by 100 µM of histamine (1) 
confirmed the successful expression of the rH4R in the HEK293-CRE-Luc-SF-rH4R-His6 cells 
(see Figure 4.26). There were no significant differences detectable in forskolin stimulation 
and Gαi/o-mediated rH4R response among the 6:2 and 8:2 cells. Since the 6:2 cells were 
more readily available due to faster growth, these cells were chosen for the investigations of 
H4R ligand activity at the rH4R. 
  
 
 
Figure 4.25: Concentration-response curve of 
forskolin in HEK293-SF-mH4R-His6-CRE-Luc 
(6:2) cells. Data were analyzed by nonlinear 
regression and best fitted to sigmoidal 
concentration-response curves. Data points 
shown are the mean values of three 
independent experiments performed in 
triplicate. 
Figure 4.26: Changes in luciferase activity by Gαi/o-mediated rH4R responses. The effect of 100 µM of
the agonist histamine (1) and the inverse agonist thioperamide (12) upon pre-stimulation by 1 µM of
forskolin in HEK293-CRE-Luc-SF-rH4R-His6 cells. 6:2 transfection (A). 8:2 transfection batch (B). 
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4.2.3.3 Influence of forskolin on the potency of histamine 
The EC50 value of forskolin in HEK293-CRE-Luc cells, which were used for the transfection 
with the rH4R, was 3.75 ± 0.96 µM as shown is section 4.1.3.6. Therefore, a forskolin 
concentration of 4 µM should be used to enable the determination of both agonistic and 
inverse agonistic activity of H4R ligands. To evaluate the dependence of agonist potency on 
forskolin concentrations, the EC50 value of histamine (1) was determined in the presence of 
various forskolin concentration ranging from 0.5 µM to 5 µM in HEK293-CRE-Luc-SF-rH4R-
His6 cells (see Figure 4.27). 
  
 
Forskolin concentration-dependently increased the luciferase expression, which in turn was 
inhibited by histamine (1) to an extent of 70.2 ± 1.9 % (N = 3), 66.0 ± 1.3 % (N = 6), 56.0 ± 
0.72 % (N = 3) and 43.7 ± 2.5 % (N = 3) using 0.5 µM, 1 µM, 2.5 µM and 5 µM of forskolin, 
respectively, i.e. although the absolute inhibitory effect (RLU values) of histamine (1) seemed 
to be amplified at higher forskolin concentrations (see Figure 4.27 A), the relative inhibitory 
effect decreased. Furthermore, the higher the forskolin concentration used for pre-
stimulation, the more the concentration-response curve was shifted to the right (see Figure 
4.27 B), resulting in lower pEC50 values (see Table 4.4). With the exception of 2.5 µM of 
forskolin, the determined pEC50 values were statistically different relative to the pEC50 values 
of histamine (1) in the presence of 1 µM of forskolin (see Table 4.4). This correlated with a 
lower pEC50 value and signal-to-noise ratio of histamine (1) at the hH4R in the presence of 50 
µM IBMX (cf. section 4.1.3.5). 
Figure 4.27: Concentration response curves of HA (1) in HEK293-CRE-Luc-SF-rH4R-His6 cells upon
pre-stimulation with various forskolin concentrations (0.5 – 5.0 µM). Representative luciferase reporter
gene assay, luciferase activity is presented as RLU values (A). Inhibition of forskolin stimulated
luciferase activity (100 %) by increasing histamine (HA, 1) concentrations; the maximum inhibitory
effect of histamine corresponds to 0 % luciferase activity. Data points shown are the mean values ±
SEM of at least three independent experiments performed in triplicate (B). Data were analyzed by
nonlinear regression and best fitted to sigmoidal concentration-response curves. 
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Table 4.4: Histamine potencies determined upon pre-stimulation with various concentrations of 
forskolin in HEK293-CRE-Luc-SF-rH4R-His6 cells. Mean values ± SEM of N independent experiments 
performed in triplicate. Statistical analysis of significant differences relative to the pEC50 value of 
histamine in the presence of 1 µM of forskolin: one-way ANOVA, Bonferroni’s multiple comparison 
test. (*: p < 0.05; ***: p < 0.001; confidence intervall 95 %). 
C forskolin (µM) 
Histamine (rH4R) 
pEC50 N 
0.5 6.81 ± 0.11* 3 
1.0 6.53 ± 0.04 6 
2.5 6.29 ± 0.07 3 
5.0 5.91 ± 0.04*** 3 
The results revealed a decreasing influence of the activated Gαi/o-protein on the intracellular 
cAMP level as well as the signal-to-noise ratio with increasing concentrations of cAMP 
induced by forskolin or IBMX. The use of 1 µM of forskolin for the HEK293-CRE-Luc-SF-
rH4R-His6 cells was considered appropriate in terms of pEC50 values and signal-to-noise 
ratio.  
4.2.3.4 Functional activity of histamine H4 receptor ligands at the mouse 
and rat histamine H4 receptor 
Histamine (1) inhibited the forskolin (1 µM) stimulated luciferase reporter gene transcription 
by 74.2 ± 5.5 % (N = 4) and 66.0 ± 1.3 % (N = 6) in the HEK293-SF-mH4R-His6-CRE-Luc 
and the HEK293-CRE-Luc-SF-rH4R-His6 cells, respectively, suggesting that the signal-to-
noise ratio was appropriate for performing the luciferase reporter gene assay at the mouse 
and rat H4R. Thioperamide (12) increased the forskolin stimulated luciferase activity by 34.1 
± 2.8 (N = 4) and 10.3 ± 2.0 (N = 4) in the mH4R and rH4R expressing reporter cells, 
respectively, indicating considerable constitutive activity of the mH4R and only low 
constitutive activity of the rH4R. The H4R ligands, which were already characterized at the 
hH4R, were tested for their ability to change forskolin stimulated (1 µM) luciferase activity in 
the reporter gene on the mouse and rat H4R orthologs. The obtained results were compared 
with data from literature and from functional [35S]GTPγS binding assay on membrane 
preparations of Sf9 cells expressing the mH4R or the rH4R (D. Wifling, personal 
communication; results of the dissertation project of D.W., to be reported in detail elsewhere) 
(cf. Table 4.6). 
In addition to binding studies at the mH4R (cf. section 3.2.3.3), the separated stereoisomers 
of the phenylthioethyl-substituted (UR-RG98) and methyl-substituted (UR-RG94) cyano-
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guanidines were evaluated in the luciferase reporter gene assay at the mH4R and in part at 
the rH4R. The results are summarized in Table 4.7. 
Histamine (1), (R)-α-methylhistamine (2), (S)-α-methylhistamine (3), Nα-methylhistamine (4) 
and 5(4)-methylhistamine (5) changed forskolin stimulated luciferase activity in a 
concentration-dependent manner in HEK293-SF-mH4R-His6-CRE-Luc cells as well as in 
HEK293-CRE-Luc-SF-rH4R-His6 cells as shown Figure 4.28. Except for (S)-α-
methylhistamine (3), histamine (1) and its methylated analogs displayed full agonistic activies 
(α = 1) at the mouse and rat H4R. The potency of (S)-α-methylhistamine (3) was insufficient 
to fully activate the receptors. In comparison to the hH4R, only a slight decrease in potency 
was detected at the mH4R for compounds 1-5. Species-dependent differences became more 
obvious at the rH4R. For example, histamine (1) was 6 and 17 times less potent at the mH4R 
and the rH4R, respectively. Despite these species-dependent differences, the preference for 
the stereoisomer (R)-α-methylhistamine (2) over (S)-α-methylhistamine (3) was preserved 
among the three H4Rs species orthologs (cf. Figure 4.18). 
  
 
The comparison of the determined potency for histamine (1) and its methylated analogs at 
the mouse and rat H4R with literature, however, yielded controversial findings. Especially, the 
reported pEC50 values for histamine (1) differ by two orders of magnitude for both receptors 
as shown in Table 4.5. On the one hand, the pEC50 values of histamine (1), (R)-α-
methylhistamine (2) and Nα-methylhistamine (4) were the same or even lower compared to 
data from a Ca2+ assay using HEK293 cells co-expressing the mouse or the rat H4R and the 
Figure 4.28: Relative change of the luciferase-activity by HA (1), RAMH (2), SAMH (3), NAMH (4) and
5-MHA (5) in HEK293-SF-mH4R-His6-CRE-Luc (A) and HEK293-CRE-Luc-SF-rH4R-His6 (B) cells.
Maximum change of 1 is defined as full agonism, whereas 0 indicates the luminescence signal
detected after direct stimulation of adenylyl cyclase 1 µM forskolin in the absence of H4R ligands
(control). Data were analyzed by nonlinear regression and best fitted to sigmoidal concentration-
response curves. Data points shown are the mean values ± SEM of at least three independent
experiments performed in triplicate. 
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chimeric G-protein Gαqi5, which directed the H4R signaling to the Gq pathway (Liu et al., 
2001a; Strakhova et al., 2009). On the other hand, the potencies of histamine (1) and 5(4)-
methylhistamine (5) were significantly higher compared to the steady state [33P]GTPase 
assay (Schnell et al., 2011). Nevertheless, next to more comparable agonist potencies of the 
aforementioned Ca2+ assay, discrepancies regarding efficacies became obvious. Contrary to 
the luciferase reporter gene assay, (R)-α-methylhistamine (2) and Nα-methylhistamine (4) 
only reached 80 % and 40 - 50 % of the maximal response of histamine at the mH4R and the 
rH4R, respectively (Liu et al., 2001b). 
Table 4.5: Potencies of histamine at the mouse and rat H4R in various assay systems reported in 
literature. 
Assay 
mouse H4R  rat H4R 
pEC50  pEC50 
CRE controlled β-galactosidase reporter 
gene assay in SK-NM-C cells  6.47
a  - 
SRE-controlled luciferase reporter gene 
assay in HEK293 cells (co-expressing 
chimeric Gαqi) 
5.27a  6.77a 
Ca2+ assay in HEK293 cells (co-expressing 
chimeric Gαqi5) 7.23
b  6.49b 
Ca2+ assay in (HEK)293-EBNA cells (co-
expressing chimeric Gαqi5) 7.52
c  7.10c 
Steady-state [33P]GTPase activity assay on 
Sf9 membranes (co-expressing Gαi2, β1γ2 
and RGS19 (regulator of G-protein 19)) 
5.81d  5.23d 
Data taken from: a (Yu et al., 2010); b (Strakhova et al., 2009); c (Liu et al., 2001a); d (Schnell et al., 
2011). 
Immepip (6) fully activated the mouse and the rat H4R, compared to the hH4R, with only 
slightly lower pEC50 values of 6.85 ± 0.17 and 7.17 ± 0.06, respectively (see Figure 4.29). 
These results were in disagreement with the [35S]GTPγS binding assay. In the latter immepip 
(6) was a partial agonist with 10- and 100-fold lower potencies at the mH4R and rH4R, 
respectively (see Table 4.6). In line with results at the hH4R, extension of the spacer length 
in immepip (6) by two carbon atoms led to substantial decrease in potency and intrinsic 
activity at the mH4R, as shown for VUF 5681 (7) in Figure 4.29 A. Surprisingly, the hH4R 
partial agonist immethridine (8) exhibited almost full agonist activity at both the mouse and 
rat H4R, and the pEC50 values (5.95 ± 0.03 and 5.80 ± 0.13, respectively) were comparable 
to that at the hH4R (see Figure 4.29). 
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Furthermore, the isothiourea containing H4/3R ligands imetit (9), clobenpropit (10) and 
iodophenpropit (11) as well as the H3/4R inverse agonist thioperamide (12) were examined 
(see Figure 4.30). Interestingly, at the mouse and the rat H4R, imetit (9) retained almost the 
same potency (pEC50 values: 7.41 ± 0.11 and 7.21 ± 0.12) as at the hH4R. Moreover, imetit 
(9) acted at all three H4R species orthologs as nearly full agonist with α values of 0.94 – 0.96. 
The conserved activity of imetit (9) at the species orthologs is in agreement with reported 
data from Ca2+ assays on HEK293 cells at the human, mouse and rat H4R, however, 
although imetit (9) was more potent and less efficacious at all three receptors (Liu et al., 
2001b). By contrast, clobenpropit (10) and iodophenpropit (11) displayed a clear decrease in 
potency and efficacy at the mouse and rat H4R compared to the hH4R. Whereas clobenpropit 
(10) potently and fully activated the hH4R, this compounds was only a partial agonist with 
moderate pEC50 values at the mouse and rat H4R in the luciferase reporter gene assay (α = 
0.55 ± 0.05 and α = 0.37 ± 0.03, respectively). Potency and efficacy were only slightly higher 
than in the [35S]GTPγS binding assay (see Table 4.6). Iodophenpropit (11) exhibited partial 
agonistic activity at the hH4R, but was a neutral antagonist at the mouse and the rat H4R (α 
values close to zero, pKB values comparable to data from the [35S]GTPγS binding assay; cf. 
Table 4.6). Surprisingly, thioperamide (12) acted as an inverse agonist at the mH4R 
achieving a pEC50 values of 6.52 ± 0.13. This was unexpected, since neither in the 
[35S]GTPγS binding assay nor in the [33P]GTPase assay (Schnell et al., 2011) constitutive 
activity was detectable with thioperamide (12) at the mH4R. Furthermore, thioperamide (12) 
revealed a clear decrease in affinity at the mH4R in competition binding assays, and proved 
to be unsuitable for the determination of non-specific binding in saturation binding 
Figure 4.29: Potencies and efficacies of IMMEP (6), VUF 5681 (7) and IMMET (8) at the mH4R (A)
and the rH4R (B) stably co-expressed with a CRE-controlled luciferase reporter gene in HEK293T
cells. Maximum change of 1 is defined as full agonism, whereas 0 indicates the luminescence signal
detected after direct stimulation of adenylyl cyclase by 1 µM forskolin in the absence of H4R ligands
(control). Data were analyzed by nonlinear regression and best fitted to sigmoidal concentration-
response curves. Data points shown are the mean values ± SEM of at least three independent
experiments performed in triplicate. 
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experiments with [3H]UR-PI294 and [3H]histamine on HEK293-SF-mH4R-His6 cells (cf. 
section 3.2.3.2 and 3.2.3.3). Thioperamide (12) displayed negligible inverse agonistic activity 
at the rH4R, but revealed a pKB value of 6.89 ± 0.14 in the antagonist mode, which was in 
agreement with results from the [35S]GTPγS binding assay (see Table 4.6). 
  
 
As at the hH4R, proxyfan (13) was a partial agonist at the mouse and rat H4R, although with a 
significantly lower potency. Clozapine (18) fully activated both the mouse and the rat H4R 
with low pEC50 values (see Figure 4.31). In contrast, 18 did not show any activity at both 
species orthologs, neither in the agonist mode nor in the antagonist mode, in the [35S]GTPγS 
binding assay (Wifling, 2012). The standard H4R antagonist JNJ 7777120 (19) behaved as 
neutral antagonist in the luciferase reporter gene assay at the mH4R. The pKB value of 7.58 ± 
0.13 was in good correlation with the pKi value of 7.40 ± 0.14 (cf. section 3.2.3.3) and did not 
significantly differ from the pKB value determined at the hH4R. In contrast, JNJ 7777120 (19) 
acted as partial agonist (α = 0.49 ± 0.05) with a pEC50 value of 8.21 ± 0.10 at the rH4R. 
However, compared to reported functional data gained from other assays, discrepancies 
became obvious. Antagonist behavior at both receptors was determined in a CRE-driven β-
galactosidase reporter gene assay in SK-N-MC cells (Thurmond et al., 2004) and in a Ca2+ 
assay in HEK293 cells (Strakhova et al., 2009). Partial agonistic activity at the mouse and rat 
receptor was found in the [33P]GTPase (Schnell et al., 2011) and the [35S]GTPγS binding 
assay (see Table 4.6). The determined pKB value at the mH4R was consistent with the pKB 
value in the Ca2+ assay (Strakhova et al., 2009), whereas the potency at the rH4R was about 
Figure 4.30: Percental change in forskolin (1 µM) stimulated luciferase activity induced by IME (9),
CLOB (10), IODO (11) and THIO (12) in HEK293-SF-mH4R-His6-CRE-Luc (A) and HEK293-CRE-Luc-
SF-rH4R-His6 (B) cells. Maximum change of 1 indicates full agonism, -1 is defined as “full” inverse
agonism, whereas 0 indicates the luminescence signal detected after direct stimulation of adenylyl
cyclase by 1 µM forskolin in the absence of H4R ligands (control). Data were analyzed by nonlinear
regression and best fitted to sigmoidal concentration-response curves. Data points shown are the
mean values ± SEM of at least three independent experiments performed in triplicate. 
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two orders of magnitude higher compared to the [33P]GTPase assay (Schnell et al., 2011). 
The discrepancies between the activities of JNJ 7777120 (19) at the H4R orthologs in the 
different assay systems may be caused by different basal equilibria (presence and absence 
of constitutively active receptors) of the H4R as described recently (Seifert et al., 2011). 
Constitutive activity, unmasked by the inverse agonist thioperamide (12), was considerable 
at the mH4R, but very low at the rH4R. As suggested by Seifert et al., JNJ 7777120 (19) may 
influence the equilibrium between active and inactive state for all H4R orthologs in a 
comparable manner (Seifert et al., 2011). This might appear as neutral antagonistic activity 
at the mH4R, i.e. no shift toward the active or inactive state, whereas in case of the rH4R 
(only low constitutive activity unmasked by thioperamide (12)), JNJ 7777120 (19) shifted the 
equilibrium toward the active state and thus agonistic activity appeared. VUF 8430 (20) had 
about the same potency at both the mH4R and the hH4R, whereas the potency at the rH4R 
was distinctly lower (see Figure 4.31). At both rodent H4R orthologs, VUF 8430 (20) was 
almost as efficacious as histamine (α = 0.96–0.98). However, VUF 8430 (20) exhibited 
distinctly lower potencies and efficacies at the mouse and rat H4R in the [35S]GTPγS binding 
assay compared to the reporter gene assay (see Table 4.6). 
  
 
The potency of ST-1006 (30) was comparable at the mH4R (pEC50 = 7.76 ± 0.11) and the 
hH4R, whereas this compound displayed partial agonistic activity at the mH4R (α = 0.37 ± 
0.04) with lower maximal response than at the hH4R (α = 0.91 ± 0.01) (see Figure 4.32 A). 
Surprisingly, 30 proved to be an inverse agonist at the rH4R with a pEC50 value of 6.08 ± 0.17 
and an α value of -0.55 ± 0.12 (see Figure 4.32 B). This was unexpected, since the standard 
Figure 4.31: Potencies and efficacies of CLOZ (18), JNJ 7777120 (19) and VUF 8430 (20) at the
mH4R (A) and the rH4R (B) stably co-expressed along with a CRE controlled luciferase reporter gene
in HEK293T cells. Maximum change of 1 indicates full agonism, -1 is defined as “full” inverse agonism,
whereas 0 indicates the luminescence signal detected after direct stimulation of adenylyl cyclase by
1µM forskolin in the absence of H4R ligands (control). Data were analyzed by nonlinear regression and
best fitted to sigmoidal concentration-response curves. Data points shown are the mean values ± SEM
of at least three independent experiments performed in triplicate. 
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inverse agonist thioperamide (12) only acted as neutral antagonist at the rH4R (cf. Figure 
4.30). ST-1012 (31) acted as inverse agonist at the hH4R, but revealed partial agonistic 
activity at both the mouse and the rat H4R with pEC50 values of 7.49 ± 0.09 and 8.12 ± 0.08, 
respectively.  
  
 
The acylguanidine-type compound UR-PI294 (15) fully activated the mH4R and the rH4R with 
pEC50 values of 8.29 ± 0.18 and 8.16 ± 0.03 (see Figure 4.33) and was the most potent 
agonist studied at the two rodent H4R othologs and at the hH4R. However, these results were 
not in agreement with data from the [35S]GTPγS binding and the [33P]GTPase assays. 
Although UR-PI294 (15) acted also as full agonist on the Sf9 cell membrane preparations, 
the pEC50 values were about two orders of magnitude lower for the mH4R and even about 
three orders of magnitude lower at the rH4R (see Table 4.6 and (Schnell et al., 2011)). The 
cyanoguanidine UR-PI376 (16) exhibited only partial agonistic activity at the mH4R and no 
agonism at the rH4R, although full agonistic activity was determined at the hH4R (see Figure 
4.33). At the mH4R, the decrease in intrinsic activity was accompanied with roughly 10-fold 
lower potency, which was in accordance to data from the [33P]GTPase assay (Schnell et al., 
2011). At the rH4R, UR-PI376 (16) only reached a pKB value of 5.15 ± 0.05, suggesting only 
very weak binding. In agreement with this result, UR-PI376 (16) showed no agonism in the 
[35S]GTPγS binding assay at the rH4R, and the determined pKB value was just as low as in 
the luciferase reporter gene assay (see Table 4.6). 
Figure 4.32: Concentration response curves of ST-1006 (30) and ST-1012 (31) at mH4R (A) and rH4R
(B) stably co-expressed with a CRE controlled luciferase reporter gene in HEK293T cells. Maximum
change of 1 indicates full agonism, -1 is defined as “full” inverse agonism, whereas 0 indicates the
luminescence signal detected after direct stimulation of adenylyl cyclase by 1 µM forskolin in the
absence of H4R ligands (control). Data were analyzed by nonlinear regression and best fitted to
sigmoidal concentration-response curves. Data points shown are the mean values ± SEM of at least
three independent experiments performed in triplicate. 
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Figure 4.33: Potencies and efficacies of UR-PI294 (15), UR-PI376 (16) and trans(+)-(1S,3S)-UR-
RG98 (17) in HEK293-SF-mH4R-His6-CRE-Luc(A) and HEK293-CRE-Luc-SF-rH4R-His6 (B) cells.
Maximum change of 1 is defined as full agonism, whereas 0 indicates the luminescence signal
detected after direct stimulation of adenylyl cyclase by 1 µM forskolin in the absence of H4R ligands
(control). Data were analyzed by nonlinear regression and best fitted to sigmoidal concentration-
response curves. Data points shown are the mean values ± SEM of at least three independent
experiments performed in triplicate. 
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Trans-(+)-(1S,3S)-UR-RG98 (17), which was the most potent and selective stereoisomer 
among the conformationally constrained cyanoguanidine-type agonists at the hH4R (cf. 
section 4.1.3.8), revealed lower intrinsic activity at the mH4R (α = 0.67 ± 0.04), but acted, 
contrary to UR-PI376 (16), as potent partial agonist at the rH4R (α = 0.81 ± 0.08) (see Figure 
4.33). Nevertheless, a roughly 10-fold decrease in potency was observed at both H4R 
species orthologs compared to the hH4R. trans-(-)-(1R,3R)-UR-RG98 (23) (pEC50 6.23 ± 
0.14) was equipotent at the mH4R and hH4R, but the intrinsic activity at the murine receptor 
was clearly lower (α = 0.29 ± 0.02) (see Table 4.7 and cf. Table 4.3). Also cis-(-)-(1S,3R)-
UR-RG98 (24) displayed low intrinsic activity (α = 0.31 ± 0.03) and moderate potency at the 
mH4R (pEC50 = 6.45 ± 0.22). Surprisingly, cis-(+)-(1R,3S)-UR-RG98 (25) seemed to be 
preferred by the mouse and rat H4R compared to the hH4R. In comparison to recently 
described functional [35S]GTPγS binding data at the hH4R (Geyer, 2011), cis-(+)-(1R,3S)-UR-
RG98 (25) acted more potently at the mouse and rat H4R (pEC50 = 6.97 ± 0.10 and pEC50 = 
6.98 ± 0.02, respectively) and produced higher maximal responses (α = 0.81 ± 0.03 and α = 
1.00 ± 0.03, respectively). Interestingly, the methyl-substituted cyanoguanidines (UR-RG94) 
revealed all strong partial to full agonism at the mH4R and thus an increased intrinsic activity 
compared to the [35S]GTPγS binding assay at the hH4R (Geyer, 2011). Both trans-(-)-
(1R,3R)-UR-RG94 (26) and trans-(+)-(1S,3S)-UR-RG94 (27) fully activated the mH4R with 
pEC50 values of 5.44 ± 0.15 and 6.27 ± 0.03, respectively, suggesting that the mH4R, just as 
the hH4R, preferred trans-(+)-(1S,3S)-UR-RG94 (27) over trans-(-)-(1R,3R)-UR-RG94 (26), 
though at lower potency for both stereoisomers (Geyer, 2011). Stereodiscrimination by the 
mH4R was even more pronounced for the cis-configured stereoisomers (-)-(1R,3S)-UR-RG94 
(28) and (+)-(1R,3S)-UR-RG94 (29). Compound 29 was 60 times more potent than 28 at the 
mH4R and, with a pEC50 values of 6.83 ± 0.08, equipotent with its phenylthioethyl-substituted 
analog 25. In summary, the cis-(+) stereoisomers of RG98 (25) and RG94 (29) were 
identified as the most potent agonists among the investigated conformationally contrained 
cyanoguandine-type stereoisomers in the luciferase reporter gene assay at the mH4R. 
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Table 4.7: Pharmacological activities of the conformationally constrained cyanoguanidines 17, 23-29 
at the mH4R and rH4R in the luciferase reporter gene assay using HEK293-CRE-Luc-SF-mH4R-His6 
cells and HEK293-CRE-Luc-SF-rH4R-His6 cells, respectively. Mean values ± SEM of N independent 
experiments performed in triplicate. 
Ligand 
mH4R  rH4R 
pEC50 α N  pEC50 α N 
trans-(+)-(1S,3S)-UR-RG98 
(17) 6.78 ± 0.06 0.67 ± 0.04 3  6.70 ± 0.03 0.81 ± 0.08 3 
trans-(-)-(1R,3R)- UR-RG98 
(23) 6.23 ± 0.14 0.29 ± 0.02 3  n.d. n.d. - 
cis-(-)-(1S,3R)-UR-RG98 
(24) 6.45 ± 0.22 0.31 ± 0.03 4  n.d. n.d. - 
cis-(+)-(1R,3S)-UR-RG98 
(25) 6.97 ± 0.10 0.81 ± 0.03 4  6.98 ± 0.02 1.00 ± 0.03 3 
trans-(-)-(1R,3R)-UR-RG94 
(26) 5.44 ± 0.15 1.00 ± 0.02 4  n.d. n.d. - 
trans-(+)-(1S,3S)-UR-RG94 
(27) 6.27 ± 0.03 0.96 ± 0.02 3  n.d. n.d. - 
cis-(-)-(1S,3R)-UR-RG94 
(28) 5.04 ± 0.16 0.87 ± 0.04 4  n.d. n.d. - 
cis-(+)-(1R,3S)-UR-RG94 
(29) 6.83 ± 0.08 0.98 ± 0.04 4  n.d. n.d. - 
n.d.: not determined. 
In summary, HEK293T cells co-expressing a CRE-controlled luciferase reporter gene and 
the mouse or rat H4R are useful systems to functionally characterized H4R agonists, inverse 
agonists and antagonists. However, comparison of the agonist activities at the mouse and rat 
H4R revealed striking discrepancies. On the one hand, potencies of the agonists 1, 5, 6, 15, 
18 and 19 (rH4R) were significantly higher compared to data from the [33P]GTPase and 
[35S]GTPγS binding assay (Schnell et al., 2011) (cf. Table 4.6). On the other hand, agonist 
potencies of 1, 2, 4 and 9 were comparable or lower compared to results from a Ca2+ assay 
using HEK293 cells, co-expressing the mouse or the rat H4R and Gαqi5 (Liu et al., 2001a; 
Strakhova et al., 2009). In contrast to discrepancies regarding agonist pharmacology, the pKB 
values of neutral antagonists such as 11 at the mouse and rat H4R as well as 12 and 16 at 
the rH4R were comparable with data from the [35S]GTPγS binding assay (cf. Table 4.6). 
Activation of the mouse and rat H4R in the luciferase assay resulted in higher potencies 
compared to functional assays, which exclusively address the proximal hydrolysis of 
radiolabled GTP ([γ33P]GTP) or the binding of radiolabel GTP ([35S]GTPγS) to the Gα-protein. 
This may be interpreted as a hint to either signal amplification or to the activation of 
alternative signaling pathways that potentiate the inhibition of the reporter gene transcription. 
For instance, H4R mediated Ca2+ signaling via activation of phospholipase C (PLC) (Hofstra 
et al., 2003) was reported as pathway with the potential to trigger a cross-talk with the cAMP 
cascade: Ca2+ was described as inhibitor of (forskolin) stimulated and Ca2+ sensitive 
adenylate cyclases type V/VI (Fagan et al., 1998; Guillou et al., 1999; Mou et al., 2009), 
which are endogenously expressed in HEK293T cells (Atwood et al., 2011; Rybin et al., 
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2000) and interactors of the Gαi/o protein (Pavan et al., 2009). Furthermore, the relevance of 
Ca2+ dependent inhibition of the cAMP pathway was demonstrated by the inhibitory effect of 
the Gαq coupled histamine H1R on the cAMP level (Wong et al., 2000) in U373 cells and, 
more importantly, by facilitation of the Gαi/o coupled M2 mACh receptor mediated inhibition of 
forskolin-stimulated cyclic AMP production by the Gαq coupled M3 mACh receptor at low 
agonists concentrations (Hornigold et al., 2003). However, further studies are needed to 
clarify the influence of Ca2+ in general on the present reporter gene assay and whether only 
the rodent H4Rs were concerned by this cross-talk, since agonist potencies at the hH4R were 
consistent with data from the [33P]GTPase and [35S]GTPγS binding assay (cf. section 
4.1.3.8). A hint could be the fact that histamine (1) and UR-PI376 (16) increased [Ca2+]i 2.5-
fold less effective than the chemokine eotaxin via the CCR3 receptor in human eosinophils 
(Reher et al., 2012). Unfortunately, such a control experiment was not included in a study 
reporting on Ca2+ mobilization in mouse bone mast cells (Hofstra et al., 2003). 
Despite these discrepancies, two new pharmacological tools for the mouse and rat H4R were 
identified within this study. The acylguanidine type compound UR-PI294 (15) fully and 
potently activated all three H4R orthologs, and the aminopyrimidine type compound ST-1012 
(31) revealed excellent agonistic potency at the rH4R. 
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4.3 Concluding Remarks  
Using a CRE- controlled luciferase reporter gene assay agonistic, inverse agonistic and 
antagonistic activity can be determined in HEK293T cells, stably expressing the human, rat 
and mouse H4R receptor, respectively. The adaptation to the 96-well format provided high 
sensitivity and reliability in addition to the potential of higher throughput. Monitoring the time 
course of the luciferase expression revealed an optimal incubation period of 5 h. The time 
course was nearly identical for the different tested reporter cells. In contrast, the EC50 value 
of forskolin varied, probably due to different expression levels of the CRE-controlled 
luciferase within the different HEK293T transfection approaches. Moreover, due to an 
optimum in luciferase expression, beyond a concentration of 10 µM of forskolin, a downturn 
of the concentration-response curve became obvious, possibly caused by endogenous ICER 
activation at high cAMP concentrations in HEK293T cells. The presence of the PDE inhibitor 
IBMX increased basal luciferase expression and shifted the forskolin concentration response 
curve to the left, thus lowering the EC50 value of forskolin. The influence of the activated 
Gαi/o-protein on the intracellular cAMP level as well as the signal-to-noise ratio seemed to be 
lowered by increasing cAMP levels. This was reflected by lower relative effects and 
potencies of histamine (1). All in all, these findings demonstrated that high forskolin 
concentration should be avoided. 
HEK293-CRE-Luc cells stably expressing the CRE-linked luciferase reporter gene were 
established for the investigation of non-H4R mediated effects and successfully used for the 
transfection with the rH4R. The determined potencies of the H4R ligands at the hH4R were in 
accordance to reported results, regardless of a tendency toward increased intrinsic activities, 
presumably, due to signal amplification in the reporter gene assay. Even compounds 
characterized as neutral antagonists in other assays showed partial agonistic activity in the 
luciferase reporter gene assay. Surprisingly, differences in agonist potencies between the 
H4R othologs were mostly less pronounced compared to [33P]GTPase assay and [35S]GTPγS 
binding assay. The causes may be multifactorial, including activation/amplification of or 
crosstalk between different signaling pathways influencing the ultimate readout in the 
luciferase reporter gene assay. Nevertheless, UR-PI294 (15) and ST-1012 (31) were 
identified as potent new pharmacological tools for the mouse and rat H4R. 
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5.1 Radioligand binding assay for the human histamine 
H3 receptor 
5.1.1 Introduction 
After the first cloning of the H3R cDNA in the year 1999 by Lovenberg and co-workers 
(Lovenberg et al., 1999), several binding assays using [3H]Nα-methylhistamine ([3H]NAMH) 
and more rarely [3H](R)-α-methylhistamine ([3H]RAMH) on membrane preparations of the 
full-length (445 aa) hH3R expressing rat C6 glioma cells (Lovenberg et al., 1999; Witte et al., 
2006), SK-N-MC cells (Barbier et al., 2004; Bongers et al., 2007; Kitbunnadaj et al., 2003; 
Lovenberg et al., 2000; Wieland et al., 2001) and Sf9 insect cells (Schnell et al., 2010) were 
established. Furthermore, the antagonistic radioligand [125I]iodoproxyfan was successfully 
applied on membrane preparations of CHO-K1 (Coge et al., 2001) and HEK293 cells (Wulff 
et al., 2002). Due to the presence of several introns in the H3R gene, alternative splicing 
revealed at least 20 different isoforms of the hH3R, of which, however, the full length receptor 
(445 aa) is the best characterized one (Leurs et al., 2005). 
In contrast to reported binding assays with broken cell systems, the present work focused on 
radioligand binding studies with whole HEK293T cells stably expressing the full length hH3R 
(HEK293-SF-hH3R-His6). As radioactive tracer, the standard agonist [3H]NAMH was utilized. 
For validation, the affinities of imidazoles and non-imidazoles, comprising agonists, 
antagonists and inverse agonists, were determined. 
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5.1.2 Materials and Methods 
5.1.2.1 Whole cell radioligand binding assay 
The HEK293-SF-hH3R-His6 cells, stably expressing the tagged hH3R, were kindly provided 
by Dr. Schnell (Department of Pharmacology and Toxicology, University of Regensburg, 
Germany), and cultured as described in section 3.1.2.1. The preparation of the HEK293-SF-
hH3R-His6 cells, the separation of bound from free radioligand and data processing were 
identical to that described in section 3.1.2.4. [3H]Nα-methylhistamine ([3H]NAMH) was used 
as radioligand (85.3 Ci/mmol) (Perkin Elmer). 
 
Figure 5.1: Structure of the radioactive tracer [3H]Nα-methyl-
histamine ([3H]NAMH). 
In saturation binding assays with [3H]NAMH, non-specific binding was determined in the 
presence of JNJ 5207852 at a final concentration of 10 µM. In competition binding assays, 
displacement of 1 nM of [3H]NAMH by the H3/4R ligands listed in section 3.1.2.3 was 
measured. The Ki values are presented as as the mean ± SEM of at least three independent 
experiments performed in duplicate (see Table 5.1). 
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5.1.3 Results and discussion 
5.1.3.1 Saturation binding assay 
The radioligand [3H]NAMH exhibited specific and saturable binding to HEK293-SF-hH3R-His6 
cells (see Figure 5.2 A). The non-specific binding was less than 10 % of the total binding 
within the investigated concentration range using 10 µM of JNJ 5207852 as competitor. 
Scatchard plot analysis of the specific binding isotherm revealed a linear correlation between 
the ratio bound/free versus bound [3H]NAMH, indicating the presence of a single binding site 
(see Figure 5.2 B). The reported KD values was in the range of 0.5-1.1 nM (Bongers et al., 
2007; Lovenberg et al., 2000; Schnell et al., 2010; Witte et al., 2006) and thus slightly lower 
than the KD value of 5.09 ± 1.21 nM (N = 3) using whole HEK293-SF-hH3R-His6 cells. In 
studies using [3H]NAMH, a minor nucleotide sensitivity of the high affinity state was 
demonstrated, wherein the KD value was 2-5 times higher in the presence of GDP or GTPγS 
(Schnell et al., 2010; Witte et al., 2006). Therefore, also the slightly increased KD value in the 
present study might be attributed to high GTP concentration in whole cells (cf. section 
3.1.3.3). 
  
 
5.1.3.2 Competition binding assay 
In competition binding experiments, a large variety of H3R ligands comprising imidazoles and 
non-imidazoles (cf. section 3.1.2.3) were investigated for their ability to displace 1 nM of 
[3H]NAMH on HEK293-SF-hH3R-His6 cells. The results were compared with hH3R ligand 
binding data reported in literature as well as with ligand affinities determined at the hH4R 
Figure 5.2: Representative [3H]NAMH saturation binding experiment, performed in triplicate, using
HEK293-SF-hH3R-His6 cells. Non-specific binding was determined in the presence of 10 µM JNJ
5207852. Saturation binding curve was best fitted by nonlinear regression to a one-site model (A). The
corresponding Scatchard plot of saturation binding data was best fitted by linear regression (B). 
0 5 10 15 20 25
0
5000
10000
15000
20000
25000
total binding
non-specific binding
specific binding
A
[3H]N-methylhistamine [nM]
dp
m
[3H]NAMH bound / pmol 106cells-1
bo
un
d/
fr
ee
0 5.010- 5 1.010- 4 1.510- 4 2.010- 4
0
5.010- 5
1.010- 4
1.510- 4
2.010- 4
2.510- 4
r2 = 0.93B
 Results and discussion 135 
using [3H]UR-PI294 (cf. section 3.1.3.3). Most of the reported studies used [3H]NAMH as 
radioactive tracer and invariably broken cell systems such as membrane preparations. The 
results and reported data are summarized in Table 5.1. 
Histamine (1) and its methylated analogs (R)-α-methylhistamine (2), (S)-α-methylhistamine 
(3) and Nα-methylhistamine (4) concentration dependently inhibited specific binding of 
[3H]NAMH on HEK293-SF-hH3R-His6 cells (see Figure 5.3). In line with reported data, the 
hH3R affinities of 2–4 were distinctly higher compared to the hH4R. Nevertheless, a 
pronounced stereoselectivity in favor of (R)-α-methylhistamine (2) (pKi = 8.60 ± 0.12) 
compared to (S)-α-methylhistamine (3) (pKi = 7.34 ± 0.08) was also found at the hH3R. 
Whereas the affinity of 1 was lower than described in literature, the pKi values of 2-4 were in 
agreement with reported data. 
 
Figure 5.3: Displacement of specifically bound 
[3H]NAMH by HA (1), RAMH (2), SAMH (3) and 
NAMH (4) on HEK293-SF-hH3R-His6 cells. 
Reaction mixtures contained 1 nM [3H]NAMH 
and ligand concentrations indicated on the 
abscissa. Data were analyzed by nonlinear 
regression and best fitted to one-site 
(monophasic) competition curves. Data points 
are the mean of at least three independent 
experiments performed in duplicate. 
Immepip (6) and its analogs VUF5681 (7) and immethridine (8) displayed low nanomolar 
affinities at the hH3R, which were consistent with reported data. Interestingly, the ligands 
showed, regardless of higher affinities, the same rank order as at the hH4R (6 > 8 > 7). Imetit 
(9), derived from 1 by replacement of the amino group with an isothiourea, revealed 
nanomolar affinity at the hH3R. The isothiourea-type ligands clobenpropit (10) and 
iodophenpropit (11) yielded also comparably high affinities at the hH3R. The results were in 
good accordance with reported data, and the rank order was again the same as at the hH4R 
(9 > 10 > 11). The H3/4R inverse agonist thioperamide (12) revealed a pKi value of 6.71 ± 
0.09, which is the same as at the hH4R and marginally lower compared to reported data. The 
hH3R affinities of proxyfan (13) as well as of the proxyfan-class compound ciproxifan (14) 
were consistent with data described in literature. As for most of the aforementioned 
compounds which were originally designed as H3R ligands, the hH4R affinity of proxyfan (13) 
and ciproxifan (14) was clearly lower. In contrast, the acylguanidine-type ligand UR-PI294 
reached low nanomolar affinities at both the hH3R and the hH4R, as expected from 
[32P]GTPase assays at both histamine receptor subtypes (Igel et al., 2009a) (see Figure 
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5.4). In line with literature, the affinity at the hH3R was low for clozapine (18) and only 
moderate for VUF8430 (20). The investigated non-imidazoles displayed thus only 4-10-fold 
selectivity for the hH4R over the hH3R (cf. section 3.1.3.3). Whereas the affinity of JNJ 
7777120 (19) at the hH3R was slightly lower compared to literature, the selectivity of 19 for 
the hH4R was in good agreement (see Figure 5.4) (Lim et al., 2005). Although the hH3R 
affinities of JNJ 5207852 (21) and conessine (22) were lower than reported, these non-
imidazoles showed 6000- and 1000-fold selectivity, respectively, for the hH3R over the hH4R 
in the present cellular binding system (see Figure 5.4). 
 
 
 
 
 
 
In summary, by performing competition binding experiments using whole HEK293-SF-hH3R-
His6 cells and [3H]NAMH, affinities of H3R ligands at the hH3R were determined in a highly 
reproducible manner. With the exception of histamine (1), which displayed a lower pKi value 
at the hH3R as described in literature, the affinities of all agonists (2-4, 6-9, 13, 18, 20) and 
antagonists (10, 11, 14) were comparable with reported data (see Table 5.1 and Figure 5.5). 
Hence, there was no evidence for a “GTP-shift” as at the hH4R (cf. section 3.1.3.3). However, 
it is noticeable that ligands with inverse agonistic activity at the hH3R (thioperamide (12), JNJ 
7777120 (19), JNJ 5207852 (21) and conessine (22)) displayed lower affinities at the hH3R 
than determined on membranes (see Table 5.1). 
  
Figure 5.4: Displacement of specifically bound [3H]NAMH binding by UR-PI294 (15), JNJ 7777120
(19), JNJ 5207852 (21) and CON (22) on HEK293-SF-hH3R-His6 cells. Reaction mixtures contained 1
nM [3H]NAMH and ligand concentrations indicated on the abscissa. Data were analyzed by nonlinear
regression and best fitted to one-site (monophasic) competition curves. Data points are the mean of at
least three independent experiments performed in duplicate. 
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Table 5.1: pKi values of reference H3R ligands determined in competititon binding experiments, using 
HEK293-SF-hH3R-His6 cells and [3H]Nα-methylhistamine, in comparison to pKi values reported in 
literature. 
Ligand 
hH3R 
pKi N  pKi 
HEK293-SF-hH3R-His6   reported 
Histamine (1) 7.52 ± 0.08 5  7.8-8.6b, c, e, g, i, j, k, n, o 
(R)-α-Methylhistamine (2) 8.60 ± 0.12 6  8.2-9.3c, e, g, j, m, n, o, k 
(S)-α-Methylhistamine (3) 7.34 ± 0.08 3  7.2-7.6g, n, o 
Nα-Methylhistamine (4) 8.85 ± 0.17 6  8.4-9.5c, g, j, k, n 
Immepip (6) 9.28 ± 0.14 5  8.8-9.8b, c, e, g, I, j, n, o 
VUF 5681 (7) 8.20 ± 0.05 3  8.35e 
Immethridine (8) 8.98 ± 0.20 5  9.1f, g 
Imetit (9) 9.19 ± 0.12 8  8.8-9.7c, g, I, j, k, m, n, o 
Clobenpropit (10) 8.81 ± 0.09 6  8.4-9.5c, d, g, I, j, k, m, n 
Iodophenpropit (11) 8.78 ± 0.06 6  8.2-9.1g, m, n, o 
Thioperamide (12) 6.71 ± 0.09 10  6.9-7.7a, b, c, g, I, j, k, m, n, o, p 
Proxyfan (13) 7.80 ± 0.13 3  7.9-8.4g, k, n, o 
Ciproxyfan (14) 6.92 ± 0.26 4  6.7-7.3c, k, n, o, p 
UR-PI294 (15) 8.28 ± 0.07 3  - 
Clozapine (18) 4.46 ± 0.23 3  > 5i, j 
JNJ 7777120 (19) 4.86 ± 0.13 3  5.3g, l 
VUF 8430 (20) 6.21 ± 0.05 3  6.0h 
JNJ 5207852 (21) 7.79 ± 0.14 3  9.2a 
Conessine (22) 7.00 ± 0.10 3  8.3p 
Mean values ± SEM. N: number of independent experiments performed in duplicate. Reference data 
taken from: [3H]NAMH binding on SK-N-MC cell membranes a (Barbier et al., 2004), b (Bongers et al., 
2007), j (Lovenberg et al., 2000), l (Thurmond et al., 2004); [125I]iodoproxyfan binding on CHO-K1 cell 
membranes c (Coge et al., 2001); [3H]NAMH binding on C6 cell membranes d (Esbenshade et al., 
2003), i (Lovenberg et al., 1999), n (Witte et al., 2006), p (Zhao et al., 2008); [3H]NAMH binding on SK-
N-MC cell homogenates e (Kitbunnadaj et al., 2003), f (Kitbunnadaj et al., 2004), g (Lim et al., 2005), h 
(Lim et al., 2006), m (Wieland et al., 2001); [3H]NAMH binding on Sf9 cell membranes k  (Schnell et al., 
2010); [125I]iodoproxyfan binding on HEK293 cell membranes o (Wulff et al., 2002). 
Witte et al. showed that the tritiated antagonist/inverse agonist [3H]A-349821 detected about 
50% more receptors than [3H]NAMH in saturation binding assays at the human H3R and 
rH3R, suggesting that the agonist [3H]NAMH only recognized the active conformation of the 
H3R, whereas [3H]A-349821 bound to both receptor states (active and inactive) (Witte et al., 
2006). This observation was confirmed in saturation binding studies with [3H]NAMH on rH3R 
expressing HEK293-CRE-Luc cells (see section 5.2.3.1). According to theory agonists can 
distinguish between the inactive (low affinity) and the active (high affinity) conformation of a 
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receptor, whereas antagonists have the same affinity for both receptor sates (Lefkowitz et al., 
1993). The conversion to the active conformation of a receptor can be provoked by an 
agonist or can occur spontaneously in the absence of an agonist (constitutive activity) 
(Samama et al., 1993). The agonist-induced active state in whole cells is hampered by the 
high cytosolic GTP concentration (cf. section 3.1.3.3), but pronounced constitutive activity, i. 
e. an increased basal activity, of the hH3R in HEK293-CRE-Luc cells became obvious upon 
addition of the inverse agonists JNJ 5207852 (21) (α = -1.42) and conessine (22) (α = -1.33) 
(see section 6.3.2). Therefore, it can be assumed that [3H]NAMH within the covered 
concentration range bound to the constitutively active receptor population on HEK293-SF-
hH3R-His6 cells. Furthermore, the specific binding isotherm revealed one binding site in the 
Scatchard plot analysis (Figure 5.2). Agonists and antagonists presumably displaced 
[3H]NAMH from the active receptor state resulting in pKi values comparable with those 
determined in broken cell systems (see Figure 5.5), where the ternary complex can 
accumulate (cf. section 3.1.3.3 ).  
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Surprisingly, affinities of the inverse agonists thioperamide (12), JNJ 7777120 (19), JNJ 
5207852 (21) and conessine (22) were lower than those described in literature, and 
differences in affinity even seemed to correlate with the magnitude of the inverse efficacy 
(see Figure 5.5). In fact, inverse agonists were reported to bind with lower affinity to a 
constitutively active mutant (CAM) of the β2 adrenergic receptor (β2-AR), albeit determined 
with a radiolabeled antagonist (Samama et al., 1994). Hence, the affinity determined at the 
wild-type β2-AR, used as a control with low constitutive activity, was mainly attributable to the 
inactive states, whereas binding data from the CAM β2-AR mainly reflected the active state 
(Samama et al., 1994). In contrast, as in the present study, the reported affinities of JNJ 
Figure 5.5: Affinities (left) and intrinsic activities (right) of selected agonists, antagonists and inverse
agonists at the hH3R. pKi values determined on whole cells (dark grey bars) and in broken cell
systems reported in literature (bright grey bars). Data are the mean values according to table 5.1.
“Error bars” indicate the range covered by reported pKi values. Intrinsic activities were adopted from
section 6.3.2. 
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7777120 (19), JNJ 5207852 (21) and conessine (22) were obtained from [3H]NAMH 
competition binding assays, which are presumably addressing only the active receptor 
population. Furthermore, guanine nucleotides were reported to have no effect on the 
competition binding experiments with an inverse agonist (Samama et al., 1994), suggesting 
that the  whole cell system used in the present study should not have affected the affinity of 
inverse agonists, too. Therefore, discrepancies regarding binding data of the inverse 
agonists have to be investigated in more detail in further studies. 
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5.2 Radioligand binding assay for the rat histamine H3 
receptor 
5.2.1 Introduction 
The third histamine receptor was discovered by pharmacological investigations on rat brain 
slices, where the H3R acts as presynaptic autoreceptor that inhibits histamine release from 
histaminergic neurons (Arrang et al., 1983). [3H]RAMH was the first radio-labeled H3R 
agonist used for binding studies on rat cerebral cortical membranes, at which this radioligand 
binds with high affinity (KD = 0.5 nM) to a single binding site (Arrang et al., 1987). Shortly 
after the hH3R cDNA (Lovenberg et al., 1999) also the rH3R cDNA (445 aa) was cloned 
(Lovenberg et al., 2000) and subsequently expressed in SK-N-MC cells (Barbier et al., 2004; 
Lovenberg et al., 2000; Wieland et al., 2001), HEK293 cells (Wulff et al., 2002), C6 cells 
(Witte et al., 2006) or Sf9 cells (Schnell et al., 2010). Radioligand binding assays were 
usually performed with [3H]NAMH. Although rat and human H3Rs share 93 % of the amino 
acid sequence, species-dependent differences, for instance, higher antagonist affinities at 
the rH3R, were reported (Lovenberg et al., 2000; Schnell et al., 2010; Yao et al., 2003). 
Membrane preparations were used without exception in the reported binding studies. 
Therefore, the aim of this work was to establish a whole cell radioligand binding assay with 
HEK293T cells, stably expressing the rH3R. For this purpose HEK293-CRE-Luc cells, which 
already expressed the CRE-controlled firefly luciferase (cf. section 4.1.3.6), were transfected 
with the rH3R. The resulting HEK293-CRE-Luc-SF-rH3R-His6 cells were selected by 
performing the luciferase reporter gene assay (see section 6.3.1). Thereafter, both binding 
and functional (see section 6.3.2) assays were performed at the same time. As radioactive 
tracer the standard radioligand [3H]NAMH as well as the recently described H3/4R radioligand 
[3H]UR-PI294 (Igel et al., 2009b) were evaluated. In competition binding assays selected 
agonists, inverse agonists and antagonists were investigated to validate the assay. For 
comparison only reference data gained from recombinant systems were considered. 
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5.2.2 Materials and Methods 
5.2.2.1 Whole cell radioligand binding assay 
Due to new equipment in the radionuclide laboratory allowing a higher throughput, several 
modifications of the method described in section 3.1.2.4 became necessary. Only one 
densely grown 75 cm2 culture flask with HEK293-CRE-Luc-SF-rH3R-His6 cells was used for 
preparing a cell suspension with a lower cell density of 1.7 106 cells/mL. Cell-bound 
radioactivity was separated from free radioactivity by filtration through a 0.3 % (v/v) 
polyethyleneimine (Sigma) pretreated GF/C glass fiber filter (Whatman, Maidstone, UK) and 
washed twice with PBS (4 °C) using a 96-sample semi-auto harvester (Brandl, Gaithersburg, 
USA). Cell-containing filter discs were punched out and transferred to a flexible 24- or 96-
well scintillation microplate (Perkin Elmer). Each cavity was filled with 500 µL or 200 µL, 
respectively, Rotiszint® eco plus (Carl Roth) before the plates were incubated overnight 
under gentle shaking. On the next day, radioactivity was determined by liquid scintillation 
counting using a 2450 MicroBeta2TM (Perkin Elmer). Subsequent data processing was 
performed as described in section 3.1.2.4. 
In saturation binding experiments with [3H]NAMH (cf. section 5.1.2.1) and [3H]UR-PI294 (cf. 
section 3.1.2.4), 10 µM of thioperamide (12) were used for determining the non-specific 
binding. The KD values were calculated as means of two independent experiments, each 
performed in triplicate. Competition binding experiments, using [3H]UR-PI294 at a final 
concentration of 2.5 nM, were conducted in triplicate, too. The number of replicates and 
independent experiments for the determination of the pKi value is given in Table 5.2. 
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5.2.3 Results and discussion 
5.2.3.1 Saturation binding assay 
The transfection of the HEK293-CRE-Luc cells with the rH3R and the selection of 
transfectants are described in section 6.3.1. Although [3H]NAMH bound specifically in a 
saturable manner to a single binding site, the non-specific binding in the presence of 10 µM 
of thioperamide (12) occasionally amounted to about 50 % of the total binding (see Figure 
5.6). Furthermore, the Bmax value of the specific binding (maximum amount of specifically 
bound radioligand) was rather low in two independent saturation binding experiments, 
suggesting that the expression level of the rH3R was similarly low in HEK293-CRE-Luc-SF-
rH3R-His6 cells (see Figure 5.6). However, the determined KD value of 6.05 ± 1.07 nM (N = 
2) was comparable with that at the hH3R and, probably due to the high cytosolic GTP 
concentration in whole cells, slightly higher compared to the reported range of 0.5 – 1.37 nM 
(Lovenberg et al., 2000; Schnell et al., 2010; Witte et al., 2006). Nevertheless, the application 
of [3H]NAMH as radioligand for competition binding experiments at the rH3R could be 
exceedingly difficult due to the very low specific binding. Therefore, [3H]UR-PI294 was 
evaluated as a possible radioligand for the rH3R. 
  
 
[3H]UR-PI294 was recently described as non-selective radioligand for the human H3R and 
H4R with a KD value 1.1 nM at the hH3R (Igel et al., 2009b). Since [3H]UR-PI294 bound with 
nearly the same affinity to HEK293-CRE-Luc-SF-rH3R-His6 cells (KD value = 1.93 ± 0.35 (N 
=2)) the radioligand also proved to be a useful pharmacological tool at the rH3R (see Figure 
Figure 5.6: Representative [3H]NAMH saturation binding experiment with HEK293-CRE-Luc-SF-rH3R-
His6 cells. Non-specific binding was determined in the presence of 10 µM of thioperamide (12).
Saturation binding curve was best fitted by nonlinear regression to a one-site model (A). The
corresponding Scatchard Plot was best fitted by linear regression (B). 
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5.7). Using 10 µM of thioperamide (12) non-specific binding was surprisingly low, not 
exceeding 15 % of the total binding.  
  
 
The comparison of Bmax values of [3H]NAMH and [3H]UR-PI294 in HEK293-CRE-Luc-SF-
rH3R-His6 cells revealed that [3H]NAMH addressed only about 7,000 receptors per cell, 
whereas [3H]UR-PI294 recognized 34,000 receptors per cell, despite comparable KD values 
and specific activities of the radioligands (cf. Figure 5.6 and Figure 5.7). Therefore, it can be 
assumed that, by analogy to the observations of Witte et al. (Witte et al., 2006), the full rH3R 
agonist [3H]NAMH (cf. section 6.3.2) only labeled the constitutively active rH3Rs. The partial 
rH3R agonist [3H]UR-PI294 (cf. section 6.3.2) achieved a 5-fold higher Bmax value owing to its 
ability to recognize both receptor states. The constitutive activity of the rH3R was rather low 
compared to the hH3R, as reflected by α values of about -0.3 of the inverse agonists 
thioperamide (12), JNJ 5207852 (21) and conessine (22) (cf. section 6.3.2). Thus, only a 
small (active state) portion of the receptor was detected by [3H]NAMH. The affinity of [3H]UR-
PI294 to both receptor states seemed to be equal, since the specific binding isotherm was 
best described by a one-site model (see Figure 5.7). Competition binding assays were 
performed using [3H]UR-PI294. 
5.2.3.2 Competition binding assay 
In competition binding experiments with HEK293-CRE-Luc-SF-rH3R-His6 cells, a selection of 
H3R ligands containing agonists, inverse agonists and antagonists were investigated for their 
ability to inhibit specific binding of 2.5 nM [3H]UR-PI294. The results were compared with 
Figure 5.7: Representative [3H]UR-PI294 saturation binding experiment using HEK293-CRE-Luc-SF-
rH3R-His6 cells. Non-specific binding was determined in the presence of 10 µM thioperamide (12).
Saturation binding curve was best fitted by non-linear regression to a one-site model (A). The
corresponding Scatchard Plot was best fitted by linear regression (B). 
0.0 2.5 5.0 7.5 10.0 12.5 15.0
0
500
1000
1500
2000
2500
3000
3500
total binding
non-specific binding
specific binding
[3H]UR-PI294 [nM]
dp
m
A
[3H]UR-PI294 bound / pmol 106cells-1
bo
un
d/
fr
ee
0 210- 0 5 410- 0 5 610- 0 5 810- 0 5
0
110- 0 5
210- 0 5
310- 0 5
410- 0 5
510- 0 5
B r2 = 0.91
144 Chapter 5 
data from literature as well as with the determined affinities at the hH3R (cf. section 5.1.3.2). 
The data are summarized in Table 5.2. 
Histamine (1), (R)-α-methylhistamine (2), Nα-methylhistamine (4), imetit (9) and proxyfan (13) 
displaced [3H]UR-PI294 in a concentration-dependent manner (see Figure 5.8 A). However, 
the affinities of the rH3R agonists were without exception about one order of magnitude lower 
compared to binding data at the hH3R and those reported in literature. 
  
 
In contrast, the rH3R revealed in agreement with literature a 70-120-fold higher affinity to the 
antagonists thioperamide (12) and ciproxifan (14) as well as a 2-fold higher affinity to 
clobenpropit (10) compared to the hH3R (see Figure 5.8 B). Thus, the recently described 
species-dependent increased affinity of the rH3R to antagonists (Lovenberg et al., 2000; 
Schnell et al., 2010; Yao et al., 2003) was confirmed in this cellular binding study. 
  
Figure 5.8: Displacement of specifically bound [3H]UR-PI294 by the agonists HA (1), RAMH (2),
NAMH (4), IME (9) (A) and by the antagonists CLOB (10), THIO (12), PRO (13) and CIP (14) (B) on
HEK293-CRE-Luc-SF-rH3R-His6 cells. Reaction mixtures contained 2.5 nM [3H]UR-PI294 and ligand
concentrations indicated on the abscissa. Data were analyzed by nonlinear regression and best fitted
to one-site (monophasic) competition curves. Data points are the mean of two independent
experiments performed in triplicate. 
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Table 5.2: pKi values of reference H3R ligands determined in competitive binding experiments using 
HEK293-CRE-Luc-SF-rH3R-His6 cells and [3H]UR-PI294 compared to data reported in literature. 
Ligand 
rH3R 
pKi N  pKi 
HEK293-CRE-Luc-SF-
rH3R-His6 
  reported 
Histamine (1) 6.43 ± 0.02 2  7.9-8.6a, b, d 
(R)-α-Methylhistamine (2) 7.20 ± 0.01 2  8.0-9.29a, b, c, d, e 
Nα-Methylhistamine (4) 7.35 ± 0.06 2  8.7-9.5a, b, d 
Imetit (9) 8.18 ± 0.02 2  9.0-10.1a, b, d, e 
Clobenpropit (10) 9.12 ± 0.11 3  8.9-9.8a, b, c, d, e 
Thioperamide (12) 8.57 ± 0.02 2  7.9-8.6a, b, c, d 
Proxyfan (13) 7.01 ± 0.10 3  8.0-8.6b, d, e 
Ciproxifan (14) 8.99 ± 0.15 3  8.6-9.4b, d, e 
Mean values ± SEM. N: number of independent experiments performed in duplicate. Reference data 
taken from:  [3H]NAMH binding on SK-N-MC cell membranes a (Lovenberg et al., 2000); 3H]NAMH 
binding on Sf9 cell membranes b (Schnell et al., 2010); [3H]NAMH binding on SK-N-MC cell 
homogenates c (Wieland et al., 2001); [3H]NAMH binding on C6 cell membranes d (Witte et al., 2006); 
[125I]iodoproxyfan binding on HEK293 cell membranes e (Wulff et al., 2002). 
Figure 5.9 clearly illustrated that the determined affinities of the full agonist histamine (1), 
(R)-α-methylhistamine (2), Nα-methylhistamine (4), imetit (9) and the strong partial agonist 
proxyfan (13) were lower compared to broken cell systems even though the rank order of 
affinity was the same. In contrast, the affinities of the inverse agonist thioperamide (12), the 
antagonist ciproxifan (14) and the very weak partial agonist clobenpropit (10) were 
comparable with reference values. These results show again the existence of a “GTP-shift” 
for agonists as described in section 3.1.3.3 for [3H]UR-PI294 displacement studies at the 
hH4R. Similarly, GDP induced a rightward shift of the [3H]A-349821 competition binding curve 
of histamine (1) (Witte et al., 2006). The displacement of the antagonist/inverse agonist 
[3H]A-349821 by agonists at the H3R was biphasic, because agonists displaced the 
radioligand initially from the high affinity binding sites and then from the low affinity sites 
(Witte et al., 2006). However, no distinct binding sites were detected by displacement of 
[3H]UR-PI294 with agonists (see Figure 5.8 A). Maybe there was only a minor portion of 
receptors in the active state or the number of data points was insufficient to unequivocally 
discriminate two binding sites. 
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Figure 5.9: Binding data (left) and intrinsic activities in the reporter gene assay (right, cf. section 6.3.2) 
of compounds 1, 2, 4, 9, 10, 12, 13, 14 at the rH3R. Depicted are the determined affinities in whole 
cells (dark grey bars) and in broken-cell preparations from literature (bright grey bars). Data are the 
mean values according to table 5.2. “Error bars” indicate the range covered by reported pKi values. 
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5.3 Summary 
Due to high constitutive activity and the resulting predominance of the active state, 
[3H]NAMH bound with high affinity to the hH3R expressed in HEK293T cells. Only minor 
sensitivity to high cytosolic GTP concentration became apparent, when the KD values were 
compared with results from literature. Furthermore, pKi values determined by displacement of 
[3H]NAMH with agonists and antagonists were consistent with published data for the hH3R, 
whereas, surprisingly, inverse agonists revealed lower affinities.  
[3H]UR-PI294 was able to recognize a distinctly higher number of receptors than [3H]NAMH 
in the rH3R expressing HEK293-CRE-Luc cells, probably due to binding to the receptor 
protein in both the active and inactive state. As a consequence, GTP shifted the binding data 
of agonists toward lower affinities in competition binding experiments. Since antagonists 
were not affected by this “GTP-shift”, the reported higher affinities of antagonists at the rH3R 
compared to the hH3R could be confirmed with this cellular binding assay. 
In the established binding assays, affinities of agonists, inverse agonists and antagonists 
were determined in a highly reproducible manner. 
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6.1 Introduction 
The histamine H3R couples to Gαi/o proteins (Clark and Hill, 1996) and can functionally be 
investigated, for instance, in cAMP accumulation (Wieland et al., 2001), steady state 
[32P]GTPase (Schnell et al., 2010a) or in [35S]GTPγS assays (Coge et al., 2001). A major 
characteristic of the H3R is to display constitutive activity in both, recombinant (Wieland et al., 
2001) and native ex-vivo systems (Morisset et al., 2000). Regardless of a high degree of 
similarity among the human and rat H3R, species-related pharmacological heterogeneity was 
described, which becomes especially evident from increased affinities of antagonists (cf. 
section 5.2.3.2) and higher potencies of inverse agonists at the rH3R (Schnell et al., 2010b; 
Wulff et al., 2002). 
The aim of this study was to develop a CRE-controlled reporter gene assay for the human 
and rat H3Rs in HEK293T cells. For this purpose, the CRE-luciferase expressing HEK293-
CRE-Luc cells were stably co-transfected with either the full length (445 aa) human or rat 
H3R. The use of the same host cells for the expression of H3R orthologs enabled comparism 
of the transfectants in terms of basal receptor activity, which is increased in the presence of 
constitutive active receptors (Samama et al., 1993). For validation, a variety of imidazoles 
and non-imidazoles, comprising H3R agonists, inverse agonists and antagonists was 
examined. 
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6.2 Material and methods 
6.2.1 Preparation of the pcDNA3.1(+)-SF-rH3R-His6 vector and 
sequencing 
The pcDNA3.1(+)-SF-rH3R-His6 vector was kindly provided by Prof. Dr. Seifert (Institute of 
Pharmacology, Medical School of Hannover, Hannover, Germany). Media and agar plates 
were prepared as described in section 3.2.2.1.4. The transformation of competent E. coli 
cells was performed according to section 3.2.2.1.5. The resulting glycerol culture and the 
large scale preparation of plasmid DNA (Maxi-Prep) were performed as described in section 
3.2.2.1.6. The DNA concentration was determined according to section 3.2.2.1.2. 
Sequencing (performed by Entelechon) confirmed the identity and correctness of the SF-
rH3R-His6 insert in pcDNA3.1(+). 
6.2.2 Stable transfection of HEK293-CRE-Luc with the human and 
rat H3R 
HEK293-CRE-Luc cells were cultured as described in section 3.1.2.1 and section 4.1.2.4. 
Cells were transfected with pcDNA3.1(+)-SF-hH3R-His6 (kindly provided by Dr. Schnell, 
Institute of Pharmacology and Toxicology, University of Regensburg, Germany) and 
pcDNA3.1(+)-SF-rH3R-His6 according to section 3.2.2.2 with the exception that the ratios of 
transfection reagent (µL) to DNA amount (µg) were 6:2 and 8:2. The transfection batches 
were initially selected with DMEM containing 10 % FCS, 800 µg/mL of G418 and 200 µg/mL 
of hygromycin B. Subsequently, HEK293-CRE-Luc-SF-hH3R-His6 and HEK293-CRE-Luc-SF-
rH3R-His6 cells were maintained with DMEM containing 10 % FCS, 600 µg/mL of G418 and 
200 µg/mL of hygromycin B. 
6.2.3 Luciferase reporter gene assay 
For implementation see section 4.1.2.6. The KB values of neutral antagonists/inverse 
agonists were determined in the antagonist mode at the hH3R and rH3R versus histamine (10 
and 15 nM, respectively) as the agonist. 
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6.3 Results and discussion 
6.3.1 Selection of the HEK293-CRE-Luc-SF-h/rH3R-His6 cells 
In order to investigate H3R ligand activity at the human and rat H3R in the luciferase reporter 
gene assay, HEK293-CRE-Luc cells were stably transfected with human and rat H3Rs, 
respectively. To select in each case the best transfection batch, the cells were incubated with 
1 µM of forskolin and either 100 µM of the full agonist histamine (1) or the inverse agonist 
thioperamide (12). 
Although the luciferase expression evoked by 1 µM of forskolin was comparable among the 
hH3R transfectants, the ligand induced effects of histamine (1) and thioperamide (12) were 
clearly higher in the 8:2 cells (see Figure 6.1). Therefore, the 8:2 cells were chosen for 
further reporter gene assays at the hH3R. In both transfection batches, the inverse agonistic 
effect of thioperamide (12) was more pronounced than the effect of histamine (1), indicating 
a high constitutive activity of the hH3R expressed in HEK293-CRE-Luc cells (see Figure 6.1). 
  
 
The 8:2 transfection batch of the rH3R expressing cells was also selected for subsequent 
reporter gene assays at the rH3R, since the effect of 100 µM of histamine (1) and 
thioperamide (12) were clearly higher compared to the 6:2 cells (see Figure 6.2). The EC50 
values of forskolin in the HEK293-CRE-Luc-SF-hH3R-His6 (8:2) and the HEK293-CRE-Luc-
SF-rH3R-His6 (8:2) cells were 6.06 ± 0.47 (N = 3) and 5.59 (N = 1), respectively, and thus 
comparable with HEK293-CRE-Luc cells devoid of H3R (cf. section 4.1.3.6). By analogy with 
the HEK293-CRE-Luc (cf. section 4.1.3.6) and HEK293-CRE-Luc-SF-rH4R-His6 cells (cf. 
4.2.3.3), 1 µM of forskolin was used for pre-stimulation in subsequent reporter gene assays. 
Figure 6.1: hH3R/Gαi/o mediated effect of HA (1) and THIO (12) upon stimulation with 1 µM forskolin in
HEK293-CRE-Luc-SF-hH3R-His6 cells. 6:2 transfection batch (A). 8:2 transfection batch (B). 
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6.3.2 Functional characterization of ligands at the human and rat 
histamine H3R 
Histamine (1) decreased forskolin (1 µM) stimulated luciferase activity by 58.0 ± 4.2 % (N = 
5) and 72.3 ± 3.3 % (N = 4) in HEK293-CRE-Luc-SF-hH3R-His6 and HEK293-CRE-Luc-SF-
rH3R-His6 cells, respectively, which was sufficient for the conduction of the luciferase reporter 
gene assay at both receptor orthologs. A variety of 23 H3R ligands comprising agonists, 
inverse agonists and antagonists was investigated in the luciferase assay at the human and 
rat H3R (cf. section 3.1.2.3). These results and data reported in the literature are summarized 
in Tabelle 6.1. 
Histamine (1), (R)-α-methylhistamine (2), (S)-α-methylhistamine (3), Nα-methylhistamine (4) 
and 5(4)-methylhistamine (5) changed the luciferase activity in a concentration-dependent 
manner via activation of the human and rat H3R in HEK293-CRE-luc cells (see Figure 6.3). 
At the rH3R the concentration response curves of 1-5 were slightly rightward-shifted 
compared to the hH3R, but the rank order was same for histamine (1) and its methylated 
analogs (2 = 4 > 3 > 1 > 5). Interestingly, methylation at position 5(4) of the imidazole ring (5) 
resulted in a dramatic decrease in potency of about 1000-fold as shown by and 5(4)-
methylhistamine (5). This was in accordance with the low binding affinity of 5 at the hH3R 
(Lim et al., 2005). By contrast, the introduction of a methyl substituent in the side chain, 
whether at the α-carbon (2 and 3) or at the α-nitrogen (4), increased the potency at the H3R. 
As at the H4R (cf. section 4.1.3.8 and 4.2.3.4), the human and rat H3R preferred (R)-α-
methylhistamine (2) over (S)-α-methylhistamine (3). Whereas the potencies of (S)-α-
methylhistamine (3) and Nα-methylhistamine (4) were higher than reference data at the hH3R, 
Figure 6.2: Change of the luciferase activity by Gαi/o-mediated rH3R response. The effect of 100 µM of
the agonist histamine (1) and the inverse agonist thioperamide (12) upon pre-stimulation with 1 µM of
forskolin in HEK293-CRE-Luc-SF-rH3R-His6 cells. 6:2 transfection batch (A). 8:2 transfection batch
(B). 
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the pEC50 values of histamine (1) and (R)-α-methylhistamine (2) were comparable. At the 
rH3R functional data of 1-4 were without exception consistent with literature. 
  
 
Immepip (6) and immethridine (8) fully activated both H3R orthologs with pEC50 values >10 at 
the hH3R and >9 at the rH3R, respectively (see Figure 6.4). The hH3R potency of 
immethridine (8) was 10-fold higher than reported, whereas the results for Immepip (6) were 
in good agreement with literature regarding both H3R orthologs. As already shown for the 
human and mouse H4R (cf. section 4.1.3.7 and 4.2.3.4), VUF 5681 (7) displayed a clear 
decrease in terms of potency and intrinsic activity at the H3R compared to its analog immepip 
(6) (see Figure 6.4). Surprisingly, VUF 5681 (7) acted as partial agonist at the hH3R, 
whereas no intrinsic activity was detected in a CRE-β-galactosidase assay in SK-N-MC/hH3R 
cells (Kitbunnadaj et al., 2003). Inversely, at the rH3R VUF 5681 (7) displayed no intrinsic 
activity, and the pKB value of 6.74 ± 0.23 was about two log units lower compared to the 
pEC50 value at the hH3R. 
  
Figure 6.3: Relative change of luciferase activity by HA (1), RAMH (2), SAMH (3), NAMH (4) and 5(4)-
MHA (5) in HEK293-CRE-Luc-SF-hH3R-His6 (A) and HEK293-CRE-Luc-SF-rH3R-His6 (B) cells.
Maximum change of 1 is defined as full agonism, whereas 0 indicates the luminescence signal
detected after direct stimulation of adenylyl cyclase by 1 µM forskolin in the absence of H3R ligands
(control). Data were analyzed by nonlinear regression and best fitted to sigmoidal concentration-
response curves. Data points shown are mean ± SEM of at least three independent experiments
performed in triplicate. 
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The isothiourea analog of histamine (1), imetit (9), was 30 times more potent than 1 at the 
human and rat H3R (see Figure 6.5 A, B). The pEC50 value at the hH3R was in agreement 
with the β-galactosidase reporter gene assay (Lim et al., 2005), but higher than data 
obtained in [32P]GTPase (Schnell et al., 2010a) and [35S]GTPγS assays (Coge et al., 2001). 
In contrast, at the rH3R the potency of imetit (9) was lower compared to the [32P]GTPase 
assay (Schnell et al., 2010b). Clobenpropit (10) and iodophenpropit (11) were mostly 
described as inverse agonist at both receptor orthologs (see Tabelle 6.1). Surprisingly, 
clobenpropit (10) acted as a potent partial agonist with low intrinsic activity and 
iodophenpropit (11) as neutral antagonist at both H3R receptor orthologs (see Figure 6.5 A, 
B). Both ligands showed also tendency toward increased agonist intrinsic activity at the hH4R 
(cf. section 4.1.3.8), suggesting a special signal amplification for these structurally related 
compounds in the luciferase assay. At the hH3R the pKB values of Clobenpropit (10) and 
iodophenpropit (11) were consistent with their binding affinity (cf. section 5.1.3.2) as well as 
with data from literature. By contrast, at the rH3R the pKB values were lower compared to 
reported data and in the case of clobenpropit (10) distinctly lower than the binding affinity 
(see Figure 6.5 C, D) (cf. section 5.2.3.2). 
Figure 6.4: Potencies and efficacies of IMMEP (6), VUF 5681 (7) and IMMET (8) at the hH3R (A) and
the rH3R (B) stably co-expressed with a CRE-controlled luciferase reporter gene in HEK293T cells.
Maximum change of 1 is defined as full agonism, whereas 0 indicates the luminescence signal
detected after direct stimulation of adenylyl cyclase by 1 µM forskolin in the absence of H3R ligands
(control). Data were analyzed by nonlinear regression and best fitted to sigmoidal concentration-
response curves. Data points shown are mean ± SEM of at least three independent experiments
performed in triplicate. 
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In line with literature, thioperamide (12) behaved as inverse agonist at the H3R (see Figure 
6.5 A, B). The potency at the hH3R was in accordance with reported data and in the same 
order of magnitude as at the hH4R (cf section 4.1.3.8). Inversely, at the rH3R the potency of 
thioperamide (12) was distinctly lower as determined, for example, in the [33P]GTPase assay 
(Schnell et al., 2010b). Surprisingly, the pKB value of thioperamide (12) was 30 times lower 
than its binding affinity at the rH3R in section 5.2.3.2 (see Figure 6.5 D). Proxyfan (13) was a 
potent and almost full agonist at the human and rat H3R, which was in accordance to data 
from literature (see Figure 6.5 A, B). UR-PI294 (15) reached pEC50 values >9 at both H3R 
orthologs (see Figure 6.6). Moreover, UR-PI294 (15) was able to fully activate the hH3R in 
the reporter gene assay. In contrast, the potency in the [32P]GTPase assay was slightly lower 
and only partial agonistic activity (α = 0.39) was detected (Igel et al., 2009b). At the rH3R, 
UR-PI294 (15) was a strong partial agonist. The reported H4R-selectivity of UR-PI376 (16), 
Figure 6.5: Effects of several standard ligands on H3R orthologs in the luciferase reporter gene assay
in HEK293T cells. Maximum change of 1 indicates full agonism, -1 is defined as “full” inverse agonism,
whereas 0 indicates the luminescence signal detected after direct stimulation of adenylyl cyclase by 1
µM forskolin in the absence of H3R ligands (control). Potencies and efficacies of IME (9), CLOB (10),
IODO (11), THIO (12) and PRO (13) at the hH3R (A) and the rH3R (B) (agonists mode). Reversal of
the HA (1) (10 – 15 nM) mediated inhibition of the forskolin-stimulated luciferase activity by CLOB (10)
and IODO (11) at the hH3R (C) and by CLOB (10), IODO (11) and THIO (12) at the rH3R (D)
(antagonist mode). Data were analyzed by nonlinear regression and best fitted to sigmoidal
concentration-response curves. Data points shown are the mean ± SEM of at least three independent
experiments performed in triplicate. 
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trans-(+)-(1S,3S)-UR-RG98 (17), JNJ 7777120 (19) and the amino-pyrimidine ST-1006 (30) 
could be confirmed in the luciferase assay. Interestingly, with the exception of trans-(+)-
(1S,3S)-UR-RG98 (17), all of the aforementioned selective H4R ligands displayed weak 
inverse agonistic activity. trans-(+)-(1S,3S)-UR-RG98 (17) was ~40-fold less potent at the 
hH3R compared to the hH4R, but in contrast to the [35S]GTPγS binding assay (Geyer, 2011), 
residual intrinsic activity was measured. For the first time also for ST-1012 (31) a ~30-fold 
selectivity for the hH4R over the hH3R was found in the present luciferase reporter gene 
assay. As at the hH4R, ST-1012 (31) showed inverse agonistic activity at the hH3R. 
Clozapine (18) and VUF8430 (20) fully activated the hH3R. The potencies were only 
moderate and consistent with literature. 
  
 
Surprisingly, JNJ 5207852 (21) and the alkaloid conessine (22) displayed exceptionally high 
inverse agonistic activity at the hH3R, whereas both compounds were described as neutral 
antagonists (see Figure 6.6 A) in assay systems devoid of pronounced constitutive activity 
(Barbier et al., 2004; Zhao et al., 2008). Obviously, the exceptionally high constitutive activity 
of the hH3R in HEK293-CRE-Luc cells is a prerequisite for the detection of inverse agonism 
in case of reported neutral antagonists (Kenakin, 2004). Control experiments with HEK293-
CRE-Luc cells did not reveal a non-specific, off-target mediated increase in luciferase 
activity, indicating that the inverse agonistic activity of JNJ 5207852 (21) and conessine (22) 
was actually hH3R-dependent (data not shown). At the rH3R both ligands acted also as 
inverse agonists, but the intrinsic activities were clearly lower than at the hH3R and in the 
same range as that of thioperamide (12). However, pKB values determined in the antagonist 
Figure 6.6: Potencies and efficacies of UR-PI294 (15), JNJ 5207852 (21) and CON (22) at the hH3R
(A) and the rH3R (B) stably co-expressed with a CRE-controlled luciferase reporter gene in HEK293T
cells. Maximum change of 1 indicates full agonism, -1 is defined as “full” inverse agonism, whereas 0
indicates the luminescence signal detected after direct stimulation of adenylyl cyclase by 1 µM
forskolin in the absence of H3R ligands (control). Data were analyzed by nonlinear regression and best
fitted to sigmoidal concentration-response curves. Data points shown are mean ± SEM of at least
three independent experiments performed in triplicate. 
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mode at the rH3R were lower than the pEC50 values and also lower than the reported pA2 
(JNJ 5207852 (21)) and pKB values (conessine (22)). 
The constitutive activity of the rH3R seemed to be considerably lower compared to the hH3R. 
A major hallmark of constitutive activity is increased basal activity of the receptor (Samama 
et al., 1993; Wieland and Seifert, 2006). Since HEK293-CRE-Luc-SF-hH3R-His6 and 
HEK293-CRE-Luc-SF-rH3R-His6 cells were both derived from the HEK293-CRE-Luc cells (cf. 
section 6.2.2), comparison of the forskolin (1 µM) stimulated activity in the presence and 
absence of the H3R was possible. The basal activity of HEK293-CRE-Luc cells served as 
control and HEK293-CRE-Luc-SF-rH4R-His6 cells were additionally considered for 
comparison. Rat H4R and H3R expressing cells displayed almost the same level of luciferase 
activity as the control (see Figure 6.7). This was expected due to moderate constitutive 
activity of inverse agonists at both rat histamine receptor subtypes (cf. section. 4.2.3.4 and 
Figure 6.6). In contrast, the hH3R expressing cells showed clearly decreased luciferase 
activity compared to the HEK293-CRE-Luc cells, reflecting high constitutive activity of the 
Gαi/o coupled hH3R (see Figure 6.7). 
 
Figure 6.7: Luciferase activity stimulated by 
1 µM forskolin in HEK293-CRE-Luc cells 
devoid of HxR (control) (N = 2) and 
expressing the rH4R (N = 12), the rH3R (N = 
18) or the hH3R (N = 13). RLU values were 
normalized to the cell number. Data are 
mean values ± SEM of N independent 
experiments. 
Investigating a small series ligands at the human and rat H3R, Schnell et al. detected neither 
difference in the constitutive activities of these receptor orthologs nor in the potencies of the 
respective full agonists in the GTPase assay (Schnell et al., 2010b). At a constitutively active 
mutant (CAM) of the β2-AR, (full) agonists showed higher binding affinities in concert with 
higher potencies compared with the wild-type receptor (cf. section 5.1.3.2) (Samama et al., 
1993). Likewise, in the luciferase assay, agonists (1, 2, 3, 4, 6, 7, 8) revealed higher 
potencies at the highly constitutively active hH3R compared to the rH3R. 
In the luciferase assay, increased intrinsic activities were found for the partial agonists 
proxyfan (13) and UR-PI294 (15) at the hH3R compared to the [32P]GTPase assay (Schnell 
et al., 2010a). This could be due to constitutive activity (Samama et al., 1993) or to signal 
amplification as a result of the very distal readout in the reporter gene assay (cf. sections 
4.1.3.8 and 4.2.3.4). The increased intrinsic activity of VUF 5681 (7), reported as a neutral 
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hH3R antagonist (Kitbunnadaj et al., 2004), presumably reflects the pronounced constitutive 
activity of the hH3R in HEK293-CRE-Luc cells. Interestingly, no partial agonism was 
observed at the rH3R, characterized by relatively low constitutive activity in reporter gene 
assay. 
The pKB values of clobenpropit (10) and iodophenpropit (11) were in agreement with binding 
affinities at the hH3R (cf. section 5.1.3.2) as well as with reported data. In contrast, at the 
rH3R pKB values of clobenpropit (10), iodophenpropit (11), thioperamide (12), JNJ 5207852 
(21) and conessine (22) were lower than reported and distinctly lower than the respective 
binding affinities (10, 12) (cf. section 5.2.3.2). This was unexpected, since antagonist affinity 
should be independent from the system (Kenakin, 2009). 
Distinctly higher potencies of inverse agonists at the rH3R in comparison to the hH3R were 
reported in the literature (Schnell et al., 2010b; Wulff et al., 2002; Yao et al., 2003). By 
contrast, the potencies were only slightly higher for thioperamide (12) and JNJ 5207852 (21) 
and even lower for conessine (22). Thus, distinctly higher potency of inverse agonists could 
not be confirmed in this luciferase reporter gene assay. 
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6.4 Summary and conclusion 
HEK293-CRE-Luc cells were stably co-transfected with full length (445 aa) human and rat 
H3Rs. The established luciferase assays were successfully used for the quantification of 
agonist, inverse agonist and antagonist activities in a highly sensitive and reliable manner. In 
contrast to the rH3R, the hH3R displayed exceptionally high constitutive activity in the 
luciferase assay. This became obvious by increased basal activity of the hH3R in HEK293-
CRE-Luc cells and was confirmed by means of inverse agonists. The presence of high 
constitutive activity led to increased potency of full agonists. Ligands with lower intrinsic 
activities such as partial agonists were less affected. Although radioligand binding 
experiments confirmed higher affinities of antagonists and inverse agonists at the rH3R (cf. 
section 5.2.3.2), pKB values and pEC50 values were lower than reported. Thus, the reported 
distinctly increased potencies of inverse agonists at the rH3R compared to the hH3R were not 
confirmed in the present luciferase reporter gene assay.  
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170  
G-protein coupled receptors (GPCRs) represent the most important class of drug targets for 
the currently available pharmacotherapeutics. In the histamine receptor (HR) field, 
antagonists of H1 and H2 receptors are well established drugs for many decades, whereas 
the more recently identified H3 (H3R) and H4 receptors (H4R) are considered promising 
biological targets for drug discovery programs. Translational animal models are 
indispensable for investigations on the (patho)physiological role of novel receptors as well as 
for preclinical studies of potential drug candidates. Thus, with respect to the predictivity of 
such studies, pharmacological differences between H3R and H4R species orthologs should 
be identified as early as possible, both in binding and functional assays, in particular on 
human (h) compared to rodent (m, r) HR subtypes. This thesis aimed at the development of 
cellular binding and functional assays for the hH4R, mH4R, rH4R, hH3R and rH3R.  
In a whole-cell radioligand binding assay, saturation binding experiments on HEK293T cells, 
stably expressing the hH4R, the H3,4R ligand [3H]UR-PI294 was bound with high affinity. 
Competition binding experiments revealed affinities of reference ligands in a highly 
reproducible manner. Affinities of agonists were lower than reported data from binding 
assays using broken cell preparations, probably due to high GTP concentrations in intact 
cells. Regarding the mH4R, saturation binding experiments on HEK293T cells stably 
transfected with the mH4R gene revealed substantially lower affinities of [3H]UR-PI294 and 
[3H]histamine compared to the hH4R. Therefore, it turned out to be exceedingly difficult to 
obtain valid and robust mH4R binding data for reference ligands. 
To establish functional assays for the hH4R and mH4R, using a more distal and non-
radioactive readout, compared to [32P]GTPase or [35S]GTPγS assays, the aforementioned 
transfectants were stably co-transfected with a vector encoding the firefly luciferase (Luc), 
the transcription of which is under the control of the cAMP responsive element (CRE). Assay 
parameters were optimized, and a luciferase reporter gene assay was established in the 96-
well format of a luminescence plate reader. Moreover, HEK293T cells lacking the H4R were 
stably transfected with the CRE-linked luciferase gene (HEK293-CRE-Luc) and established 
to uncover off-target effects in control experiments. To develop a reporter gene assay for the 
rH4R, HEK293-CRE-Luc cells were stably co-transfected with the rH4R gene. For validation, 
functional data of agonists, antagonists and inverse agonists were determined. In case of 
agonism at the hH4R, the data correlated well with data gained from [32P]GTPase or 
[35S]GTPγS assays. This also held for the rank order of agonists at the mH4R and rH4R, 
however, the potencies were up to 100-fold higher in the luciferase assay. Obviously, there 
was a positive effect on the distal readout by activation/amplification of or cross-talk between 
different signaling pathways in the established reporter gene assay. 
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Saturation binding experiments on whole HEK293T cells, stably expressing the hH3R, 
revealed high-affinity binding of [3H]N(alpha)methylhistamine ([3H]NAMH). This is consistent 
with recognition of the active receptor population, which was predominantly present due to 
high constitutive activity of the hH3R expressed in HEK293T cells. Whereas affinities of 
agonists and antagonists determined in competition binding experiments were in agreement 
with published data, inverse agonists achieved lower affinities. In studies at the rH3R stably 
expressed in HEK293-CRE-Luc cells, [3H]UR-PI294 was able to label a distinctly higher 
number of rH3Rs than [3H]NAMH, presumably, due to binding to the receptor protein in both, 
the active and inactive state. Consequently, in competition binding experiments with [3H]UR-
PI294, cytosolic GTP shifted the binding data of agonists toward lower affinities, whereas 
affinities of antagonists and inverse agonists were consistent with reported data from broken 
cell systems. 
For the functional characterization of H3R ligands at the human and rat H3 receptors, a 
luciferase assay was established. HEK293-CRE-Luc cells were stably co-transfected with a 
vector encoding for the hH3R. In case of the rH3R the aforementioned rH3R expressing 
transfectant was used. In contrast to the rH3R, the hH3R displayed exceptionally high 
constitutive activity. This became obvious by increased basal activity of the hH3R and was 
confirmed by means of inverse agonists. 
The established reporter gene (luciferase) assays allowed for the quantification of agonistic, 
inverse agonistic and antagonistic activity in a highly sensitive and reliable manner. In 
summary, the developed cell-based methods will improve the predictability of in vivo results 
by characterizing compounds on H3R and H4R species orthologs regarding affinity, subtype 
selectivity, quality of action and potency. 
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